stateoftheart
manag
infect
follow
solid
organ
transplant
prevent
surveil
donorderiv
infect
solid
organ
transplant
recipi
deal
donorderiv
infect
organ
transplant
recipi
take
account
two
side
coin
one
side
safeti
import
issu
care
side
organ
shortag
nowaday
import
barrier
success
transplant
actual
mani
patient
die
await
lifesav
transplant
polici
regard
risk
infect
transmiss
organ
transplant
minim
advers
event
maxim
avail
lifesav
organ
transmiss
infect
clearli
document
via
organ
tissu
allograft
organ
donor
need
adequ
screen
presenc
latent
activ
infect
may
transmit
transplant
first
step
screen
process
complet
medic
social
histori
includ
travel
epidemiolog
exposur
addit
sever
microbiolog
screen
test
use
evalu
organ
donor
state
recent
scientif
guidelin
nation
intern
regul
paramet
elect
assay
base
clinic
paramet
increas
sensit
may
incur
fals
posit
assay
result
result
discard
uninfect
donor
tissu
howev
transmiss
potenti
fatal
life
threaten
diseas
requir
select
assay
optim
sensit
decis
must
base
urgenc
transplant
avail
altern
therapi
graft
treatment
diseas
screen
document
infect
preclud
organ
donat
hiv
uncontrol
sepsi
rabi
etc
mani
other
cytomegaloviru
bacteri
infect
hcv
hbv
etc
stop
organ
donat
process
may
modifi
elect
recipi
treat
recipi
adequ
antimicrobi
therapi
clear
mandatori
time
report
transmiss
event
procur
organ
public
health
author
crucial
manag
donorderiv
infect
clinician
requir
educ
report
event
includ
specifi
clinic
syndrom
mechan
avail
report
gener
allograft
recipi
evid
unexplain
infect
earli
graft
placement
recoveri
recognit
common
unusu
organ
uncommon
clinic
syndrom
merit
report
practic
approach
diagnos
mix
anaerob
infect
real
time
antibiot
resist
determin
dilut
method
vs
disk
diffus
old
stori
come
back
us
justesen
odens
dk
antimicrobi
suscept
test
ast
anaerob
bacteria
use
dilut
method
broth
microdilut
agar
dilut
describ
clsi
guidelin
still
gold
standard
mani
year
method
use
primarili
research
surveil
nation
local
suscept
pattern
order
choos
appropri
antimicrobi
agent
empir
therapi
howev
increas
resist
observ
mani
frequent
encount
anaerob
bacteria
need
simpl
method
routin
clinic
microbiolog
laboratori
gradient
strip
use
simpl
expens
method
ast
disk
diffus
wilkinschalgren
agar
former
clsi
recommend
agar
anaerob
bacteria
also
evalu
sever
year
ago
although
result
promis
time
method
gener
accept
introduct
eucast
disk
diffus
method
intent
develop
standardis
method
anaerob
bacteria
follow
test
condit
suggest
brucella
blood
agar
medium
supplement
hemin
vitamin
k
bba
current
recommend
clsi
strictli
control
test
condit
temperatur
atmospher
time
incub
use
disk
diffus
method
limit
rapidli
grow
hour
anaerob
bacteria
member
bacteroid
fragili
group
clostridium
spp
fusobacterium
necrophorum
studi
bba
progress
preliminari
studi
bacteroid
fragili
group
fusobacterium
necrophorum
refer
strain
promis
furthermor
studi
clinic
isol
clostridium
difficil
show
isol
reduc
suscept
metronidazol
vancomycin
separ
wildtyp
isol
disk
diffus
clostridium
perfringen
clostridium
spp
may
well
next
candid
evalu
ast
disk
diffus
although
refer
method
still
ast
method
choic
larg
number
slow
grow
anaerob
speci
disk
diffus
seem
potenti
altern
certain
rapidli
grow
anaerob
bacteria
updat
viral
hepat
deal
guidelin
hepat
c
treatment
last
year
sever
nation
intern
guidelin
treatment
hepat
c
publish
compar
differ
guidelin
are
controversi
issu
without
clear
evid
larg
studi
guidelin
address
expert
opinion
issu
treatment
durat
usag
respons
guid
therapi
ii
indic
liver
biopsi
iii
treatment
special
patient
subgroup
idu
hiv
coinfect
patient
dialysi
children
liver
transplant
patient
iv
treatment
patient
advanc
cirrhosi
howev
avail
directli
activ
antivir
scenario
rapidli
chang
new
guidelin
usag
drug
recent
publish
american
associ
studi
liver
diseas
probbali
next
year
guidelin
wait
publish
bacteriophag
plasmid
helicobact
come
helicobact
pylori
chronic
infect
gastric
mucosa
human
popul
coevolv
human
host
genom
analysi
sever
strain
reveal
extens
h
pylori
pangenom
like
grow
genom
sampl
helicobact
natur
transform
describ
plasmid
bacteriophag
identifi
plasmid
alreadi
observ
helicobact
form
free
cryptic
plasmid
share
signific
homolog
bacteri
plasmid
contrari
littl
known
h
pylori
phage
report
prophag
helicobact
speci
also
rare
particular
one
genom
helicobact
acinonychi
one
helicobact
feli
recent
data
indic
high
percentag
isol
carri
phage
integras
gene
possibl
shape
genom
least
term
divers
strain
found
worldwid
well
contribut
virul
evolut
phylogen
analysi
phage
integras
gene
show
pattern
biogeograph
separ
agreement
model
coevolut
viru
bacteri
host
sinc
biogeograph
separ
also
observ
within
h
pylori
model
geograph
constrain
viral
dispers
also
fit
ie
h
pylori
differ
geograph
region
may
infect
distinct
phage
lineag
geograph
separ
bacteri
host
anoth
hypothesi
could
bacteri
infect
viru
diverg
bacterium
also
accompani
diverg
integr
viru
argu
h
acinonychi
strain
sheeba
deriv
h
pylori
prophag
acquir
host
jump
human
felin
equal
like
scenario
prophag
present
bacteri
genom
host
jump
ampl
evid
continu
exchang
genet
materi
phage
bacteri
genom
variou
genet
element
explain
sometim
fuzzi
distinct
phage
plasmid
pathogen
island
pai
chimer
natur
phage
genom
origin
cag
pai
current
unknown
excit
hypothesi
would
cagpai
well
newli
describ
plastic
zone
consid
increasingli
true
pai
phage
origin
infect
menu
foodand
waterborn
hazard
immunocompromis
patient
come
kitchen
foodborn
infect
vulner
patient
lund
obrien
suggest
popul
may
regard
vulner
food
born
infect
homogen
group
vulner
often
consid
term
increas
likelihood
infect
exposur
increas
risk
seriou
advers
outcom
infect
increas
frequenc
intens
exposur
also
consid
vulner
group
clearli
demarc
physiolog
patholog
condit
pregnant
women
hivaid
etc
therapi
associ
increas
risk
includ
cytotox
chemotherapi
immunomodul
eg
antitnf
proton
pump
inhibitor
infant
older
peopl
also
vulner
although
age
boundari
normal
increas
risk
somewhat
arbitrari
poverti
poor
educ
lack
access
facil
hygien
storag
prepar
increas
frequenc
intens
exposur
consid
four
categori
microb
classic
pathogen
eg
salmonella
ii
pathogen
risk
group
eg
l
monocytogen
iii
environment
organ
eg
pseudomona
aeruginosa
iv
cultur
promot
probiot
lactobacillu
casei
industri
prepar
cater
food
free
classic
pathogen
challeng
issu
relat
pathogen
risk
group
extent
foodsafeti
vulner
group
address
labellingeduc
oppos
zerotoler
environment
speci
occur
fresh
fruit
veget
associ
infect
neutropaen
patient
avoid
food
reduc
infect
food
contain
probiot
cultur
associ
infect
common
balanc
protect
vulner
group
public
prefer
divers
traditionallyminim
process
food
challeng
also
one
need
ensur
qualiti
life
vulner
peopl
unduli
impair
loss
favourit
food
beverag
freshli
prepar
thoroughli
cook
food
freshli
prepar
wash
fruit
veget
safe
boil
water
minut
failsaf
immunecompromis
patient
reput
bottl
water
properli
filter
treat
water
pasteuris
bottledpackag
beverag
unlik
caus
problem
anim
product
thermal
treatment
equival
avoid
likewis
certain
processedcat
food
high
risk
contamin
l
monocytogen
hospitalassoci
listeriosi
caus
consequ
f
allerberg
vienna
invas
listeriosi
rare
seriou
infect
fatal
newborn
immunocompromis
elderli
highest
risk
although
cluster
lateonset
neonat
listeriosi
identifi
newborn
nurseri
demonstr
nosocomi
transmiss
possibl
case
foodborn
nosocomi
outbreak
listeriosi
rel
infrequ
least
eight
outbreak
report
england
wale
germani
oct
one
public
health
offic
report
two
patient
stay
hospit
onset
listeriosi
activ
case
find
retrospect
investig
listeriosi
notif
state
perform
avail
isol
character
pfge
altogeth
case
identifi
patient
link
hospit
begin
dec
nine
avail
isol
indistinguish
isol
food
sampl
previous
obtain
routin
inspect
food
compani
readytoeat
cold
cut
sausag
use
wurstsalat
identifi
sourc
outbreak
food
item
serv
hospit
could
classifi
food
intend
special
medic
purpos
defin
commiss
would
includ
absenc
l
monocytogen
g
food
howev
special
food
consid
patient
sever
neutropenia
day
fact
none
patient
review
hospit
met
criterion
consequ
receiv
regular
food
stay
hospit
oct
texa
compani
b
recal
product
ship
sinc
jan
outbreakbegin
patient
five
fatal
shown
recent
eaten
hospit
set
food
environment
sampl
collect
hospit
strain
found
chicken
salad
made
prepackag
dice
celeri
trace
celeri
back
led
compani
b
cut
celeri
sold
restaur
institut
set
groceri
store
austria
total
popul
million
averag
one
three
citizen
stay
hospit
year
hospitaladmiss
mean
day
median
day
due
prevail
high
hygien
standard
hospit
kitchen
readytoeat
food
remain
residu
risk
everi
hospitalassoci
listeriosi
outbreak
seen
chanc
elucid
problem
gener
food
chain
vaccin
malaria
pregnant
women
vaccin
effici
prevent
infect
malaria
parasit
plasmodium
falciparum
unlik
becom
avail
near
futur
vaccin
prevent
diseas
feasibl
altern
approach
develop
goal
appear
achiev
particular
context
pregnancyassoci
malaria
evid
base
assert
rest
sever
interconnect
epidemiolog
parasitolog
immunolog
observ
epidemiolog
level
known
area
stabl
transmiss
malaria
primigravid
women
suscept
multigravida
infect
p
falciparum
patholog
consequ
latter
directli
relat
fact
parasiteinfect
erythrocyt
pfie
accumul
placenta
result
especi
primigravida
frequent
intens
monocyt
inflammatori
activ
multigravida
render
less
suscept
specif
immun
acquir
cours
earlier
pregnanc
immun
character
antibodybas
genderspecif
natur
respons
particular
parasitederiv
protein
antigen
express
surfac
pfie
protein
question
act
ligand
mediat
adhes
interact
pfie
placent
receptor
chondroitin
sulphat
csa
express
syncytiotrophoblast
antigen
refer
design
deriv
fact
encod
gene
var
famili
member
respons
product
protein
although
inde
polymorph
characterist
protein
display
compar
reduc
degre
variabl
latter
emphas
fact
antibodi
acquir
multigravida
live
given
distinct
geograph
region
inhibit
adher
csa
infect
erythrocyt
placenta
women
live
elsewher
detail
molecular
understand
process
involv
avail
thu
provid
foundat
ongo
effort
aim
develop
vaccin
vaccin
would
repres
extrem
valuabl
addit
tool
reduc
burden
diseas
mother
offspr
recommend
manag
chaga
diseas
pregnanc
control
congenit
infect
approxim
million
women
fertil
age
estim
chronic
infect
trypanosoma
cruzi
chaga
diseas
endem
area
latin
america
well
nonendem
area
latin
american
peopl
migrat
mainli
unit
state
canada
europ
australia
japan
main
impact
chronic
cruzi
infect
pregnanc
transmiss
parasit
foetus
occur
infect
pregnant
women
develop
congenit
chaga
diseas
detect
infect
pregnanc
perform
use
serolog
test
serolog
test
recommend
pregnant
women
live
diseas
endem
area
diseas
nonendem
area
born
live
previous
diseas
endem
area
whose
mother
born
area
way
identifi
advanc
infect
mother
transmit
infect
foetus
antiparasit
treatment
recommend
pregnanc
congenit
infect
prevent
present
intern
consensu
technic
group
control
congenit
chaga
diseas
recommend
detect
congenit
infect
newborn
infect
mother
treatment
posit
neonat
best
strategi
limit
shortterm
morbid
mortal
acut
congenit
infect
prevent
longterm
effect
chaga
diseas
detect
live
parasit
perform
microscop
examin
umbil
cord
neonat
venou
blood
microhematocrit
test
parasitolog
test
eg
hemocultur
pcr
assay
detect
low
amount
cruzi
dna
standard
valid
still
develop
detect
igm
iga
antibodi
placent
histopatholog
contribut
diagnosi
case
neg
result
close
birth
detect
specif
antibodi
use
standard
serolog
assay
carri
month
birth
ie
antibodi
transfer
mother
elimin
posit
serolog
result
time
indic
infant
current
infect
case
congenit
cruzi
infect
treat
benznidazol
nifurtimox
soon
diagnosi
confirm
treatment
gener
success
without
advers
reaction
seen
adult
administ
within
first
year
life
colistin
use
clinic
practic
colistin
pkpd
lesson
recent
studi
abandon
mani
year
suspect
nephrotox
colistin
increasingli
use
last
line
defenc
mdr
gramneg
pathogen
colistin
compos
least
differ
polymyxin
compound
mainli
colistin
b
administ
intraven
nebulis
complex
mix
colistin
methanesulfon
cm
deriv
therefor
pharmacokinet
rel
complex
could
investig
specif
analyt
assay
becam
avail
yet
major
studi
recent
conduct
colistin
pharmacokinet
nowaday
mostli
understood
demonstr
healthi
volunt
inact
cm
dose
lost
direct
excret
urin
accordingli
observ
patient
rel
well
preserv
renal
function
treat
usual
mainten
dose
steadyst
plasma
concentr
colistin
could
hardli
reach
valu
greater
lgml
also
observ
colistin
concentr
virtual
constant
two
consecut
administr
steadyst
real
peak
trough
valu
furthermor
colistin
concentr
increas
slowli
treatment
initi
take
day
reach
steadyst
suggest
need
load
dose
data
confirm
studi
conduct
greater
number
critic
care
patient
includ
hemodialysi
continu
renal
replac
shown
cm
load
dose
could
adjust
bodi
weight
mainten
dose
creatinin
clearanc
howev
also
conclud
colistin
may
best
use
part
highli
activ
combin
especi
patient
moder
good
renal
function
creatinin
clearanc
mlmin
andor
organ
mic
lgl
new
data
open
perspect
term
colistin
therapeut
drug
monitor
also
suggest
altern
rout
administr
nebulis
could
serious
consid
colistin
reintroduc
clinic
practic
treatment
carbapenemresist
gramneg
bacteria
necess
studi
last
decad
attempt
reconstruct
path
presentday
medic
undergo
prior
clinic
use
median
halflif
activ
colistin
hour
criticallyil
patient
normal
renal
function
pharmacokineticpharmacodynam
studi
show
dose
higher
convent
use
europ
need
load
dose
amount
total
daili
dose
recommend
criticallyil
patient
colistimeth
sodium
produg
colistin
effici
remov
hemodialysi
daili
dose
million
intern
unit
miu
recommend
patient
undergo
continu
hemofiltr
miu
intermitt
hemodialysi
cerebrospinalfluid
csf
serum
ratio
colistin
intrathec
dose
iuday
need
reach
trough
concentr
mg
l
csf
colistin
associ
lower
mortal
effect
treatment
higher
unadjust
mortal
betalactam
nonrandom
compar
clinic
studi
two
studi
compar
colistin
inappropri
antibiot
treatment
show
lower
mortal
colistin
pool
odd
ratio
ci
prospect
studi
match
retrospect
studi
n
show
pool
death
confid
interv
indic
significantli
higher
mortal
colistin
four
nonmatch
retrospect
studi
report
pool
death
ci
howev
studi
colistin
administ
sicker
patient
carabapenemresist
bacteria
overal
nephrotox
rate
higher
colistin
studi
compar
colistin
antiobiot
colistininduc
nephrotox
revers
patient
emerg
colistin
resist
describ
high
use
set
synergi
carbapenem
rifampin
antibiot
report
invitro
random
control
trial
ongo
plan
assess
aspect
colistin
use
clinic
practic
pathogenesi
treatment
recurr
clostridium
difficil
infect
cdi
clostridium
difficil
symbiot
gut
microbiota
c
rousseau
p
lepag
collignon
bondi
jouyenjosa
fr
clostridium
difficil
major
enter
pathogen
respons
antibioticassoci
diarrhoea
pseudomembran
coliti
larg
spectrum
antibiot
major
risk
factor
c
difficil
infect
cdi
lead
intestin
dysbiosi
disrupt
microbiota
barrier
effect
c
difficil
multipli
colon
intestin
tract
molecular
method
base
rdna
metagenom
given
new
insight
composit
intestin
microbiota
three
major
phyla
compos
adult
intestin
microbiota
bacteroidet
firmicut
clostridium
leptumclostridium
coccoid
actinobacteria
human
gut
microbiota
speci
level
sever
speci
howev
share
least
healthi
human
popul
constitut
phylogenet
core
bacteri
composit
human
microbiota
vari
greatli
accord
age
sever
studi
profil
microbiota
infant
adult
elderli
colon
c
difficil
loss
colon
resist
c
difficil
associ
qualit
quantit
chang
microbiota
asymptomat
infant
colon
c
difficil
adult
cdi
speci
divers
intestin
microbiota
affect
presenc
c
difficil
contrast
microbiota
adult
recurr
cdi
present
signific
biodivers
decreas
patient
multipl
recurr
cdi
mark
reduct
bacteroid
c
coccoid
c
leptum
group
increas
enterobacteriacea
veillonella
spp
young
healthi
infant
c
difficil
colon
associ
chang
intestin
microbiota
ecosystem
bifidobacterium
longum
associ
faecal
microbiota
c
difficil
noncolon
infant
colon
infant
present
frequent
ruminococcu
gnavu
klebsiella
pneumonia
speci
microbiota
elderli
patient
cdi
character
reduc
number
bacteroid
bifidobacteria
greater
divers
facult
speci
lactobacilli
clostridia
bacteri
signatur
associ
absenc
c
difficil
colon
provid
inform
bacteri
group
involv
barrier
effect
c
difficil
data
pave
way
defin
therapeut
approach
microbiota
modul
antic
difficil
object
febril
neutropenia
past
present
futur
febril
neutropenia
shortli
thing
past
intens
myelosuppress
chemotherapi
introduc
manag
acut
leukaemia
enabl
substanti
rate
longterm
complet
remiss
surviv
infect
emerg
bone
marrow
aplasia
becam
predomin
caus
death
risk
sever
infect
directli
correspond
durat
profound
neutropenia
past
decad
antineoplast
treatment
strategi
elabor
base
upon
pathogen
molecular
mechan
design
target
therapi
small
molecul
epigenet
strategi
instanc
toxic
convent
chemotherapi
includ
myelosuppress
becom
less
burdensom
one
major
advanc
treatment
acut
myeloid
leukaemia
myelodysplast
particularli
elderli
patient
introduct
demethyl
agent
provid
treatment
modal
aim
dna
repair
malign
myeloid
precursor
cell
instead
cytotox
erad
associ
transient
profound
critic
longlast
marrow
aplasia
remark
effect
approach
enabl
antileukaem
therapi
also
fragil
comorbid
patient
formerli
exclud
myelosuppress
treatment
modal
howev
sinc
malign
clone
erad
treatment
indefinit
typic
result
emerg
resist
clinic
relaps
although
nonmyeloabl
treatment
modal
includ
histon
deacetylas
inhibitor
multityrosin
kinas
inhibitor
develop
also
leukaemia
treatment
recent
year
approach
substitut
classic
myelabl
chemotherapi
treatment
acut
leukaemia
fiction
option
avoid
febril
neutropenia
could
agent
protect
physiolog
haematopoiesi
antineoplast
drug
toxic
cytokin
stimul
haematopoiet
precursor
cell
much
earlier
effect
gcsf
optim
infect
prevent
howev
none
field
substanti
progress
achiev
past
two
decad
therefor
febril
neutropenia
remain
one
predomin
clinic
problem
cours
myelosuppress
antineoplast
treatment
mainli
manag
acut
leukaemia
myelodysplast
syndrom
allogen
haematopoiet
stem
cell
transplant
laboratori
clinic
diagnosi
manag
infect
due
intracellular
fastidi
bacteria
whippl
diseas
primari
infect
late
clinic
manifest
g
greub
lausann
ch
whippl
diseas
alreadi
describ
g
whippl
howev
etiolog
agent
tropheryma
whipplei
identifi
kh
wilson
cultiv
raoult
last
year
whippl
diseas
consid
rare
chronic
diseas
although
abdomin
involv
malabsopt
diarrhea
andor
weight
loss
repres
classic
form
chronic
whippl
diseas
neurolog
involv
arthriti
endocard
uveiti
may
also
occur
alon
combin
recent
acut
whippl
diseas
without
bacteremia
document
among
patient
gastroenter
lower
respiratori
tract
infect
symptomat
primoinfect
also
name
earlyonset
whippl
diseas
appear
much
common
lateonset
manifest
support
hypothesi
evolut
chronic
form
diseas
ii
healthi
carriag
iii
spontan
recoveri
might
least
partial
genet
determin
thu
import
summar
recent
knowledg
review
current
knowledg
epidemiolog
clinic
present
diagnost
approach
treatment
pathogenesi
whippl
diseas
basi
tuberculosi
diagnosi
manag
case
host
immun
respons
tuberculosi
j
friedland
london
uk
caseat
granuloma
recognis
hallmark
tissu
respons
infect
mycobacterium
tuberculosi
also
clear
immun
respons
infect
gener
excel
sinc
billion
infect
peopl
worldwid
activ
diseas
howev
patient
activ
infect
widespread
inflammatori
tissu
destruct
talk
focu
role
innat
immun
system
host
defenc
patholog
tuberculosi
princip
innat
inflammatori
cell
involv
host
defenc
phagocyt
cell
macrophag
lineag
includ
multinucl
giant
cell
other
includ
stromal
cell
neutrophil
nk
cell
key
import
innat
immun
respons
act
seri
pattern
recognit
receptor
orchestr
host
respons
secret
rang
mediat
cytokin
chemokin
innat
immun
target
pathogen
secret
molecul
cathelicidin
defensin
addit
upregul
gene
express
secret
matrix
metalloproteinas
enzym
critic
destruct
host
tissu
prerequisit
spread
infect
hallmark
sever
infect
lead
morbid
mortal
innat
immun
function
influenc
physiolog
metabol
environ
talk
divers
aspect
innat
immun
discuss
potenti
novel
applic
immun
modul
improv
patient
outcom
examin
biocid
nosocomi
pathogen
resist
mechan
antisept
effect
use
biocid
crucial
prevent
infect
particularli
light
emerg
spread
highli
antibiot
resist
pathogen
biocid
increasingli
use
number
applic
concern
rais
biocid
exposur
might
act
select
forc
develop
biocid
resist
mutant
may
cross
resist
antibiot
laboratori
studi
consequ
exposur
bacteria
variou
biocid
term
surviv
develop
antibiot
resist
assess
exposur
use
concentr
biocid
suboptim
exposur
determin
abil
strain
surviv
characteris
surviv
mutant
use
combin
flow
cytometri
phenotyp
characteris
transcriptom
genom
analysi
virul
assay
found
bacteria
surviv
high
level
biocid
exposur
surviv
mutant
demonstr
lowlevel
multipl
antibiot
resist
phenotyp
mediat
derepress
multidrug
efflux
similarli
biocid
exposur
result
select
multidrug
efflux
mutant
howev
propens
select
antibiot
resist
mutant
vari
differ
biocid
evalu
true
biocid
resist
rare
hard
achiev
biocid
must
use
appropri
line
recommend
dilut
ensur
success
potenti
develop
antibiot
resist
consid
develop
novel
biocid
formul
biocid
resist
infect
control
biocid
substanc
use
disinfect
antisept
play
import
role
prevent
healthcar
associ
infect
prevent
spread
antibiot
resist
bacteria
appropri
disinfect
antisepsi
advis
correspond
guidelin
question
rais
whether
repeat
continu
use
biocid
substanc
lead
promot
biocid
resist
even
antibiot
resist
assess
avail
data
resist
crucial
use
appropri
definit
antibiot
resist
usual
defin
minimum
inhibitori
concentr
level
reach
affect
human
tissu
biocid
resist
defin
significantli
increas
biocid
concentr
need
pass
accept
disinfect
test
standard
use
subleth
biocid
concentr
lead
phenotyp
adapt
microb
differ
resist
hereditari
also
select
unspecif
resist
mechan
confer
cross
resist
antibiot
observ
biocid
use
microbicid
concentr
sever
studi
clinic
isol
infect
patient
demonstr
resist
biocid
substanc
use
set
antibiot
target
specif
microbi
structur
metabol
process
biocid
broad
unspecif
mechan
action
target
site
conclud
appropri
use
disinfect
antisept
infect
prevent
use
concentr
defin
test
accord
accept
standard
bear
relev
risk
develop
biocid
resist
promot
antibiot
resist
laboratori
clinic
diagnosi
manag
infect
due
intracellular
fastidi
bacteria
antimicrobi
resist
centuri
gramneg
enterobacteriacea
strike
back
abc
multidrugresist
enterobacteriacea
ctxm
cmi
kpc
ndm
oxa
j
pitout
calgari
ca
enterobacteriacea
among
import
caus
seriou
nosocomi
communityonset
bacteri
infect
human
resist
antimicrobi
agent
speci
becom
increasingli
relev
problem
health
care
provid
variou
member
betalactam
antibiot
remain
import
drug
often
use
treat
seriou
infect
caus
enterobacteriacea
betalactamas
product
remain
import
contribut
factor
betalactam
resist
among
enterobacteriacea
betalactamas
often
refer
newer
betalactamas
activ
gener
cephalosporin
describ
escal
sinc
mid
newer
betalactamas
consist
follow
plasmidmedi
ampc
betalactamas
eg
cmi
type
extendedspectrum
betalactamas
eg
ctxmtype
carbapenemas
eg
kpc
type
metallobetalactamas
eg
vim
imp
ndm
oxacillinas
eg
present
give
brief
overview
use
clinic
exampl
import
laboratori
detect
enterobacteriacea
produc
newer
betalactamas
molecular
epidemiolog
multidrugresist
enterobacteriacea
molecular
character
multiresist
enterobacteriacea
requir
two
insepar
entiti
consid
resist
bacteria
resist
determin
bacteria
character
compar
myriad
phenotyp
genotyp
method
one
may
choos
method
suitabl
finefocus
local
outbreak
investig
other
give
panoram
perspect
popul
structur
background
resist
isol
strain
clone
one
must
consid
complex
gene
integron
transposon
plasmid
confer
resist
fundament
unit
resist
spread
bacteri
popul
vertic
associ
success
strain
lineag
horizont
strain
speci
genera
appli
epidemiolog
aspect
molecular
investig
addit
requir
us
factor
whether
resist
bacteria
isol
human
hospit
nurs
home
commun
set
anim
food
product
companion
wild
foodstuff
environment
sampl
ideal
includ
denomin
demograph
tempor
geograph
data
depth
investig
ultim
depend
goal
resourc
avail
natur
multiresist
enterobacteriacea
highli
complex
involv
spread
repeat
select
success
clonal
lineag
horizont
spread
resist
plasmid
local
investig
use
guid
infect
control
maximum
inform
obtain
set
nation
intern
context
current
wellcoordin
global
network
seek
address
issu
clinic
issu
infect
due
multidrugresist
enterobacteriacea
control
usual
confound
multidrugresist
mdr
bacteria
associ
wors
outcom
may
due
reason
combin
increas
virul
rare
prove
delay
appropri
therapi
probabl
prescrib
inappropri
empir
antimicrobi
therapi
increas
diminish
efficaci
increas
toxic
avail
secondlin
drug
case
enterobacteriacea
invas
infect
caus
esblproduc
shown
associ
increas
mortal
may
assum
effect
similar
isol
produc
mechan
resist
infect
caus
mdre
occur
frequent
predispos
patient
underli
diseas
admit
healthcar
centr
undergon
invas
procedur
recent
receiv
antimicrobi
treatment
may
also
happen
increasingli
healthi
patient
communityacquir
infect
thu
front
patient
seriou
infect
clinician
frequent
need
decid
empir
use
broad
spectrum
antimicrobi
even
secondlin
drug
cover
mdre
reserv
order
avoid
spread
resist
sever
clue
may
help
decis
makingprocess
first
pretest
probabl
may
estim
base
local
preval
antibiot
resist
second
evalu
individu
risk
factor
mdre
may
help
identifi
patient
lower
higher
risk
infect
caus
organ
posttest
probabl
third
care
assess
sever
acut
diseas
system
inflammatori
respons
syndrom
would
help
identifi
patient
appropri
empir
therapi
absolut
prioriti
absenc
randomis
clinic
trial
decis
empir
therapi
deescal
strategi
use
altern
agent
differ
situat
need
base
deep
knowledg
avail
microbiolog
data
pkpd
model
clinic
studi
follow
manag
acut
infect
centuri
demand
certain
degre
superspecialis
perform
adequ
time
clinic
workup
correctli
identifi
potenti
sourc
infect
sever
specif
determin
modifi
potenti
risk
aetiolog
antimicrobi
suscept
decis
antimicrobi
therapi
optimis
new
dawn
natur
product
antimicrobi
drug
discoveri
thiomarinol
complex
molecul
produc
marin
bacteria
appear
amid
form
condens
marinol
acid
similar
antimrsa
antibiot
mupirocin
also
known
pseudomon
acid
except
possess
acid
instead
acid
pyrrothin
similar
holomycin
understand
antibiot
made
provid
genet
inform
construct
hybrid
pathway
analys
thiomarinol
biosynthet
gene
use
underpin
analysi
pathway
mupirocin
cluster
thiomarinol
cluster
encod
isoleucyltrna
synthetas
known
target
mupirocin
clone
resist
gene
mup
tml
cluster
e
coli
show
tmlm
protein
confer
complet
resist
thiomarinol
mupm
confer
resist
mupirocin
target
gene
knockout
allow
deriv
strain
produc
pyrrothin
marinol
acid
marinol
acid
pyrrothin
compon
separ
product
thiomarinol
mutant
unabl
produc
marinol
acid
fed
mupirocin
shown
produc
novel
analogu
thiomarinol
abl
inhibit
growth
mupirocinresist
mrsa
tmlu
gene
respons
join
marinol
acid
pyrrothin
togeth
product
thiomarinol
surprisingli
introduc
mupirocin
produc
tmlu
appear
interfer
elong
hydroxynonano
acid
compon
also
test
whether
amid
synthetas
relat
tmlu
substitut
reaction
thu
allow
larger
number
divers
substrat
use
also
manipul
express
gene
mupirocin
cluster
order
increas
product
without
accumul
side
product
pseudomon
acid
b
fukuda
hain
song
z
murphi
hothersal
j
stephen
er
cox
r
crosbi
j
willi
c
simpson
tj
thoma
cm
natur
plasmid
uniqu
encod
two
antibiot
pathway
creat
potent
hybrid
plo
one
murphi
c
fukuda
song
z
hothersal
j
cox
rj
willi
cl
thoma
cm
simpson
tj
novel
thiomarinol
antibiot
activ
mrsa
gener
mutagenesi
mutasynthesi
pseudoalteromona
angewandt
chemi
intern
edit
deepest
ocean
l
gram
lyngbi
dk
ocean
environ
cover
planet
make
biospher
marin
environ
home
multitud
life
form
exist
differ
condit
pressur
low
temperatur
salin
condit
believ
secondari
metabolit
produc
marin
organ
hold
great
potenti
novel
compound
biotech
industri
isol
approximatli
antibacteri
bacteria
global
research
cruis
purpos
purifi
identifi
novel
small
molecul
antibacteri
activ
bacteria
belong
roseobact
clade
vibrionacea
famili
pseudoalteromona
genu
isol
sever
antibiot
pentabromopseudilin
andrimid
tropodithiet
acid
found
marin
bacteria
also
isol
sever
antibiot
holomycin
indolmycin
known
antibiot
hithero
isol
terrestri
streptomycet
fact
predominantli
found
alreadi
known
antibiot
could
use
growth
condit
mani
previou
studi
genom
sequenc
one
pseudoalteromona
strain
two
antibiot
isol
reveal
least
seven
pksnrp
gene
found
henc
manipul
cultur
condit
express
host
may
induc
express
hithero
silent
gene
code
bioactiv
metabolit
certainli
cultur
one
antibiot
produc
vibrionacea
substrat
mimick
natur
condit
contain
exclus
chitin
cand
nsourc
led
dramat
alter
secondari
metabolit
profil
natur
growth
condit
antibiot
becam
almost
metabolit
produc
strain
vibrionacea
also
produc
compound
socal
solonamid
antibacteri
per
se
specif
inhibit
quorum
sens
system
staphylococcu
aureu
like
via
bind
agr
also
quorum
sens
system
pseudomona
aeruginosa
inhibit
yet
unidentifi
compound
produc
roseobact
clade
strain
whilst
known
roseobact
clade
bacteria
pseudoalteromona
speci
produc
bioactiv
compound
vibrionacea
predominantli
research
due
role
pathogen
symbiot
bacteria
work
demonstr
bacteri
group
like
also
harbour
organ
biotechnolog
interest
multidrugresist
mdr
strain
bacteria
continu
provid
consider
challeng
clinician
face
deceas
arsen
antibiot
mani
analogu
compound
resist
alreadi
arisen
mdr
strain
mycobacterium
tuberculosi
gramposit
pathogen
aureu
clostridium
difficil
intrinsicallyresist
gramneg
bacteria
salmonella
enterica
pseudomona
aeruginosa
requir
develop
new
class
antibacteri
opaqu
efflux
altern
strategi
reduc
mdr
phenotyp
exampl
use
efflux
pump
inhibitor
epi
plant
untap
sourc
antibacteri
chemotyp
present
exampl
phytochem
use
clinic
unusu
given
wide
use
plant
materi
tradit
system
medicin
mani
commun
develop
world
resourc
avail
treatment
topic
even
system
infect
studi
plant
use
medicin
antibacteri
resist
modifi
properti
isol
number
compound
display
potenti
garlic
natur
product
display
mic
valu
mgl
tuberculosi
aureu
respect
collabor
also
investig
abil
plantderiv
compound
natur
product
three
inhibit
multidrug
efflux
dual
antibacteri
epi
activ
lectur
cover
need
antibacteri
resistancemodifi
agent
propos
plant
natur
product
use
sourc
molecul
exampl
work
date
influenc
directli
act
antivir
current
treatment
regimen
hepat
c
hepat
c
viru
entri
molecular
mechan
clinic
implic
tf
baumert
strasbourg
fr
hepat
c
viru
hcv
major
caus
liver
cirrhosi
hepatocellular
carcinoma
worldwid
develop
effici
strategi
prevent
treatment
hcv
infect
hamper
rapid
develop
viral
resist
escap
viral
entri
target
cell
promis
target
antivir
prevent
therapeut
strategi
sinc
essenti
initi
spread
mainten
infect
inde
crossneutr
antibodi
inhibit
hcv
entri
shown
associ
control
hcv
infect
prevent
hcv
reinfect
cohort
selflimit
acut
infect
hcv
entri
multistep
process
involv
sever
host
factor
includ
heparan
sulfat
scaveng
receptor
occludin
use
function
genomewid
rnai
kinas
screen
recent
identifi
network
receptor
tyrosin
kinas
rtk
hcv
entri
factor
function
studi
indic
kinas
act
postbind
step
interf
coreceptor
associ
membran
fusion
use
infecti
cell
cultur
model
demonstr
target
host
entri
factor
receptorspecif
monoclon
antibodi
inhibit
rtk
approv
protein
kinas
inhibitor
block
entri
infect
hcv
genotyp
includ
viral
escap
variant
resist
autolog
host
immun
respons
result
suggest
target
host
entri
factor
use
receptorspecif
monoclon
antibodi
small
molecul
constitut
novel
antivir
approach
prevent
primari
hcv
infect
liver
transplant
may
also
restrain
viru
spread
chronic
infect
patient
clinic
challeng
communityacquir
pneumonia
deal
non
respond
j
lisbon
pt
assess
non
respond
although
commun
acquir
pneumonia
cap
diagnosi
may
straightforward
criteria
commonli
use
physic
examin
chest
radiographi
high
sensibl
low
specif
furthermor
microbiolog
document
may
possibl
especi
viral
infect
result
usual
avail
hour
present
evalu
respons
antibiot
may
even
problemat
reli
normal
unspecif
criteria
previous
use
non
respons
mostli
defin
subject
criteria
like
clinic
deterior
within
hour
lack
respons
worsen
clinic
radiolog
statu
persist
fever
clinic
symptom
malais
cough
expector
dyspnoea
pattern
creactiv
protein
kinet
cap
name
failur
decreas
concentr
also
associ
non
respons
non
respons
antibiot
may
simpli
unveil
wrong
diagnosi
howev
presenc
true
cap
differ
factor
relat
host
bacteria
antibiot
may
lead
therapeut
failur
host
bacteria
antibiot
host
age
comorbid
condit
genet
polymorph
name
toll
like
gene
tumor
necrosi
factor
bacteria
caus
health
care
relat
cap
especi
pseudomona
implic
slow
respons
cap
may
mimic
non
respons
common
caus
antibiot
failur
bacteria
resist
antibiot
presenc
suppur
complic
empyema
abscess
final
polymicrobi
cap
includ
viral
bacteri
coinfect
usual
sever
often
associ
therapeut
failur
mortal
complianc
antibiot
therapi
especi
outpati
set
anoth
caus
non
respons
alway
exclud
antibiot
may
also
fail
achiev
adequ
concentr
especi
lung
tissu
consequ
pharmacokinet
chang
host
sepsi
moreov
adequ
infect
control
may
requir
larger
antibiot
exposur
although
antibiot
therapi
utmost
import
especi
sever
cap
adequ
antibiot
therapi
alon
even
use
optim
probabl
suffici
reduc
associ
mortal
therefor
interest
nonantibiot
adjunct
therapi
continu
grow
howev
singl
drug
proven
benefici
patient
cap
myocard
inflammatori
heart
diseas
usual
caus
infecti
agent
europ
north
america
common
caus
myocard
viral
agent
patient
acut
myocard
present
rang
symptomatolog
asymptomat
cours
sever
manifest
lead
intens
care
therapi
howev
diagnosi
myocard
base
histolog
thank
endomyocardi
biopsi
possibl
identifi
viral
genom
use
molecular
biolog
techniqu
pcr
situ
hybrid
moreov
idiopath
dilat
cardiomyopathi
underli
caus
around
patient
heart
failur
associ
myocard
incid
biopsydiagnos
myocard
patient
unexplain
congest
heart
failur
reach
two
third
case
long
time
enterovirus
consid
common
caus
acut
viral
myocard
possibl
transit
acut
myocard
dilat
cardiomyopathi
recent
investig
shown
howev
virus
also
frequent
encount
acut
myocard
patient
suggest
persist
variou
viru
speci
may
play
pathogen
role
transit
acut
myocard
dilat
cardiomyopathi
thank
extend
use
endomyocardi
biopsi
diagnosi
myocard
new
viral
agent
new
mechan
damag
detect
enteroviru
parvoviru
cytomegaloviru
eb
viru
genom
identifi
myocard
mechan
damag
character
exampl
acut
myocard
caus
enteroviru
sever
mechan
myocyt
damag
actual
recogn
includ
induct
inflammatori
reaction
infecti
agent
ii
releas
destruct
proteas
host
iii
activ
intracellular
apoptot
pathway
complex
process
determin
viral
infect
chang
entir
heart
anatom
function
structur
lead
activ
adapt
mechan
known
heart
remodel
involv
heart
dilat
ventricular
dysfunct
patient
congest
heart
failur
therapeut
approach
infecti
myocard
myocard
defin
inflamm
heart
induc
either
inflammatori
process
directli
infect
among
therapeut
mean
distinguish
non
specif
specif
goal
mrscan
could
help
greatli
diagnos
quickli
acut
myocard
could
help
chose
appropri
treatment
nevertheless
could
assess
particular
infect
emb
remain
goldstandard
even
scarc
perform
specif
treatment
recommend
prove
cardiac
infect
theoric
case
posit
endomyocardialbiopsi
emb
among
numer
infecti
agent
specif
treatment
avail
bacteri
infect
case
sever
sepsi
lyme
tuberculosi
parasit
chaga
diseas
toxoplasmosi
mainli
case
viral
infect
coxsackiesvirus
cmv
ebv
immunomodul
could
endli
offer
new
possibl
treatment
cytokin
modul
could
help
redirect
wrong
immunolog
answer
interferon
could
help
sever
situat
illustr
import
immunomodul
new
medic
hypothes
actual
explor
arrhythmia
possibl
specif
action
non
specif
treatment
even
interest
cardiac
frequenc
non
specif
treatment
aim
improv
cardiac
physiolog
cei
arb
betablock
case
sever
left
ventricular
dysfunct
spironolacton
also
possibl
diuret
often
necessari
symptom
relief
treatment
probabl
also
involv
therapeut
way
especi
antiinflammatori
effect
cei
arb
mainli
recent
french
registri
betablock
seem
lower
mortal
antiinflammatori
treatment
aspirin
colchicin
often
propos
decreas
system
cardiac
inflamm
point
remain
controversi
method
chifnet
first
nationwid
invas
fungal
infect
surveil
studi
china
cover
tertiari
hospit
nine
provinc
import
note
yeast
isol
blood
steril
bodi
site
collect
isol
identifi
amplif
sequenc
intern
transcrib
region
antifung
suscept
test
fluconazol
flc
voriconazol
voc
perform
use
disk
diffus
method
accord
clsi
document
result
overal
total
yeast
isol
collect
assign
speci
candida
speci
account
follow
cryptococcu
speci
trichosporon
speci
within
candida
genu
c
albican
predomin
follow
c
parapsilosi
c
tropicali
c
glabrata
c
metapsilosi
c
krusei
c
guilliermondii
candida
spp
first
three
predomin
specimen
type
blood
sampl
drainag
fluid
cerebrospin
fluid
csf
yeast
isol
blood
assign
c
parapsilosi
previous
report
closelyrel
catheterrel
candidemia
yeast
isol
csf
cryptococcu
speci
commonest
result
antifung
suscept
test
flc
voc
reveal
c
albican
c
parapsilosi
highli
suscept
nonsuscept
rate
although
higher
rate
c
tropicali
isol
seven
isol
resist
flc
voc
six
resist
isol
found
hospit
thu
potenti
outbreak
hospit
consid
comparison
c
glabrata
show
much
lower
suscept
flc
voc
suscept
rate
respect
lesscommon
yeast
speci
eg
c
quercitrusa
pichia
anomala
yarrowia
lipolytica
also
shown
high
resist
azol
like
relat
bloodstream
infect
conclus
result
chifnet
provid
distinct
evid
sustain
activ
fluconazol
voriconazol
broad
rang
yeast
speci
speci
identif
molecular
method
made
result
credit
r
maini
k
henderson
lamagni
g
nichol
n
phin
v
delpech
e
sheridan
colindal
uk
object
anecdot
report
suggest
incid
pneumocysti
jirovecii
pneumonia
may
increas
studi
undertaken
describ
epidemiolog
pneumocysti
pneumonia
england
use
number
data
sourc
method
microbiolog
diagnos
extract
health
protect
agenc
routin
laboratori
surveil
system
clinic
code
use
extract
pneumocysti
pneumonia
data
nh
inform
centr
hospit
episod
statist
he
offic
nation
statist
on
death
certif
data
dataset
individu
analys
trend
time
crosscompar
hiv
surveil
data
use
analys
occurr
pneumocysti
pneumonia
among
new
diagnos
hiv
conclus
data
numer
sourc
suggest
increas
diagnosi
p
pneumonia
primarili
among
nonhiv
infect
person
caus
increas
may
multifactori
aetiolog
recent
chang
microbiolog
method
use
detect
p
jirovecii
last
year
occur
mani
laboratori
switch
immunofluoresc
pcr
method
organ
detect
investig
impact
chang
diagnost
method
requir
observ
increas
incid
pneumocysti
pneumonia
renal
transplant
recipi
indic
investig
rang
potenti
risk
group
warrant
evalu
fungicid
activ
micafungin
flow
cytometri
ap
silva
fariaramo
costadeoliveira
c
pinavaz
ag
rodrigu
porto
pt
object
candida
spp
respons
sever
infect
contribut
increas
morbid
mortal
particularli
immunocompromis
patient
micafungin
recent
fungicid
drug
inhibit
synthetas
standard
suscept
test
time
consum
give
result
hour
propos
new
approach
micafungin
suscept
evalu
base
upon
flow
cytometr
assess
method
candida
spp
suscept
n
resist
n
strain
micafungin
accord
clsi
protocol
assay
yeast
cell
incub
sever
concentr
micafungin
object
multidrugresist
organ
includ
extendedspectrum
betalactamas
esbl
produc
enterobacteriacea
rapidli
emerg
worldwid
contact
isol
recommend
author
limit
spread
esblhowev
rate
transmiss
without
contact
isol
nonepidem
set
unknown
addit
major
esbl
case
communityacquir
like
commonli
esbl
contamin
food
therefor
aim
determin
rate
spread
esblproduc
enterobacteriacea
tertiari
carecentr
five
icu
elevenyear
studi
period
use
standard
precaut
without
contact
isol
figur
evid
infect
two
patient
esblproduc
klebsiella
pneumonia
e
coli
therefor
detect
interpret
colon
conclus
estim
rate
spread
esblproduc
enterobacteriacea
low
tertiari
care
univers
affili
hospit
high
level
standard
hygien
precaut
low
level
nosocomi
transmiss
rapid
emerg
communityacquir
esbl
like
contamin
meat
veget
challeng
recommend
routin
use
contact
isol
nonepidem
set
prevent
spread
longer
use
patient
care
overflow
hole
becam
appar
outbreak
icu
item
list
made
outbreak
icu
anoth
icu
respect
patient
care
water
use
type
water
suppli
sewag
wast
dispos
remov
strap
chang
two
sink
disconnect
new
patient
identifi
sink
remain
posit
despit
strict
separ
clean
wastewat
wet
dri
area
reinforc
isol
measur
clean
protocol
closur
unit
juli
august
extens
clean
unit
sink
sewag
tube
ekp
posit
patient
identifi
hand
sink
remain
posit
conclus
sink
serv
environment
sourc
ekp
may
remain
contamin
mani
year
outbreak
low
fluctuat
incid
due
extern
sourc
remain
undetect
long
period
continu
fingerprint
clinic
isol
lead
earli
detect
updat
drug
develop
antibacteri
global
public
health
concern
intensifi
medic
scienc
busi
fail
cope
indisput
spread
pandem
multidrug
resist
mdr
pathogen
spread
known
well
continu
emerg
resist
mechan
fewer
fewer
effect
clinic
treatment
option
remain
physician
often
find
without
viabl
treatment
option
near
absenc
antimicrobi
relat
invest
larg
small
pharmaceut
compani
mean
critic
pauciti
novel
antibiot
use
treat
infect
mdr
pathogen
continu
mani
year
pharmaceut
pipelin
bare
trickl
call
altern
busi
fund
model
intensifi
action
plan
recent
introduc
european
commiss
along
joint
intern
activ
hope
prime
antibacteri
pipelin
howev
action
plan
bear
fruit
sever
new
antibacteri
drug
base
known
class
antibiot
may
becom
avail
next
year
show
benefit
new
analog
partial
address
clinic
crisi
mdr
pathogen
talk
look
deepli
new
antibiot
affect
clinic
treatment
option
next
year
critic
time
point
cours
antibiot
treatment
import
earli
antifung
therapi
durat
b
barsic
zagreb
hr
fact
earli
antimicrobi
therapi
crucial
success
diseas
outcom
known
sinc
introduct
antibiot
clinic
medicin
univers
goal
start
appropri
treatment
soon
possibl
logic
fact
also
valid
patient
invas
fungal
infect
ifi
problem
ifi
often
easili
recognis
suspect
patient
risk
prospect
random
studi
lack
retrospect
studi
use
differ
criteria
time
although
major
defin
time
period
cultur
sampl
start
appropri
treatment
despit
result
uniformli
show
delay
associ
poorer
outcom
patient
candidemia
import
time
assess
analyz
time
period
time
posit
blood
cultur
drawn
start
aft
delay
treatment
hour
increas
hospit
mortal
fold
neg
impact
delay
diagnosi
consequ
aft
shown
patient
candidemia
blood
cultur
posit
would
almost
doubl
risk
patient
death
studi
hematolog
patient
invas
aspergillosi
zygomycosi
show
delay
appropri
antifung
therapi
aft
day
appear
first
symptom
almost
doubl
mortal
rate
neg
impact
treatment
delay
patient
outcom
urg
physician
start
aft
empir
highrisk
patient
clinic
suspect
ifi
empir
therapi
posit
new
diagnost
test
associ
imag
find
preemptiv
therapi
mostli
mould
infect
avoid
overtreat
new
expens
antifung
rapid
diagnost
test
necessari
background
renal
transplant
recipi
increas
risk
develop
invas
pneumococc
diseas
may
poor
respons
pneumococc
polysaccharid
vaccin
ppv
aim
studi
compar
antibodi
respons
sequenti
vaccin
schedul
ppv
sequenti
schedul
pneumococc
conjug
vaccin
follow
ppv
twelv
month
later
adult
renal
transplant
recipi
method
conduct
random
doubleblind
control
studi
evalu
quantit
serolog
respons
pneumococc
serotyp
use
isotypespecif
elisa
twofold
antibodi
respons
compar
baselin
determin
week
first
vaccin
second
vaccin
week
second
vaccin
respect
patient
fill
diari
vaccin
record
systemat
symptom
measur
oral
bodi
temperatur
determin
diamet
red
swell
inject
site
screen
patient
patient
random
patient
complet
studi
result
compar
baselin
eight
week
revaccin
ppv
significantli
higher
increas
antibodi
respons
serotyp
seen
ppvppv
group
group
vs
p
vs
p
respect
trend
toward
improv
respons
ppvppv
group
also
seen
serotyp
p
number
patient
seroconvers
serotyp
defin
minimum
titer
increas
serum
concentr
least
lgml
greater
ppvppv
group
group
significantli
greater
respons
seen
serotyp
p
signific
differ
percentag
patient
respond
least
one
serotyp
revaccin
ppv
detect
vs
ppv
ppv
p
conclus
although
higher
immun
respons
seen
ppv
ppv
group
signific
increas
antibodi
respons
seen
two
serotyp
antibodi
respons
polysaccharid
antistreptococcu
pneumonia
vaccin
relat
select
immunolog
paramet
patient
chronic
lymphocyt
leukaemia
e
grywalska
koronaglowniak
malm
j
rolinski
lublin
pl
object
aim
present
studi
investig
antibodi
respons
vaccin
pneumococc
polysaccharid
assess
relat
select
paramet
may
act
prognost
factor
vaccin
effect
chronic
lymphocyt
leukaemia
cll
patient
although
vaccin
streptococcu
pneumonia
recommend
immunocompromis
patient
protect
effect
predictor
respons
suffici
character
method
prospect
studi
includ
previous
untreat
patient
cll
individu
receiv
capsular
polysaccharid
pneumococc
vaccin
respons
vaccin
accord
manufactur
instruct
defin
increas
repeat
test
prevaccin
day
postvaccin
patient
antipneumococc
antibodi
concentr
pool
serotyp
determin
elisa
blood
sampl
collect
valu
peripher
blood
cell
count
paramet
immunoglobulin
iga
igm
igg
level
measur
use
standard
method
order
assess
lymphocyt
subpopul
peripher
blood
mononuclear
cell
separ
lymphocyt
separ
medium
stain
combin
relev
fluorescein
isothiocyan
fitc
phycoerythrin
pe
cychromelabel
monoclon
antibodi
analyz
use
flow
cytometri
method
result
lack
effect
observ
patient
mannwhitneyu
test
reveal
among
patient
respons
vaccin
statist
signific
higher
level
igg
p
igm
p
lower
absolut
count
p
p
p
p
p
nkt
p
high
p
cell
well
lower
ratio
p
moreov
case
vaccin
efficaci
note
median
time
elaps
cll
diagnosi
vaccin
significantli
shorter
p
analysi
use
decis
tree
method
show
patient
cell
percentag
higher
respons
vaccin
figur
strong
correl
percentag
cell
elaps
time
cll
diagnosi
r
p
conclus
vaccin
given
soon
diagnosi
cll
made
determin
postvaccin
antibodi
level
becom
standard
patient
cll
costeffect
adult
vaccin
pneumococc
conjug
vaccin
unit
kingdom
charo
v
barzey
lloyd
p
balmer
walton
oak
london
uk
object
pneumococc
diseas
pd
burden
remain
high
among
elderli
particular
among
consid
highrisk
pneumococc
infect
anticip
indirect
protect
paediatr
vaccin
pneumococc
conjug
vaccin
reduc
burden
pd
adult
time
howev
atrisk
group
age
year
individu
age
year
high
risk
pd
benefit
direct
protect
studi
object
assess
costeffect
vs
pneumococc
polysaccharid
vaccin
adult
vaccin
unit
kingdom
uk
method
dynam
cohort
model
develop
depict
lifetim
risk
associ
cost
pd
model
use
timedepend
serotyp
specif
pd
incid
rate
account
indirect
effect
infant
vaccin
estim
increment
benefit
adult
vaccin
diseas
case
estim
use
uk
incid
vaccin
effect
indirect
effect
vaccin
effect
base
data
children
adjust
age
risk
profil
assum
similar
level
effect
addit
six
serotyp
effect
base
analysi
health
protect
agenc
analysi
use
uk
nh
payer
perspect
therefor
direct
cost
outcom
includ
health
outcom
measur
term
qualityadjust
life
year
qali
cost
outcom
discount
annual
rate
assumpt
paramet
uncertainti
test
sensit
analys
result
estim
adult
vaccin
instead
costeffect
current
nh
list
price
despit
uncertainti
around
individu
paramet
sensit
analys
suggest
result
robust
adult
vaccin
would
costeffect
due
high
risk
pneumococc
infect
among
group
conclus
reason
assumpt
direct
protect
adult
vaccin
expect
costeffect
even
consid
potenti
herd
impact
use
infant
prompt
introduct
adult
vaccin
like
effici
use
nh
resourc
direct
adult
vaccin
reduc
remain
pd
burden
rapidli
object
deep
sternal
wound
infect
dswi
follow
cardiac
surgeri
occur
patient
frequent
attribut
staphylococcu
aureu
associ
increas
morbid
mortal
novel
vaccin
candid
contain
highli
conserv
aureu
surfac
protein
iron
surfac
determin
b
isdb
shown
immunogen
gener
welltoler
healthi
immunocompromis
subject
purpos
studi
evalu
efficaci
safeti
prevent
aureu
bactaeremia
andor
dswi
patient
undergo
cardiac
surgeri
method
groupsequenti
randomis
multicentr
doubleblind
placebocontrol
studi
evalu
immunogen
safeti
efficaci
singl
intramuscular
lg
dose
patient
year
old
schedul
undergo
full
median
sternotomi
within
day
vaccin
primari
efficaci
endpoint
prevent
aureu
bactaeremia
andor
dswi
includ
mediastin
postop
day
secondari
endpoint
invas
infect
surgicalsit
infect
caus
aureu
postop
day
eventdriven
studi
estim
total
enrol
base
number
subject
requir
accru
primari
efficaci
endpoint
three
interim
analys
includ
futil
assess
one
final
analysi
vaccin
efficaci
plan
result
recommend
independ
data
monitor
committe
sponsor
termin
studi
interim
analysi
n
subject
randomis
vaccin
base
efficaci
safeti
result
significantli
efficaci
placebo
prevent
either
primari
secondari
endpoint
associ
significantli
higher
incid
vaccinerel
injectionsit
advers
event
ae
vs
system
ae
vs
signific
differ
system
vaccinerel
ae
seriou
ae
margin
signific
increas
multiorgan
failur
vaccin
recipi
compar
placebo
group
rate
per
vs
p
signific
differ
allcaus
mortal
tabl
tabl
efficaci
safeti
summari
efficaci
safeti
data
trial
support
use
prevent
aureu
bactaeremia
andor
dswi
patient
undergo
cardiac
surgeri
utilis
median
sternotomi
object
pertussi
pt
incid
steadili
increas
unit
state
sinc
mortal
highest
children
month
age
younger
incid
pt
quadrupl
highest
among
younger
month
first
pt
vaccin
recommend
administr
children
month
age
us
vaccin
person
care
expos
infant
recommend
decreas
transmiss
therebi
incid
pt
atrisk
age
group
rural
hospit
opportun
avail
address
vaccin
statu
patient
mechan
administ
pneumococc
influenza
vaccin
avail
howev
assess
tool
mechan
avail
nurs
determin
appropri
administ
pt
vaccin
without
physician
order
increas
complianc
center
diseas
control
prevent
cdc
recommend
tool
develop
nurs
assess
patient
elig
pt
vaccin
order
vaccin
educ
session
tool
implement
matern
ward
juli
overal
object
studi
examin
impact
tool
rate
vaccin
pt
among
postpartum
women
method
number
dose
pt
vaccin
order
administ
record
monthli
januari
octob
number
dose
order
bill
use
surrog
marker
number
dose
administ
patient
comparison
preimplement
period
januari
june
made
postimplement
period
julyoctob
trend
note
number
admiss
matern
also
record
per
month
number
dose
per
admiss
calcul
statist
analysi
homogen
done
result
preimplement
period
dose
order
month
dosesmonth
postimplement
period
dose
order
month
dosesmonth
number
dose
per
admiss
preimplement
period
postimplement
period
one
number
dose
bill
order
analysi
indic
signific
increas
number
dose
order
bill
two
time
period
conclus
tool
significantli
increas
number
patient
vaccin
pt
rural
hospit
accord
cdc
guidelin
antipertussi
toxin
igg
antibodi
respons
decay
follow
primari
preschool
vaccin
acellular
pertussi
vaccin
uk
infant
children
use
modifi
oral
fluid
assay
background
immunis
pertussi
vaccin
confound
diagnost
assay
detect
antipertussi
toxin
pt
igg
seraor
fluid
case
week
histori
cough
absenc
uk
data
use
year
time
interv
result
consid
potenti
confound
sought
better
defin
interv
follow
infantschildren
postvaccin
use
antipt
igg
captur
elisa
assay
threshold
au
consid
indic
recent
infect
object
model
declin
titr
arbitrari
unit
au
estim
posit
predict
valu
ppv
assay
assist
interpret
result
ofserum
sampl
submit
diagnost
purpos
method
origin
assay
modifi
use
pt
commerci
sourc
antipt
monoclon
detect
antibodi
oral
fluid
swab
collect
month
interv
subject
follow
administr
dtap
primari
preschool
booster
psb
postprimari
analysi
swab
taken
day
follow
third
dose
well
date
third
dose
psb
analysi
shortli
dose
interv
ca
day
total
igg
also
measur
may
impact
assay
potenti
lower
au
titr
total
igg
low
mg
ml
result
result
avail
infant
postprimari
vaccin
sampl
taken
valid
titr
result
result
also
avail
total
postpsb
result
sampl
valid
titr
result
declin
titr
model
take
log
titr
perform
regress
analysi
time
primari
postthird
dose
relationship
show
reduct
doubl
time
postpsb
titr
reach
higher
reduct
slower
per
doubl
time
assum
preval
postprimari
data
show
high
ppv
day
postvaccin
postpsb
data
show
ppv
day
threshold
evid
reduc
titr
found
total
igg
low
mgml
conclus
model
postvaccin
titr
allow
calcul
ppv
assay
correct
low
total
igg
estim
preval
interpret
postvaccin
titr
express
ppv
work
determin
distribut
titr
threshold
assist
interpret
result
object
group
b
streptococc
gb
infect
lead
caus
bacteri
infect
pregnanc
newborn
mortal
exist
ten
capsular
serotyp
among
gb
strain
produc
challeng
develop
effect
polysaccharid
vaccin
studi
variou
combin
five
recombin
polypeptid
exhibit
immunogen
protect
properti
examin
neonat
mous
model
furthermor
advantag
pentaval
polypeptid
vaccin
demonstr
method
recombin
polypeptid
construct
base
bac
scaab
scpb
cspa
pcrgener
dna
fragment
clone
express
ecoli
three
differ
mixtur
polypeptid
includ
two
five
compon
administ
subcutan
femal
mice
alum
adjuv
immunogen
evalu
elisa
use
antimous
igg
conjug
hrp
gb
strain
serotyp
iac
use
intraperiton
challeng
newborn
pup
result
clone
dna
fragment
appropri
recombin
polypeptid
success
express
purifi
immun
mice
bred
polypeptid
vaccin
booster
offspr
group
infect
intraperiton
gb
monitor
next
day
within
hour
newborn
mice
mortal
regist
control
group
offspr
surviv
group
mice
immun
two
compon
vaccin
meanwhil
offspr
surviv
mice
immun
five
compon
vaccin
notic
igg
five
compon
detect
femal
blood
immun
period
well
mous
breed
igg
titer
estim
depend
recombin
polypeptid
igg
level
individu
compon
least
two
time
higher
administr
five
compon
vaccin
comparison
two
compon
one
specif
igg
vaccin
compon
also
found
blood
surviv
pup
might
indic
protect
effect
matern
igg
studi
demonstr
advantag
pentaval
polypeptid
vaccin
neonat
mous
protect
gb
challeng
synergist
effect
specif
igg
product
studi
support
rfbr
grant
proven
case
mostli
within
two
month
diagnosi
n
twelv
preexist
risk
factor
chronic
q
fever
five
patient
episod
acut
q
fever
diagnos
four
deceas
patient
endocard
vascular
infect
one
patient
unknown
infect
focu
data
show
mortal
overal
proven
case
proven
case
mortal
vascular
q
fever
infect
compar
mortal
endocard
although
differ
signific
p
conclus
netherland
contrast
report
countri
chronic
q
fever
manifest
mainli
vascular
infect
rather
endocard
mortal
chronic
q
fever
high
overal
proven
case
warrant
awar
clinician
acut
q
fever
episod
diagnos
fatal
proven
chronic
q
fever
case
screen
programm
high
risk
group
seem
justifi
object
earli
intervent
includ
time
antibiot
patient
sever
sepsi
admiss
hospit
improv
surviv
less
known
patient
develop
sepsi
hospit
potenti
improv
care
aim
studi
develop
implement
intervent
improv
care
patient
acut
nh
hospit
method
patient
develop
sepsi
identifi
prospect
screen
patient
blood
cultur
taken
medic
surgic
orthopaed
ward
primari
studi
outcom
measur
proport
septic
patient
receiv
antibiot
within
four
hour
sepsi
onset
baselin
data
collect
sept
postintervent
oct
design
intervent
inform
baselin
clinic
data
find
questionnair
interview
survey
junior
medic
staff
multifacet
intervent
consist
educ
care
pathway
audit
feedback
develop
effect
evalu
segment
regress
analysi
interrupt
time
seri
data
result
among
baselin
patient
ci
receiv
antibiot
within
hour
mean
median
time
administr
hour
ci
hour
hour
iqr
hour
respect
problem
identifi
clinic
data
find
questionnair
respons
rate
ten
interview
junior
doctor
includ
delay
recognit
sepsi
clinic
decisionmak
postintervent
ci
patient
met
primari
outcom
measur
antibiot
within
hour
sepsi
onset
increas
baselin
statist
signific
test
p
run
chart
data
preand
postintervent
figur
suggest
chaotic
process
formal
run
chart
analysi
indic
nonrandom
variat
segment
regress
analysi
data
show
statist
signific
intervent
effect
p
valu
chang
level
chang
slope
manag
patient
sepsi
hospit
leav
room
improv
descript
analysi
indic
intervent
effect
confirm
statist
signific
intervent
effect
analysi
rigor
research
inform
qualiti
improv
area
requir
prognosi
bacteraemia
elderli
prospect
multicentr
cohort
vs
p
present
sever
sepsi
shock
vs
p
fluoroquinoloneresist
gram
neg
pathogen
vs
p
also
associ
sourc
associ
higher
mortal
abdomin
respect
unknown
respiratori
consid
high
risk
sourc
multivari
analysi
preval
pathogen
mortal
e
coli
coagulaseneg
staphylococci
aureu
k
pneumonia
multivari
analysi
variabl
associ
mortal
day
high
risk
sourc
ci
pitt
score
ci
inadequ
empir
treatment
ci
sever
sepsi
shock
present
ci
model
interact
empir
treatment
high
risk
sourc
signific
day
mortal
independ
relat
high
risk
sourc
ci
present
sever
sepsi
shock
ci
conclus
present
sever
sepsi
shock
high
risk
sourc
bsi
independ
predictor
mortal
vep
inadequ
empir
treatment
also
predictor
earli
mortal
patient
high
risk
sourc
factor
link
treatment
failur
sever
diseas
comorbid
recurr
patient
treatment
failur
initi
antibiot
longer
mean
hospit
stay
without
vs
day
higher
proport
admit
icu
vs
treatment
failur
also
associ
septic
shock
higher
proport
patient
treatment
failur
requir
mechan
ventil
vs
blood
pressur
support
fluid
resuscit
vs
parenter
nutrit
vs
suffer
acut
renal
failur
necessit
replac
therapi
vs
major
differ
use
resourc
patient
comorbid
without
although
length
hospit
stay
slightli
longer
patient
comorbid
vs
day
conclus
treatment
failur
initi
iv
antibiot
patient
cap
hcap
result
increas
resourc
use
compar
treatment
failur
adequ
initi
antibiot
treatment
minimis
treatment
failur
prevent
associ
increas
resourc
consumpt
object
import
detect
etiolog
agent
rapid
diagnost
test
high
sensit
specif
rate
etiolog
result
may
learnt
less
hour
new
molecular
diagnost
test
therefor
proper
antimicrobi
therapi
pneumonia
manag
earli
earli
target
therapi
avoid
advers
reaction
increas
resist
profil
unnecessari
antimicrobi
decreas
total
cost
studi
aim
evalu
bacteri
viral
etiolog
cap
polymeras
chain
reaction
result
rate
specif
agent
detect
either
convent
method
pcr
patient
commun
acquir
pneumonia
pneumonia
common
agent
similar
previou
studi
tabl
fifti
four
percent
patient
one
pathogen
mostli
h
influenza
rhinoviru
viral
agent
increas
popular
last
year
detect
high
ratio
studi
tabl
detect
singl
agent
two
patient
concomit
agent
patient
unexpectedli
common
viral
agent
rhinoviru
coronaviru
human
metapneumoviru
detect
one
patient
conclus
pcr
increas
abil
delin
etiolog
upto
cap
case
use
antibiot
previou
hour
first
data
relat
newli
discov
virus
human
metapneumoviru
bocaviru
turkey
addit
data
suggest
mix
infect
common
expect
cap
requir
hospit
suggest
usag
molecular
diagnost
test
lower
respiratori
tract
infect
human
bocaviru
initi
discov
second
pathogen
member
parvoviru
famili
next
human
parvoviru
hbov
sinc
shown
extrem
common
worldwid
caus
system
infect
children
adult
often
result
respiratori
gastrointestin
diseas
parvovirus
assum
replic
via
genom
termin
hairpinlik
structur
socal
rollinghairpin
model
result
headtohead
tailtotail
intermedi
surprisingli
case
identifi
headtotail
intermedi
clinic
sampl
compat
roll
hairpin
model
typic
featur
classic
roll
circl
replic
studi
kapoor
cowork
confirm
observ
extend
conclus
headtotail
structur
may
origin
episom
genom
persist
infect
host
cell
concert
clinic
case
recent
describ
group
hypothesi
episom
persist
follow
roll
circl
replic
seem
like
explan
describ
case
child
suffer
autoimmun
diseas
unabl
produc
antibodi
respons
infect
coinfect
hbov
hbov
shed
discontinu
cidofovir
therapi
success
suppress
titr
level
detect
limit
simultan
disappear
hbov
may
interpret
depend
hbov
dna
replic
presenc
herpesvir
replic
machineri
turn
abl
initi
roll
circl
replic
ci
tran
moreov
underli
autoimmun
diseas
give
rais
hypothesi
hbov
infect
limit
directli
indirectli
cidofovir
treatment
rather
reconstitut
immun
respons
previous
shut
infect
moreov
appear
hbov
contribut
chronic
lung
diseas
observ
associ
hbov
lung
fibrosi
sever
case
identifi
luminex
rvp
assay
therebi
remain
unclear
extent
clinic
cours
aggrav
hbov
caus
hbov
persist
turn
induc
chronic
inflamm
result
fibrosi
therebi
one
patient
suffer
coinfect
cmv
anoth
herpesviru
potenti
act
helperviru
thu
support
hypothesi
hbov
may
altern
replic
roll
circl
mecham
support
helper
virus
object
paediatr
liver
transplant
ltx
patient
pt
particular
risk
develop
ebv
relat
posttranspl
lymphoprolif
disord
ptld
risk
ptld
higher
pt
high
viremia
howev
among
transplant
recipi
group
pt
chronic
high
viral
load
chvl
develop
lymphoprolifer
need
new
prognost
marker
defin
pt
risk
seriou
complic
polymorph
within
cytokin
gene
might
contribut
pathogenesi
diseas
play
key
role
antivir
immun
respons
atoc
substitut
within
gene
snp
affect
product
aim
studi
analys
polymorph
regard
chvl
carriag
paediatr
pt
ltx
method
one
hundr
seventi
nine
children
ltx
includ
studi
median
age
ltx
year
rang
pt
follow
least
month
ltx
median
group
pt
chvl
ie
presenc
ebv
dna
level
copieslg
dna
blood
sampl
min
month
select
remain
pt
moder
undetect
viremia
consist
control
group
genotyp
rflppcr
associ
genotyp
chvl
analys
multivari
logist
regress
adjust
confound
analys
impact
polymorph
length
chvl
carriag
defin
time
ebv
dna
level
copi
first
two
consecut
valu
level
proport
pt
persist
high
viremia
period
assess
genotyp
kaplanmei
curv
compar
use
logrank
test
cox
proport
hazard
model
adjust
tacrolimu
level
result
significantli
increas
frequenc
ac
genotyp
found
chvl
carrier
compar
control
vs
respect
p
timetochvl
resolv
analysi
reveal
relationship
genotyp
length
chvlcarriag
significantli
lower
proport
patient
ac
genotyp
resolv
high
ebv
dna
load
month
onset
chvl
carriag
compar
domin
aa
genotyp
vs
p
figur
conclus
polymorph
within
gene
might
contribut
high
ebv
dna
load
persist
paediatr
pt
ltx
turn
influenc
risk
ptld
develop
object
cytomegaloviru
cmv
one
frequent
opportunist
pathogen
substanti
caus
morbid
mortal
immunosuppress
patient
pt
polymorph
within
cytokin
gene
may
influenc
suscept
clinic
cours
infecti
diseas
immunogenet
factor
influenc
outcom
cmv
infect
paediatr
liver
transplant
recipi
ltx
littl
investig
aim
studi
assess
polymorph
select
cytokin
gene
impact
cmv
reactiv
children
ltx
method
one
hundr
twentysix
paediatr
pt
ltx
median
age
ltx
year
rang
includ
studi
pt
cmv
seroposit
prior
ltx
pt
receiv
graft
posit
donor
pt
donor
neg
children
follow
least
month
ltx
median
rang
month
cmv
reactiv
defin
posit
cmv
dna
blood
detect
pt
within
year
postltx
remain
pt
undetect
cmv
dna
least
month
polymorph
tnfalpha
tc
tnfalpha
ga
tnfri
ca
beta
ct
beta
ct
ag
ct
ifngamma
ag
ct
vntr
analys
pt
associ
cytokin
polymorph
cmv
reactiv
ltx
assess
multivari
logist
regress
adjust
potenti
confound
result
significantli
decreas
frequenc
ct
tt
genotyp
found
pt
cmv
reactiv
compar
pt
without
cmv
dnaemia
ltx
vs
p
addit
significantli
overrepres
heterozyg
tnfri
ca
genotyp
detect
children
experienc
cmv
reactiv
compar
cmv
dnaneg
pt
vs
ci
p
rest
polymorph
analys
show
signific
associ
viru
reactiv
conclus
genet
polymorph
within
tnfri
gene
may
contribut
cmv
reactiv
children
ltx
addit
carrier
cc
andor
heterozyg
tnfri
genotyp
may
especi
benefit
antivir
prophylaxi
background
still
controversi
import
sever
common
human
virus
unexplain
dilat
cardiomyopathi
partial
due
lack
standard
reliabl
quantit
detect
molecular
assay
cardiac
tissu
object
evalu
new
reliabl
molecular
assay
order
confirm
preval
sever
viral
infect
assess
viral
genom
load
level
heart
tissu
method
fiftytwo
fix
explant
postmortem
myocardi
sampl
obtain
patient
idiopath
dilat
cardiomyopathi
dcm
control
sampl
collect
adult
patient
die
accident
commit
suicid
viral
genom
rnadna
detect
semiquantifi
use
broadrang
pcr
amplif
assay
coupl
electrospray
ioniz
timeofflight
mass
spectrometri
analysi
pcresitof
ms
classic
quantit
realtim
pcr
q
rtpcr
assay
result
sixteen
dcm
patient
posit
singl
multipl
viral
genom
detect
human
enteroviru
ev
four
five
six
correl
well
ev
detect
classic
q
rtpcr
assay
kappa
test
object
dengu
arthropodborn
flaviviru
worldwid
distribut
persist
infect
describ
flavivirus
west
nile
viru
wnv
hepat
c
viru
hcv
group
recent
report
live
dengu
viru
persist
urin
convalesc
demonstr
viral
persist
prolong
also
differenti
bodi
compart
method
specimen
eleven
adult
patient
acut
infect
standard
elisa
serotypespecif
revers
transcript
pcr
includ
studi
viral
rna
extract
plasma
peripher
blood
mononuclear
cell
pbmc
saliva
urin
febril
convalesc
period
subject
denguespecif
sybr
green
real
time
quantit
rtpcr
serial
dilut
known
concentr
pfuml
construct
standard
curv
determin
amount
viral
shed
sampl
viral
load
sampl
compar
unit
pfumicrogram
rna
result
patient
secondari
dengu
infect
ten
dhf
dhf
dhf
ii
df
dengu
viru
detect
febril
convalesc
period
nine
patient
viral
rna
detect
plasma
n
pbmc
n
saliva
n
urin
n
febril
period
plasma
n
pbmc
n
urin
n
convalesc
viral
load
shift
among
sampl
time
point
infect
febril
period
viral
load
blood
sampl
plasma
pbmc
higher
saliva
urin
well
convalesc
sampl
interestingli
viral
load
urin
late
febril
phase
higher
blood
sampl
moreov
patient
viral
load
convalesc
urin
higher
correspond
febril
sampl
object
virusmedi
celltocel
fusion
hallmark
cytopath
effect
accompani
infect
sever
envelop
virus
virustocel
fusion
entri
extens
studi
littl
known
cellular
pathway
involv
process
celltocel
fusion
nonenvelop
reoviru
fusionassoci
small
transmembran
fast
protein
smallest
known
membran
fusion
protein
unlik
envelop
viru
fusogen
fast
protein
nonstructur
involv
viru
entri
sole
function
induc
syncytium
format
follow
infect
make
ideal
model
studi
cellular
pathway
involv
syncytiogenesi
studi
conduct
compar
tempor
analysi
fast
proteinand
influenza
hemagglutinin
ha
mediat
celltocel
fusion
order
determin
whether
viral
protein
design
entri
design
celltocel
fusion
elicit
similar
respons
fusion
pore
expans
syncytium
format
method
ha
transfect
ha
fusion
trigger
trypsin
incub
cell
pore
format
monitor
transfer
cytoplasm
fluor
quail
fibroblast
vero
epitheli
cell
syncytium
format
quantifi
count
syncyti
nuclei
indic
pore
expans
addit
develop
novel
method
analyz
pore
expans
ad
membran
curvatur
agent
lysophosphatidylcholin
lpc
tempor
analysi
syncytium
format
result
report
lpc
inhibit
fast
protein
mediat
pore
format
inhibit
pore
expans
result
revers
stall
pore
phenotyp
contrast
lpc
inhibit
hamedi
pore
format
pore
expans
stall
pore
phenotyp
also
revers
first
exampl
syncytium
develop
arrest
follow
membran
fusion
event
conclus
fusion
reaction
instig
envelop
viru
nonenvelop
viru
celltocel
fusogen
differ
syncytium
format
stage
like
similar
cellular
respons
assault
plasma
membran
stall
pore
expans
isol
celldepend
stage
cell
fusion
show
fast
model
mimic
effect
envelop
virusinduc
syncytium
format
use
system
identifi
sever
cellular
protein
involv
syncytium
format
current
investig
laboratori
object
norovirus
estim
caus
gastroenter
case
worldwid
repres
consider
public
health
burden
genotyp
lineag
predomin
healthcar
set
nucleotid
sequenc
capsid
domain
use
discrimin
outbreak
aim
studi
use
whole
genom
sequenc
provid
detail
elucid
transmiss
event
within
outbreak
method
nineteen
complet
noroviru
genom
determin
sanger
sequenc
repres
five
separ
outbreak
two
unlink
individu
submit
sampl
jan
june
detail
correspond
epidemiolog
data
collect
beast
bayesian
evolutionari
analysi
sampl
tree
packag
use
reconstruct
relationship
determin
rate
evolut
within
defin
timefram
result
complet
genom
nucleotid
nt
singl
nucleotid
polymorph
snp
includ
analysi
rate
evolut
estim
mutat
per
site
per
year
mutationsgenomemonth
compar
recent
report
rate
mutat
per
site
per
year
calcul
use
bayesian
analysi
capsid
nt
polymeras
nt
fragment
genom
isol
within
four
five
outbreak
cluster
ident
accord
capsid
domain
nt
sequenc
alon
howev
four
isol
one
snp
whole
genom
sequenc
wg
see
figur
wg
confirm
one
cluster
isol
contain
four
ident
isol
fifth
contain
two
snp
four
cluster
contain
ident
domain
wg
reveal
snp
within
cluster
suggest
part
larger
ongo
outbreak
conclus
complet
genom
sequenc
combin
detail
epidemiolog
data
provid
suffici
resolut
identifi
transmiss
within
hospit
convent
use
domain
howev
adequ
discrimin
close
relat
isol
within
outbreak
next
gener
sequenc
technolog
allow
larg
number
whole
genom
sequenc
gener
rapidli
inform
real
time
outbreak
control
method
prospect
surveil
viral
aetiolog
febril
children
acut
respiratori
tract
infect
conduct
sinc
may
two
throat
swab
obtain
concomitantli
inform
consent
one
sent
convent
viral
isol
detect
adenoviru
infect
inhous
realtim
polymeras
chain
reaction
pcr
subsequ
sequencebas
type
case
divid
adenovir
nonadenovir
group
addit
medic
record
review
appropri
statist
adopt
compar
result
group
p
valu
consid
statist
signific
result
total
febril
children
male
enrol
may
juli
viral
aetiolog
identifi
case
convent
cultur
includ
adenoviru
n
coxsakieviru
coxsakieviru
echoviru
enteroviru
hsv
type
influenza
viru
parainfluenza
viru
type
parainfluenza
viru
type
addit
cultureposit
adenovirus
two
addit
cultureneg
adenoviru
infect
identifi
realtim
pcr
nonadenocultur
pcr
neg
base
partial
hexon
sequenc
type
adenoviru
type
predomin
type
follow
unclassifi
ad
compar
laboratori
find
adenovir
n
nonadenovir
n
group
significantli
higher
leukocyt
count
higher
neutrophil
count
higher
crp
level
adenovir
group
p
conclus
inhous
develop
realtim
pcr
compar
tradit
cultur
method
detect
adenovir
infect
major
type
adenovir
epidem
taiwan
spectrum
laboratori
find
differ
posit
think
infect
manag
practic
antimicrobi
pkpd
consider
bedsid
applic
gramposit
infect
sever
antibiot
avail
treatment
seriou
gramposit
infect
agent
distinct
pharmacokinet
pharmacodynam
properti
aid
differenti
use
clinic
practic
vancomycin
histor
import
intraven
iv
treatment
sever
gramposit
infect
especi
treatment
fail
bactericid
activ
resist
bacteria
need
widespread
use
tendenc
underdos
led
problemat
emerg
reduc
bacteri
suscepti
linezolid
bacteriostat
antibiot
although
well
toler
short
term
patient
monitor
risk
myelosuppress
treatment
extend
beyond
day
appropri
select
optimis
use
antibiot
differ
clinic
circumst
promot
best
patient
outcom
reduc
likelihood
develop
resist
impact
mssa
bsi
unquantifi
like
much
larger
use
casebas
discuss
interact
session
audienc
present
explor
common
clinic
conundrum
associ
manag
aureu
bsi
conundrum
includ
initi
empir
therapi
suspect
bsi
definit
antimicrobi
therapi
role
combin
antistaphylococc
sourc
control
valu
therapeut
drug
monitor
laboratori
support
suscept
test
ongo
manag
monitor
implic
outcom
final
role
antibiot
stewardship
manag
aureu
bsi
address
ecdcemea
joint
technic
report
bacteri
challeng
time
react
doi
adapt
p
aeruginosa
acut
chronic
infect
mutat
adapt
antibiot
resist
p
aeruginosa
chronic
infect
pseudomona
aeruginosa
one
frequent
sever
caus
acut
nosocomi
infect
less
concern
chronic
respiratori
infect
p
aeruginosa
main
caus
morbid
mortal
cystic
fibrosi
cf
frequent
complic
respiratori
diseas
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
due
complex
multifactori
adapt
process
establish
p
aeruginosa
chronic
infect
almost
imposs
erad
antibiot
underli
factor
drive
situat
includ
transit
plankton
biofilm
mode
growth
associ
signific
reduct
antimicrobi
suscept
ii
extraordinari
capac
p
aeruginosa
acquir
resist
nearli
avail
antibiot
complex
interplay
intrins
mutationdriven
resist
pathway
iii
intens
genet
adapt
phenotyp
diversif
process
take
place
within
cf
lung
iv
frequent
emerg
fixat
mutat
phenotyp
often
result
nonfunct
dna
mismatch
repair
system
caus
inactiv
mut
mutl
gene
lead
increas
spontan
mutat
rate
moreov
result
recent
research
argu
four
factor
intim
interconnect
act
synergist
establish
lifelong
persist
infect
highli
recalcitr
activ
antimicrobi
agent
biofilm
mode
growth
found
facilit
develop
mutationdriven
resist
select
mutat
genet
adapt
phenotyp
diversif
convers
mutat
phenotyp
shown
significantli
enhanc
mutationdriven
resist
biofilm
develop
genet
adapt
phenotyp
diversif
diagnos
fungal
diseas
futur
perspect
epidemiolog
ifi
updat
grow
number
immunocompromis
patient
could
account
increas
number
invas
fungal
infect
ifi
detect
howev
use
corticosteroid
intravascular
devic
aggress
procedur
may
also
respons
increas
number
differ
type
patient
risk
develop
ifi
accur
studi
epidemiolog
ifi
requir
reliabl
diagnost
tool
yet
knowledg
epidemiolog
ifi
limit
difficulti
establish
diagnosi
invas
candidiasi
common
ifi
particularli
preval
patient
carri
intravascular
cathet
undergo
abdomin
surgeri
verylowbirthweight
newborn
although
candida
albican
still
main
etiolog
agent
invas
candidiasi
nonalbican
candida
speci
becom
increasingli
preval
knowledg
local
epidemiolog
import
suscept
antifung
agent
mainli
base
speci
involv
vari
geographi
furthermor
widespread
use
antifung
agent
also
contribut
antifung
resist
invas
aspergillosi
mold
infect
classic
affect
patient
hematolog
cancer
period
deep
prolong
neutropenia
recipi
solid
organ
bone
marrow
transplant
today
popul
risk
acquir
mold
infect
heterogen
includ
patient
chronic
lung
diseas
receiv
longterm
corticosteroid
therapi
environment
factor
may
also
contribut
invas
aspergillosi
patient
rel
sound
immun
statu
undergo
major
surgeri
invas
aspergillosi
caus
mainli
aspergillu
fumigatu
howev
recent
advanc
fungal
taxonomi
uncov
complex
speci
epidemiolog
final
increas
number
azoleresist
fumigatu
isol
make
patient
manag
difficult
although
restrict
north
europ
problem
potenti
spread
area
present
review
updat
current
knowledg
epidemiolog
ifi
emphasi
popul
risk
caus
agent
problem
relat
antifung
resist
statist
signific
differ
ltbi
frequenc
among
three
group
p
conclus
although
hcw
hiv
infect
patient
consid
increas
risk
ltbi
compar
popul
larg
result
show
ltbi
preval
similar
among
three
group
accord
onethird
world
popul
ltbi
risk
develop
diseas
much
lower
preval
ltbi
found
studi
one
possibl
reason
observ
fact
data
base
mantoux
test
affect
prior
bcg
vaccin
provid
lower
specif
falseposit
result
object
pott
diseas
pd
reemerg
european
countri
due
immigr
last
year
catalonia
increas
million
citizen
due
foreign
peopl
aim
studi
review
seri
pd
focus
case
associ
immigr
method
retrospect
review
consecut
episod
diagnos
univers
hospit
patient
tb
confirm
bacteriolog
andor
histolog
studi
record
sociodemograph
characterist
underli
diseas
clinic
featur
microbiolog
histopatholog
studi
treatment
outcom
result
studi
period
episod
men
median
age
year
pd
diagnos
last
year
percentag
immigr
undevelop
countri
increas
vs
p
common
underli
condit
alcohol
diabet
hiv
liver
transplant
system
steroid
therapi
chronic
renal
failur
median
durat
symptom
diagnosi
month
iqr
clinic
present
pain
neurolog
manifest
constitut
symptom
fever
extraspin
involv
diagnos
patient
among
pulmonari
tb
main
spinal
site
involv
lumbarsacr
thorac
thoracolumbar
five
multifoc
two
tuberculosi
isol
vertebr
specimen
studi
patient
suggest
histolog
complic
includ
paravertebr
abscess
mass
medullar
compress
spinal
deform
median
durat
antitubercul
chemotherapi
month
surgic
treatment
perform
patient
infect
cure
case
except
tbrelat
death
due
dissemin
diseas
end
follow
median
month
none
case
relaps
patient
persist
sequela
compar
nativ
immigr
younger
vs
year
p
requir
often
surgeri
vs
p
due
higher
proport
paravertebr
abscess
vs
p
medullar
compress
vs
p
conclus
set
proport
pd
case
occur
immigr
increas
compar
nativ
foreign
born
younger
frequent
requir
surgeri
due
higher
proport
complic
paradox
aggrav
well
describ
outcom
treat
tuberculosi
also
identifi
immun
reconstitut
inflammatori
syndrom
iri
hiv
patient
receiv
haart
case
also
notifi
biotherapi
withdraw
object
report
first
caseseri
antitnf
induc
tbiri
compar
noniri
tb
patient
order
determin
preval
iri
risk
factor
method
antitnf
associ
tbiri
case
collect
french
regist
ratio
report
case
antitnf
associ
tb
nation
casecal
antitnf
associ
tb
without
iri
month
follow
tb
diagnosi
collect
control
randomli
match
two
one
accord
year
tb
diagnosi
condit
logist
regress
done
use
sa
softwar
result
case
antitnf
associ
tbiri
collect
patient
median
yearsold
underli
inflammatori
diseas
inflammatori
arthriti
vasculitid
psoriasi
last
median
year
anti
tnfalpha
drug
monoclon
antibodi
solubl
receptor
prescrib
median
week
tb
present
mostli
dissemin
antitnf
stop
antitb
antibiot
start
eight
patient
receiv
steroid
initi
improv
iri
occur
median
day
antitubercul
therapi
begin
manifest
fever
lymph
node
swell
tuberculoma
cold
abscess
pleural
pericardi
abdomin
effus
pulmonari
cavit
increas
pulmonari
lesion
recov
requir
increas
steroid
dose
rituximab
initi
new
antitubercul
treatment
surgeri
among
ratio
cohort
iri
preval
casecontrol
studi
identifi
dissemin
tuberculosi
p
strong
immunodepress
p
iri
risk
factor
tbiri
associ
significantli
longer
antitubercul
treatment
month
vs
month
p
conclus
paradox
worsen
antitnf
inducedtuberculosi
biotherapi
withdraw
occur
highli
immunosuppress
patient
dissemin
tuberculosi
lead
prolong
antitubercul
treatment
chang
signific
immun
function
patient
pulmonari
tuberculosi
complic
copd
tang
shen
h
sun
x
hao
shanghai
cn
object
explor
chang
signific
immun
function
patient
pulmonari
tuberculosi
complic
copd
method
immun
function
case
pulmonari
tuberculosi
copd
studi
group
hospit
januari
januari
detect
compar
result
case
patient
pulmonari
tuberculosi
control
group
tb
case
healthi
peopl
control
group
healthi
peopl
hospit
period
express
percentag
nk
cell
lymphocyt
subset
peripher
whole
blood
sampl
detect
flow
cytometri
doublelabel
antibodi
level
igm
igg
iga
measur
immunoturbidimetri
level
tnfalpha
ifngamma
measur
use
sandwich
abcelisa
method
patient
result
percentag
nk
cell
ratio
studi
group
control
group
tb
lower
control
group
healthi
peopl
p
level
higher
studi
group
control
group
healthi
peopl
p
level
ratio
studi
group
lower
control
group
tb
p
level
igm
igg
iga
studi
group
lower
control
group
healthi
peopl
p
signific
differ
studi
group
control
group
tb
level
igg
iga
p
signific
differ
control
group
tb
control
group
healthi
peopl
level
igg
igm
p
level
tnfalpha
ifngamma
studi
group
control
group
tb
higher
healthi
peopl
p
level
ifngamma
studi
group
higher
control
group
tb
p
signific
differ
studi
group
control
group
tb
level
tnfalpha
conclus
patient
pulmonari
tuberculosi
mainli
impair
cellular
immun
humor
immun
damag
also
play
role
patient
pulmonari
tuberculosi
complic
copd
impair
cellular
immun
humor
immun
extent
immun
impair
seriou
patient
pulmonari
tuberculosi
object
lack
pointofcar
poc
diagnost
tuberculosi
tb
diagnosi
measur
releas
whole
blood
stimul
tb
specif
antigen
recent
propos
new
tool
diagnosi
latent
activ
tb
diagnost
accuraci
atpar
quantiferon
tb
tubeassay
qft
cellesti
higher
cytokin
releas
comparison
interferongamma
ifng
could
permit
measur
poc
test
aim
studi
compar
new
later
flow
base
poc
detect
devic
headtohead
qft
patient
activ
tb
healthi
control
method
measur
retrospect
supernat
qft
test
patient
microbiolog
confirm
activ
tb
unexpos
healthi
student
measur
use
multiplex
assay
mpa
biorad
semiquantit
later
flow
immunoassay
lfi
milenia
biotec
inhous
elisa
develop
copenhagen
denmark
sampl
mitogen
control
ngml
consid
determin
assay
compar
differ
assay
use
receiv
oper
characterist
curv
roc
analysi
set
cut
posit
poc
test
maximum
youden
index
qft
detect
assay
high
area
curv
auc
calcul
roc
measur
diagnost
valu
auc
lfi
mpa
elisa
qft
cutoff
point
posit
test
determin
ngml
ngml
ngml
lfi
mpa
elisa
respect
sensit
specif
measur
lfi
mpa
elisa
respect
sensit
specif
qft
use
manufactur
cut
iuml
determin
lfi
show
moder
correl
mpa
qft
p
strong
correl
elisa
p
pearson
conclus
studi
poc
lfi
measur
compar
sensit
specif
compar
qft
diagnosi
activ
tb
three
test
method
measur
stimul
tbspecif
antigen
correl
well
qft
prospect
studi
evalu
new
test
thu
warrant
sensor
abl
discrimin
signatur
caus
organ
use
pattern
recognit
softwar
studi
shown
may
valuabl
detect
mycobacterium
tuberculosi
directli
patient
sputa
propos
studi
evalu
use
sensor
detect
tb
directli
breath
patient
suspect
pulmonari
tb
method
object
compar
sensit
specif
sensor
nextdimens
technolog
california
tb
microscopi
cultur
genexpert
tb
suspect
recruit
phc
facil
paarl
area
western
cape
forti
smear
posit
culturexpert
posit
smear
neg
culturexpert
posit
smear
neg
culturexpert
neg
tb
suspect
recruit
month
period
septemb
addit
breath
sampl
healthi
volunt
obtain
thirtynin
percent
studi
popul
hivposit
test
perform
triplic
consist
patient
exhal
bag
attach
sensor
sampl
analys
realtim
result
linear
discrimin
analysi
sampl
reveal
sensit
specif
sensor
follow
cultur
posit
vs
healthi
volunt
smear
posit
cultur
posit
vs
cultur
neg
smear
neg
cultur
posit
vs
cultur
neg
sensor
abl
accur
discrimin
infect
group
healthi
popul
less
suspect
aetiolog
lower
respiratori
tract
symptom
conclus
devic
show
promis
rapid
point
care
diagnost
pulmonari
tuberculosi
research
still
requir
improv
sensit
specif
devic
choos
select
sensor
voc
target
object
uk
nation
guidanc
recommend
screen
tuberculosi
tb
variou
risk
group
treatment
latent
tuberculosi
evid
activ
diseas
found
undertook
retrospect
studi
evalu
manag
latent
tuberculosi
hospit
method
patient
diagnosi
latent
tuberculosi
made
adult
infecti
diseas
clinic
hospit
septemb
till
octob
includ
studi
note
review
establish
demograph
rational
screen
outcom
chemoprophylaxi
accept
result
fifti
nine
patient
includ
studi
major
patient
subsaharan
africa
half
age
patient
asymptomat
normal
clinic
examin
normal
chest
xray
cxr
abnorm
cxr
previou
histori
treatment
posit
mantoux
test
went
onto
posit
igra
interferon
gamma
releas
assay
test
posit
igra
test
screen
recent
tb
contact
part
occup
health
screen
part
port
health
screen
five
patient
await
review
regard
chemoprophylaxi
two
offer
chemoprophylaxi
one
age
second
patient
return
back
endem
area
remain
patient
offer
chemoprophylaxi
accept
although
two
defer
month
uptak
chemoprophylaxi
highest
among
tb
contact
lowest
among
health
care
worker
regimen
use
rifampicin
isoniazid
three
month
chemoprophylaxi
ongo
four
patient
start
chemoprophylaxi
success
complet
three
discontinu
regimen
due
sideeffect
one
liver
function
abnorm
one
pruritu
third
tingl
numb
patient
receiv
chemoprophylaxi
report
sideeffect
conclus
major
patient
diagnos
latent
tuberculosi
hospit
subsaharan
africa
major
screen
recent
tb
contact
accept
chemoprophylaxi
latent
tuberculosi
high
overal
compar
low
health
care
worker
high
overal
complet
rate
low
incid
seriou
sideeffect
object
evalu
use
clinic
protocol
prevent
tuberculosi
tb
associ
tumour
necrosi
factor
tnf
antagonist
therapi
assess
impact
ceas
tuberculin
skin
test
tst
practic
introduc
quantiferon
gold
intub
qft
diagnosi
strategi
method
observ
cohort
studi
patient
due
start
treatment
tnf
antagonist
evalu
tb
infect
ltbi
accord
preestablish
clinic
protocol
jan
dec
protocol
includ
diagnosi
ltbi
base
clinic
radiolog
data
follow
tst
period
tst
qft
period
tst
qft
period
ii
preemptiv
treatment
pretx
month
isoniazid
h
indic
patient
follow
pretx
adher
monitor
h
metabolit
urin
develop
tb
assess
review
electron
medic
report
includ
hospit
primari
care
data
ethic
committe
bellvitg
univers
hospit
approv
studi
result
six
hundr
seventytwo
patient
women
mean
age
year
evalu
patient
diagnos
ltbi
period
respect
p
patient
receiv
pretx
respect
p
start
antitnf
therapi
median
followup
year
patientyear
whole
cohort
year
patientyear
patient
risk
antitnf
therapi
four
patient
develop
tb
incid
per
patientsyear
ci
whole
cohort
ci
patient
risk
three
four
case
occur
patient
antitnf
therapi
one
period
anoth
patient
neg
tst
qft
receiv
neither
pretx
antitnf
therapi
conclus
systemat
evalu
treatment
patient
prior
tnfantagonist
therapi
prevent
tb
great
extent
ceas
twostep
tst
practic
introduc
qft
substanti
reduc
diagnos
preemptiv
treatment
ltbi
without
increas
risk
tb
object
evalu
clinic
efficaci
safeti
use
linezolid
treat
xdrtb
method
sinc
april
appli
linezolidbas
chemotherapi
treatment
fourteen
case
xdrtb
patient
adopt
individualbas
chemotherapi
regimen
base
patient
medic
histori
drug
suscept
test
result
dosag
linezolid
begin
mg
intraven
drip
bid
durat
week
week
later
reduc
mg
intraven
drip
qd
maximum
durat
treatment
month
minimum
month
averag
month
half
result
second
day
medic
bodi
temperatur
return
normal
three
febril
patient
patient
show
signific
improv
cough
sputum
chest
tight
breath
short
symptom
also
improv
month
treatment
linezolid
patient
present
caviti
closur
sputum
smear
neg
convers
occur
pulmonari
case
median
day
cultur
convers
occur
pulmonari
case
median
day
relaps
sputum
imag
occur
two
case
month
use
linezolid
six
case
present
nausea
vomit
gastrointestin
reaction
symptom
disappear
reduct
linezolid
three
patient
develop
peripher
neuropathi
two
patient
develop
declin
eyesight
six
case
hematolog
advers
reactionson
patient
develop
leucopenia
four
patient
develop
middl
anemia
one
patient
develop
sever
anaemia
need
blood
transfus
conclus
use
linezolid
treat
xdrtb
significantli
improv
clinic
symptom
promot
lesion
absorpt
caviti
closur
acceler
sputum
neg
convers
therefor
help
xdrtb
patient
improv
life
qualiti
mild
advers
reaction
good
drug
toler
suggest
linezolid
recommend
treatment
xdrtb
zolid
recommend
treatment
xdrtb
object
tuberculosi
mening
tbm
case
fatal
rate
optim
treatment
tbm
establish
follow
model
pulmonari
tb
treatment
moxifloxacin
potencyand
good
penetr
cerebrospin
fluid
csf
promis
drug
tbm
higher
dose
moxifloxacin
well
rifampicin
may
increas
drug
exposur
blood
csf
therebi
improv
surviv
studi
evalu
pharmacokinet
pk
safeti
efficaci
intensifi
regimen
tbm
hospit
indonesia
method
random
indonesian
tbm
patient
hivinfect
standard
dose
mg
mgkg
oral
rifampicin
high
dose
mg
mgkg
rifampicin
administ
iv
second
random
moxifloxacin
mg
moxifloxacin
mg
ethambutol
mg
qd
first
day
adjunct
standard
inh
pza
dexamethason
first
two
week
treatment
patient
continu
standard
tb
treatment
pharmacokinet
pk
assess
perform
blood
csf
within
first
critic
day
treatment
advers
event
attribut
tb
treatment
assess
month
mortal
evalu
explor
studi
power
detect
pharmacokinet
differ
group
result
far
pk
data
evalu
patient
increas
dose
led
higher
drug
exposur
plasma
rifampicin
fold
moxifloxacin
mean
csf
concentr
rifampicin
low
show
small
increas
higher
dose
vs
mgl
mean
csf
concentr
moxifloxacin
vs
mgl
p
standard
vs
high
dose
moxifloxacin
among
first
patient
includ
mild
qtc
prolong
occur
patient
take
moxifloxacin
grade
grade
hepatotox
evenli
distribut
group
onemonth
mortal
among
first
patient
includ
substanti
lower
vs
p
patient
take
highdos
rifampicin
iv
compar
take
standard
dose
oral
conclus
intensifi
antibiot
treatment
tbm
lead
favor
pk
plasma
rifampicin
moxifloxacin
csf
moxifloxacin
accept
toxic
preliminari
data
explor
studi
show
trend
lower
mortal
patient
take
high
dose
rifampicin
larger
studi
evalu
effect
intensifi
treatment
surviv
patient
tbm
pseudomona
aeruginosa
opportunist
pathogen
ubiquit
soil
water
howev
abl
caus
sever
infect
human
cystic
fibrosi
cf
patient
domin
caus
morbid
mortal
due
persist
airway
patient
main
object
character
evolutionari
rout
bacteria
switch
environment
lifestyl
one
associ
chronic
infect
help
substanti
strain
collect
cover
sever
hundr
cf
patient
lung
infect
last
year
abl
identifi
particularli
success
clone
whose
chang
genom
sequenc
global
gene
express
profil
constitut
import
platform
analysi
genom
dynam
reflect
mani
case
frequent
appear
hypermut
strain
mutat
accumul
rate
fold
increas
rel
observ
nonmut
isol
case
airway
popul
p
aeruginosa
highli
divers
adapt
chang
environ
cf
airway
seem
occur
popul
level
contrast
success
nonmut
clone
seem
harbor
sever
mutat
global
regulatori
gene
result
highli
adapt
cell
quit
homogen
airway
popul
allel
replac
wildtyp
strain
p
aeruginosa
construct
carri
one
identifi
regulatori
mutat
clinic
isol
result
strain
display
phenotyp
profil
resembl
clinic
strain
result
suggest
small
number
specif
regulatori
mutat
alter
network
transcript
bacteria
may
provid
cell
adapt
featur
lead
high
fit
level
bacteria
new
environ
latest
result
ongo
studi
gene
regul
cf
isol
synthet
counterpart
discuss
candida
score
ruizsantana
c
behalf
cava
ii
studi
group
colon
candidemia
c
invas
candidiasi
ic
difficult
distinguish
icu
patient
predict
model
adult
nonneutropen
critic
ill
patient
allow
stratif
select
highrisk
patient
cic
may
benefit
earli
antifung
therapi
group
develop
valid
candida
score
predict
model
ic
base
score
system
certain
variabl
assign
valu
point
surgeri
multifoc
colon
parenter
nutrit
valu
two
point
sever
sepsi
cutoff
highli
reliabl
identifi
patient
high
risk
cic
moreov
abdomin
surgeri
increas
significantli
risk
cic
base
result
earli
antifung
treatment
specif
direct
patient
multifoc
candida
colon
associ
candida
score
particular
abdomin
surgeri
score
system
simpl
may
help
clinician
differenti
candida
spp
colon
occult
invas
fungal
infect
earli
antifung
treatment
consid
serolog
test
recent
ad
diagnost
armamentarium
cic
includ
detect
candida
albican
germ
tube
antibodi
cagta
betadglucan
bdg
recent
metaanalysi
conclud
bdg
good
diagnost
accuraci
distinguish
patient
without
invas
fungal
infect
proper
use
test
requir
good
knowledg
characterist
particularli
fungal
pathogen
remain
undetect
factor
associ
falseposit
result
pcrbase
method
detect
candida
spp
directli
blood
sampl
may
play
import
role
improv
outcom
patient
ic
earlier
sensit
diagnosi
recent
publish
metaanalysi
demonstr
use
method
may
accompani
blood
cultur
although
serial
sampl
may
consid
patient
high
risk
ic
systemat
review
demonstr
direct
pcr
blood
sampl
may
higher
sensit
diagnosi
ic
convent
blood
cultur
specif
therefor
stratif
patient
high
risk
ic
use
predict
model
ic
togeth
measur
biomark
bdg
cagta
possibl
avail
diagnost
test
base
real
time
pcr
may
chang
outcom
patient
ic
human
papillomavirus
recent
advanc
recent
advanc
diagnosi
hpv
infect
human
papillomavirus
hpv
group
remark
divers
dna
virus
papillomavirida
famili
causal
involv
etiolog
variou
benign
malign
neoplast
lesion
mucos
skin
epithelium
approxim
differ
hpv
type
alpha
genu
known
infect
mucos
epithelium
subset
hpv
type
associ
lesion
progress
cancer
cancerassoci
hpv
design
highrisk
hpv
type
hrhpv
etiolog
agent
virtual
cervic
carcinoma
play
lead
etiolog
role
develop
anal
cancer
substanti
proport
vagin
penil
vulvar
oropharyng
mainli
tonsillar
cancer
view
fact
persist
infect
hrhpv
necessari
etiolog
factor
develop
cervic
carcinoma
hpv
test
becom
import
part
cervic
carcinoma
screen
detect
algorithm
sever
countri
test
hrhpv
four
main
clinic
applic
triag
women
ascu
borderlin
cytolog
ii
followup
women
abnorm
screen
cytolog
result
neg
initi
colposcopybiopsi
iii
predict
outcom
treatment
iv
primari
screen
women
age
year
combin
pap
smear
current
differ
commerci
assay
detect
alpha
hpv
avail
review
poljak
kocjan
bj
exp
rev
anti
infect
ther
provisori
divid
five
main
group
dnabas
screen
assay
test
presenc
hourhpv
without
determin
hpv
type
ii
assay
combin
test
hour
hpv
genotyp
iii
hpv
dna
base
genotyp
assay
iv
mrna
hrhpv
assay
v
situ
hybrid
hpv
assay
vast
major
hpv
assay
current
market
use
establish
clinic
applic
especi
primari
screen
autom
price
reduct
improv
clinic
specif
main
goal
futur
develop
hpv
assay
import
get
infecti
diseas
respons
vaccin
genderrel
immun
respons
infecti
agent
vaccin
variabl
regard
sexbas
biolog
differ
innat
humor
cellmedi
immun
respons
differ
men
women
furthermor
pregnanc
immun
respons
respons
vaccin
alter
eg
studi
humor
respons
trival
inactiv
influenza
vaccin
show
healthi
women
gener
robust
antibodi
respons
addit
women
report
sever
reaction
influenza
vaccin
overal
studi
identifi
differ
respons
vaccin
scarcenevertheless
studi
sexrel
immun
respons
respons
vaccin
need
defin
futur
strategi
vaccin
program
gender
relat
respons
vaccin
anoth
issu
address
gender
immunis
topic
assess
partner
statist
analysi
demograph
health
survey
qualit
systemat
review
case
studi
compil
data
show
vaccin
outcom
regard
sex
variabl
within
studi
countri
yet
women
children
disadvantag
group
economi
educ
like
expos
barrier
immuns
surgic
patient
isol
reidentifi
speci
level
use
standard
microbiolog
method
pcr
detect
meca
lukspvlukfpv
gene
perform
isol
characteris
spatyp
rm
test
type
agr
type
sccmec
type
mlst
perform
select
isol
repres
differ
centr
result
mrsa
isol
group
clonal
complex
name
n
n
n
n
n
n
n
n
n
n
n
isol
belong
hospitalassoci
mrsa
hamrsa
lineag
communityassoci
mrsa
camrsa
lineag
wherea
livestockassoci
mrsa
lamrsa
lineag
isol
repres
sporad
mrsa
clone
among
hamrsa
lineag
predomin
clone
southern
german
relat
n
observ
mostli
switzerland
itali
serbia
relat
n
observ
mostli
scotland
spain
n
observ
mostli
franc
camrsa
clone
european
n
southwest
pacif
relat
n
domin
greec
overal
dissemin
clone
observ
seven
nine
centr
follow
southern
german
clone
five
three
nine
centr
respect
preval
sccmec
type
iv
n
follow
sccmec
type
n
ii
n
iii
n
pantonvalentin
leukocidin
pvl
carri
isol
belong
camrsa
clone
n
conclus
although
centr
studi
characteris
specif
composit
mrsa
lineag
usual
one
preval
clone
clone
southern
german
wide
dissemin
europ
israel
european
epidemiolog
mrsa
bacteraemia
effect
prevent
requir
good
hospit
polici
borg
e
scicluna
u
frank
behalf
implement
project
group
object
incid
mrsa
bacteraemia
europ
show
substanti
geograph
variat
better
identif
effect
infect
prevent
control
ipc
practic
need
inform
success
intervent
method
march
octob
eu
fund
implement
project
survey
practic
relev
mrsa
bacteraemia
prevent
use
onlin
questionnair
sent
member
european
ipc
societi
background
demograph
inform
also
collect
includ
mrsa
proport
blood
cultur
isol
statist
analysi
perform
use
chisquar
test
result
total
repli
receiv
ipc
doctor
nurs
region
academ
hospit
locat
european
countri
mrsa
proport
among
respond
hospit
hospit
hospit
significantli
hospit
lower
mrsa
categori
perform
daili
surveil
mrsa
bacteraemia
incid
perform
root
caus
analysi
investig
possibl
aetiolog
infect
figur
proport
hospit
report
polici
insert
mainten
peripher
central
venou
cathet
show
correl
mrsa
preval
neither
presenc
polici
remov
peripher
cannula
hour
presenc
iv
line
care
team
hand
hospit
perform
compet
assess
personnel
abil
insert
maintain
line
show
significantli
lower
mrsa
proport
even
low
preval
hospit
central
venou
cathet
cvc
care
bundl
report
hospit
turn
institut
document
complianc
wherea
perform
bundl
audit
feedback
least
everi
month
conclus
wherea
ipc
polici
abundantli
present
european
hospit
effort
ensur
staff
compet
perform
polici
appear
suboptim
addit
higher
mrsa
preval
also
seem
relat
less
intens
surveil
especi
lack
effort
identifi
correct
caus
aetiolog
factor
root
caus
analysi
effect
cvc
care
bundl
also
still
absent
hospit
ipc
practic
european
hospit
seem
lack
requir
good
practic
clearli
need
learn
safer
industri
aviat
improv
mrsa
bacteraemia
epidemiolog
achiev
method
sixteen
hospit
laboratori
across
england
wale
northern
ireland
request
refer
consecut
mrsa
mssa
bacteraemia
case
within
period
januari
juli
patient
demograph
data
collat
genet
characteris
includ
spa
type
meca
pcr
mlva
sccmec
type
antibiot
suscept
determin
agar
dilut
bsac
method
interpret
use
eucast
guidelin
result
overal
isol
mssa
mrsa
refer
particip
laboratori
patient
age
year
age
group
one
mrsa
test
ciprofloxacin
resist
resist
erythromycin
clindamycin
fusid
acid
observ
nine
four
sa
isol
respect
among
mrsa
spa
type
identifi
predomin
n
mrsa
belong
infer
spa
type
data
meticillin
resist
group
associ
sccmec
type
iv
sccmec
type
detect
includ
type
v
sccmec
element
prove
nontyp
among
mssa
spa
typesclust
eight
infer
clonal
complex
genet
unrel
lineag
identifi
five
major
spa
type
account
total
mssa
mlva
increas
discriminatori
power
distinct
profil
identifi
specif
predomin
spa
type
among
mrsa
subdivid
distinct
mlva
type
pvl
detect
mrsa
mssa
pvlposit
conclus
base
spa
type
data
signific
chang
genet
structur
sa
bacteraemia
uk
compar
mssa
remain
heterogen
multipl
lineag
identifi
iv
remain
predomin
mrsa
clone
associ
bacteraemia
uk
object
aim
studi
character
invas
methicillinresist
staphylococcu
aureu
mrsa
isol
collect
period
franc
compar
data
obtain
use
protocol
method
conduct
prospect
multicent
studi
invas
bacteraemia
mrsa
strain
includ
first
five
consecut
blood
cultur
isol
collect
januari
juli
hospit
locat
throughout
franc
strain
extens
character
use
antibiot
suscept
pattern
agr
type
spa
type
sccmec
type
toxin
profil
dna
microarray
staphytyp
aler
clone
design
sequenc
type
st
follow
sccmec
type
vi
result
total
isol
includ
see
figur
five
main
clone
identifi
lyon
clone
n
new
paediatr
clone
n
old
paediatr
clone
n
n
geraldin
clone
n
european
camrsa
clone
n
seven
remain
isol
relat
six
clone
lyon
clone
remain
preval
mrsa
clone
franc
compar
similar
previou
studi
sinc
evolut
mark
signific
increas
rate
new
pediatr
clone
p
concern
emerg
clone
p
besid
latter
involv
recent
sever
outbreak
within
french
neonat
unit
data
dna
microarray
provid
accur
pictur
virul
resist
profil
variou
invas
clone
circul
franc
genet
plastic
result
highlight
interest
epidemiolog
surveil
mrsa
circul
european
countri
abl
follow
dynam
variou
clone
adapt
manag
invas
mrsa
infect
ii
dynam
mrsa
clone
demonstr
potenti
dissemin
andor
emerg
specif
mrsa
clone
countri
scale
short
period
time
use
apaipfg
seven
pulsotyp
ag
detect
type
b
account
strain
sccmec
type
v
found
isol
three
sccmec
type
iv
six
differ
spa
type
identifi
one
strain
spa
neg
pcr
microarray
analysi
tetr
mediat
tet
tet
k
isol
ciprofloxacin
resist
resist
erythromycin
clindamycin
erm
c
mediat
multiresist
detect
isol
four
show
expand
resist
pattern
r
six
antibiot
class
isol
carri
gene
codifi
type
capsul
none
strain
carri
pvl
gene
exfoli
toxin
gene
eta
etb
etd
enterotoxin
gene
cluster
tst
gene
also
neg
conclus
although
rare
pathogen
last
two
year
number
isol
infect
colon
pt
increas
significantli
set
pt
harbor
clone
often
debilit
underli
diseas
genet
variabl
high
among
isol
near
half
isol
resist
multipl
antibiot
object
four
distinct
serotyp
dengu
viru
denv
serotyp
may
caus
diseas
rang
mild
febril
ill
devast
manifest
includ
dengu
hemorrhag
fever
dengu
shock
syndrom
diseas
sever
denv
infect
appear
control
presenc
crossreact
denv
antibodi
direct
envelop
e
precursor
membran
prm
facilit
antibodydepend
enhanc
infect
recent
report
immatur
denv
turn
highli
infecti
presenc
prm
antibodi
antibodi
facilit
effici
bind
cell
entri
immatur
particl
fcreceptor
express
cell
addit
enzymat
activ
furin
present
endosom
critic
render
intern
immatur
viru
infecti
studi
analyz
antibodi
recogn
e
protein
also
promot
viral
infect
immatur
viru
particl
method
immatur
strain
particl
produc
furindefici
lovo
cell
infecti
properti
immatur
standard
denvimmun
complex
investig
fcrexpress
human
monocyt
cell
line
murin
macrophag
cell
line
human
pbmc
plaqu
assay
presenc
absenc
furin
inhibitor
result
vast
major
anti
mab
test
enhanc
viral
infect
immatur
dengu
furindepend
manner
furthermor
found
presenc
nonneutr
immun
serum
immatur
virion
normal
nonvirul
caus
lethal
diseas
mice
e
antibodi
test
facilit
bind
uptak
immatur
virion
endocyt
pathway
target
cell
antibodi
promot
infect
anti
mab
stimul
viral
infect
may
interfer
conform
chang
virion
prior
furin
cleavag
fusion
process
taken
togeth
result
support
notion
antibodi
structur
protein
prm
e
enhanc
infect
prmcontain
immatur
partial
matur
flaviviru
particl
current
run
experi
use
acut
sera
sampl
patient
develop
differ
diseas
outcom
assess
whether
immatur
particl
contribut
diseas
pathogenesi
anticip
present
result
confer
well
object
recent
report
herp
simplex
infect
enter
nervou
system
en
orogastr
rout
result
gastrointestin
inflamm
dysfunct
sinc
en
possess
molecular
machineri
recogn
react
viral
infect
decid
decod
function
relev
tolllik
receptor
tlr
mediat
respons
investig
whether
innat
immun
driven
respons
harm
neuron
function
integr
method
adult
wt
knockout
ko
mice
inocul
intranas
week
w
intragastr
ig
mice
sacrif
post
ig
rna
extract
longitudin
muscl
myenter
plexu
lmmp
evalu
viral
transcript
distal
ileum
segment
assess
chang
muscl
tension
use
electr
field
stimul
isol
organ
bath
en
integr
immunofluoresc
whole
mount
prepar
immun
cell
mucosa
lmmp
analyz
fluoresc
activ
flow
cytometri
fac
result
wt
mice
latencyassoci
transcript
lat
detect
post
ig
gc
mrna
detect
activ
macrophag
infiltr
mucosa
earli
stage
infect
wherea
resid
cell
shown
bare
phagocyt
activ
reactiv
lymphocyt
identifi
lmmp
post
ig
inde
post
ig
ileal
contractil
reduc
en
structur
damag
ie
loss
neuron
hucd
glial
immunoreact
mice
gc
mrna
detect
lmmp
post
ig
infect
lat
appear
inde
mice
infiltr
cell
identifi
resid
mucos
macrophag
preserv
phagocyt
activ
infg
product
detect
fac
analysi
infect
mice
fail
develop
strong
adapt
immun
respons
intestin
contractil
increas
post
ig
infect
object
peritonsillar
abscess
pta
frequent
complic
acut
tonsil
one
preval
caus
acut
admiss
otorhinolaryngolog
depart
viral
infect
shown
predispos
develop
acut
bacteri
complic
acut
otiti
media
sinus
pneumonia
aim
examin
whether
virus
also
play
role
pathogenesi
pta
method
examin
palatin
tonsil
patient
undergo
acut
tonsillectomi
pta
use
pcrbase
assay
specif
herp
simplex
herp
simplex
adenoviru
epsteinbarr
viru
ebv
influenza
b
respiratori
syncyti
viru
rsv
b
similarli
examin
tonsil
patient
undergo
elect
tonsillectomi
due
recurr
tonsil
rt
andor
tonsillar
hypertrophi
th
persist
sore
throat
syndrom
pst
elect
group
serv
control
group
clinic
appar
infect
time
surgeri
patient
age
year
without
antibiot
treatment
month
preced
surgeri
includ
studi
result
mean
age
pta
elect
tonsillectomi
group
compar
year
year
respect
adenoviru
ebv
detect
studi
popul
statist
signific
differ
frequenc
virus
identifi
pta
group
vs
elect
tonsillectomi
group
patient
rt
th
rt
th
quantif
ebv
load
demonstr
differ
pta
group
elect
tonsillectomi
group
pta
group
differ
abscess
nonabscess
contralater
tonsil
concord
contralater
tonsil
found
poor
adenoviru
concord
respect
high
ebv
like
reflect
rel
viral
load
virus
tonsil
conclus
summari
data
support
signific
role
examin
virus
pathogenesi
pta
howev
studi
highlight
tonsil
reservoir
adenoviru
ebv
adolesc
young
adult
furthermor
show
degre
concord
contralater
tonsil
variabl
depend
viru
studi
approach
enhanc
specif
accuraci
earli
diagnosi
precis
administr
antiretrovir
drug
hiv
manag
sustain
poc
prototyp
base
multimark
cantilev
nanosensor
platform
integr
sampl
sort
nanopillar
surfac
captur
chemistri
technolog
offer
mani
opportun
direct
detect
protein
antigen
antibodi
infecti
organ
potenti
direct
detect
organ
without
need
label
nanopillar
act
microfluid
siev
separ
concentr
differ
marker
infect
clinic
sampl
present
low
copi
antigen
detect
quantifi
flow
across
array
cantilev
nanosensor
functionalis
care
select
high
affin
captur
molecul
rais
differ
sub
type
hiv
virion
subsequ
specif
biomolecular
bind
event
translat
nanomechan
signal
analys
interfer
pattern
creat
illumin
laser
find
sensor
geometri
receptor
chemistri
key
limit
hiv
multipl
marker
detect
particularli
regimen
allow
earli
diagnosi
show
cantilev
array
potenti
highthroughput
multitarget
screen
amen
larg
scale
product
compact
portabl
poc
devic
use
anywher
world
nanomechan
sensor
microorgan
growth
detect
g
lukac
n
maloney
hegner
dublin
ie
object
fast
detect
viabl
microorgan
great
import
sever
differ
field
microbiolog
due
increas
antibiot
resist
microorgan
fast
growth
detect
method
need
clinic
environ
antibiot
suscept
test
exist
cultur
method
time
consum
materi
heavi
livedead
cell
discrimin
difficult
use
microcantilev
array
microbi
growth
detect
provid
rapid
techniqu
monitor
growth
clinic
industri
applic
method
biolog
sensor
base
oscil
cantilev
dynam
mode
reson
frequenc
respons
cantilev
array
cla
track
use
laser
beam
deflect
method
figur
frequenc
shift
caus
addit
mass
load
onto
cantilev
cantilev
function
agaros
layer
supplement
cultur
medium
aspergillu
niger
spore
seed
cantilev
surfac
use
inkjet
print
techniqu
microbi
growth
microorgan
assimil
nutrit
water
nutrit
layer
humid
air
result
increas
mass
cantilev
result
use
cla
allow
aspergillu
niger
growth
detect
within
hour
differ
magnitud
frequenc
respons
due
differ
number
viabl
spore
cantilev
observ
initi
reson
frequenc
decreas
detect
fungal
growth
subsequ
hypha
growth
along
cantilev
longitudin
axi
result
reson
frequenc
increas
use
refer
cantilev
allow
differenti
signal
record
thu
true
chang
reson
frequenc
extract
data
current
use
cantilev
array
eight
cantilev
per
array
provid
opportun
perform
parallel
measur
differ
growth
condit
egantibiot
suscept
test
conclus
growth
variou
microorgan
detect
monitor
use
microcantilev
sensor
compar
convent
method
cantilev
sensor
use
less
cultur
medium
functionalis
detect
automat
techniqu
label
free
use
multipl
cantilev
provid
opportun
test
variou
antimicrobi
agent
parallel
collabor
caltech
novarti
develop
devic
provid
userfriendli
multiplex
portabl
version
industri
hospit
measur
specif
interferongamma
measur
diagnos
previou
exposur
coxiella
burnetii
prevaccin
screen
object
recent
q
fever
epidem
netherland
vaccin
whole
bacteri
coxiella
burnetii
vaccin
qvax
csl
offer
subject
increas
risk
chronic
q
fever
vaccin
report
seriou
side
effect
individu
novel
method
diagnos
infect
subclin
infect
c
burnetii
accord
manufactur
guidelin
vaccin
candid
therefor
test
serolog
intraderm
skintest
develop
feasibl
antigenspecif
interferongamma
ifng
assay
diagnos
previou
infect
c
burnetii
recent
dutch
vaccin
campaign
compar
assay
serolog
skintest
method
ifng
assay
heparinis
blood
collect
incub
inactiv
whole
c
burnetii
nine
mile
phase
bacteria
hour
neg
control
stimulu
nonspecif
control
pha
incub
simultan
ifng
concentr
measur
supernat
elisa
assay
perform
vaccin
candid
also
test
serolog
skin
test
prior
vaccin
result
individu
conclus
result
ifng
assay
individu
evalu
result
three
test
includ
analysi
individu
either
posit
serolog
n
igg
phase
titer
posit
skintest
n
indur
mm
ifng
product
pgml
mean
se
significantli
p
higher
pgml
seroneg
skin
test
neg
individu
figur
posit
serolog
skin
test
use
marker
previou
infect
c
burnetii
roccurv
assay
show
test
accuraci
confid
interv
interestingli
ifng
product
patient
serolog
profil
compat
chronic
q
fever
defin
dutch
guidelin
chronic
q
fever
igg
phase
high
pgml
conclus
q
feverspecif
ifng
assay
use
method
detect
individu
previou
contact
c
burnetii
use
prevaccin
screen
valu
test
diagnosi
chronic
q
fever
deserv
evalu
object
q
fever
highli
contagi
zoonot
diseas
caus
coxiella
burnetii
present
q
fever
human
variabl
asymptomat
acut
chronic
diseas
q
fever
fatigu
syndrom
diagnos
princip
serolog
antibodi
pattern
phase
ii
differenti
acut
convalesc
chronic
q
fever
howev
current
serolog
method
discrimin
suffici
earli
enough
acut
chronic
q
fever
convalesc
stage
make
prevent
treatment
problemat
method
use
recent
develop
protein
microarray
character
humor
immun
respons
acut
chronic
q
fever
patient
dutch
outbreak
search
new
serolog
marker
identifi
chronic
q
fever
array
contain
proteom
c
burnetii
serolog
profil
sampl
acut
clinic
proven
chronic
patient
compar
control
sampl
antibodi
kinet
influenc
antibiot
treatment
antibodi
respons
studi
followup
sampl
patient
result
sever
serolog
marker
significantli
present
higher
level
patient
diagnos
chronic
q
fever
compar
acut
patient
detect
marker
may
therefor
better
indic
chronic
diseas
level
igg
phase
immuno
fluoresc
assay
decreas
antibodi
respons
observ
follow
serum
sampl
acut
infect
treatment
chronic
q
fever
observ
possibl
reactiv
least
two
chronic
q
fever
patient
indic
increas
antibodi
respons
identifi
marker
discontinu
antibiot
treatment
conclus
dutch
q
fever
outbreak
challeng
true
challeng
might
still
ahead
us
tri
identifi
patient
risk
allow
us
prevent
treat
chronic
q
fever
case
futur
serolog
marker
identifi
may
help
us
identifi
patient
risk
develop
chronic
q
fever
earlier
stage
current
possibl
might
also
use
follow
monitor
treatment
respons
would
prescrib
antibiot
upon
present
would
wait
symptom
persist
day
order
administ
antibiot
respond
state
cap
pt
choos
treat
outpati
amoxicillinmacrolid
combin
select
copd
exacerb
antibiot
administr
chosen
anthonisen
criteria
appli
macrolid
chosen
femal
physician
urban
region
score
better
prescrib
habit
applic
clinic
criteria
specialti
affect
antibiot
choic
cap
amoxicillinmacrolid
chosen
p
vs
gp
p
copd
exacerb
macrolid
gp
vs
amoxicillinclavulan
p
p
physician
state
ask
prescrib
antibiot
retrospect
common
area
outsid
athen
p
seem
correl
significantli
prescript
antibiot
sore
throat
p
conclus
signific
room
improv
prescrib
habit
choic
line
agent
among
communitypract
physician
respect
respiratori
tract
infect
use
simpl
clinic
tool
eg
day
watchfulwait
rule
sinus
anthonisen
criteria
streptest
need
expand
embed
daili
practic
mean
appropri
antibiot
prescrib
patient
pressur
prescrib
antibiot
may
affect
physician
habit
certain
case
educ
physician
patient
especi
nonmetropolitan
area
could
provid
viabl
solut
combat
antibiot
overprescrib
object
mani
countri
requir
sick
note
claim
sick
leav
benefit
necessit
patient
consult
physician
often
result
antimicrobi
prescript
socioeconom
cultur
healthregulatori
determin
demonstr
correl
antimicrobi
consumpt
therefor
evalu
possibl
relat
differ
legitim
period
uncertifi
sick
leav
antibiot
consumpt
method
data
length
sick
leav
without
medic
certif
slwc
collect
via
email
survey
european
foundat
improv
live
work
condit
variou
websit
countri
selfcertif
code
intrins
longest
period
data
antibiot
consumpt
obtain
european
surveil
antimicrobi
consumpt
databas
use
twotail
spearman
rho
correl
compar
slwc
mean
antibiot
consumpt
also
relat
slwc
potenti
influenti
paramet
uncertainti
avoid
index
uai
power
distanc
index
deschepp
et
al
age
group
distribut
physician
densiti
nation
incom
masiero
et
al
physician
consult
rate
chahwakilian
data
organis
econom
cooper
develop
result
sick
leav
data
could
obtain
european
countri
median
slwc
day
rang
day
import
invers
correl
slwc
antimicrobi
consumpt
rho
p
figur
also
similarli
high
correl
uai
rho
p
control
uai
greatli
reduc
correl
slwc
antimicrobi
consumpt
rho
p
factor
none
found
correl
slwc
result
indic
legal
requir
regard
sick
leav
selflimit
infect
least
partial
influenc
antimicrobi
consumpt
pattern
interact
cultur
aspect
order
reduc
antimicrobi
consumpt
differ
legisl
bodi
healthcar
regul
screen
regul
inadvert
counterproduct
effect
analysi
antibiot
prescript
done
gener
practition
urinari
tract
infect
j
prouzergu
e
dene
ducroixroubert
c
aupetit
p
weinbreck
limog
fr
object
juli
franc
guidelin
prescript
antibiot
urinari
tract
infect
uti
edit
guidelin
tri
spare
fluoroquinolon
avoid
emerg
resist
bacteria
first
line
prefer
treatment
compris
preferenti
fosfomycinetrometamol
nitrofurantoin
cystiti
gener
cephalosporin
nephriti
prostat
gener
practition
take
charg
lot
uti
want
know
knew
follow
guidelin
method
perform
prospect
studi
point
call
urinalysi
done
outpati
biolog
lab
perform
bacteriolog
analysi
mani
lab
either
town
suburb
use
select
method
coupl
criteria
urinalysi
diagnosi
sure
patient
present
uti
patient
exclud
nosocomi
infect
prescript
done
urologist
less
perman
urinari
cathet
gp
call
phone
retriev
characterist
antibiot
prescript
result
studi
includ
urinalysi
prescrib
gp
studi
popul
primarili
women
mean
age
year
diagnos
done
gp
acut
cystiti
prostat
nephriti
asymptomat
bacteriuria
main
antibiot
use
quinolon
furan
cotrimoxazol
prescript
compliant
guidelin
ie
whole
prescript
good
molecul
dose
length
treatment
right
molecul
dose
length
prescript
chosen
prescript
prescript
nephriti
wrong
employ
molecul
diffus
kidney
firstgener
quinolon
furan
mistak
also
seen
prostat
asymptomat
bacteriuria
treat
antibiot
cystiti
inappropri
prescript
accompani
cost
name
per
treatment
conclus
gp
prescript
uti
follow
guidelin
even
publish
year
studi
thu
known
appli
even
gp
assert
awar
resist
strain
emerg
seem
take
account
quinolon
spare
spirit
one
backbon
guidelin
clinic
microbiolog
liaison
broadspectrum
antibacteri
use
primari
care
joint
acut
trustprimari
care
intervent
studi
c
hill
peel
r
sharma
guleri
blackpool
uk
background
treatment
quinolon
cephalosporin
coamoxiclav
associ
increas
risk
develop
clostridium
difficil
infect
cdi
blackpool
teach
hospitalsprimari
care
partnership
healthcar
associ
infect
antibiot
stewardship
infect
control
programm
across
whole
health
economi
teamwork
sinc
last
sever
year
present
review
strateg
plan
initi
result
reduct
prescript
agent
c
diificil
infect
primari
care
object
sepsi
import
caus
neonat
morbid
mortal
especi
preterm
low
birth
infant
earli
diagnosi
pathogen
prompt
treatment
critic
prevent
sever
lifethreaten
complic
patient
howev
clinic
recognit
sepsi
neonat
difficult
sign
symptom
often
nonspecif
blood
cultur
rare
posit
recent
avail
molecular
assay
aid
rapid
detect
microorgan
improv
diagnost
flowchart
method
commerci
multiplex
realtim
pcr
lightcycl
septifast
assay
roch
molecular
system
use
male
preterm
low
birth
infant
birth
weight
g
diagnos
stenotrophomona
maltophilia
bloodstream
infect
receiv
antimicrobi
treatment
teicoplanin
netilmycin
ciprofloxacin
day
without
improv
lightcycl
septifast
assay
use
renov
technolog
enabl
direct
detect
blood
sampl
wide
panel
bacteri
fungal
microorgan
commonli
involv
system
infect
molecular
test
perform
ml
blood
instead
ml
unlik
manufactur
instruct
due
difficulti
draw
blood
small
vein
parallel
new
cultur
request
includ
peripher
blood
umbil
cathet
tip
cultur
result
within
hour
upon
recept
blood
septifast
dna
maltophilia
esherichia
coli
candida
albican
amplifi
blood
sampl
report
neonat
intens
care
unit
antifung
treatment
amphotericin
b
promptli
ad
therapi
follow
day
culturebas
approach
confirm
molecular
result
blood
cultur
posit
gramneg
rod
two
addit
day
definit
identif
maltophilia
obtain
initi
blood
cultur
e
coli
grown
hour
incub
umbil
cathet
tip
cultur
c
albican
recov
neither
blood
cultur
day
incub
cathet
tip
one
rectal
swab
cultur
detect
yeast
conclus
present
report
gave
indic
even
low
blood
volum
draw
polymicrobi
septicemia
rapidli
detect
use
septifast
assay
impact
aminoglycosid
combin
therapi
outcom
length
stay
advers
event
cost
treatment
healthcar
associ
pneumonia
object
bacteri
resist
increas
problem
threaten
use
antibiot
treat
infect
specif
multidrug
resist
mdr
gramneg
organ
becom
major
concern
limit
treatment
option
increas
length
stay
lo
cost
mortal
associ
infect
studi
cost
associ
mdr
pseudomona
aeruginosa
mean
cost
hospit
mean
lo
day
patient
mdr
isol
vs
suscept
isol
increas
cost
could
part
attribut
delay
appropri
empir
therapi
delay
advers
affect
clinic
outcom
mortal
similar
studi
p
aeruginosa
bacteremia
indic
hospit
mortal
statist
higher
inappropri
empir
therapi
compar
appropri
empir
therapi
vs
p
healthcar
associ
pneumonia
hcap
describ
differenti
pneumonia
patient
risk
factor
resist
pathogen
recommend
includ
combin
therapi
antipseudomon
betalactam
aminoglycosid
improv
probabl
initi
appropri
therapi
anoth
potenti
impact
synergist
bactericid
effect
may
result
faster
resolut
symptom
compar
monotherapi
studi
determin
impact
addit
aminoglycosid
treatment
hcap
method
data
collect
retrospect
includ
geriatr
patient
diagnosi
hcap
twoyear
period
studi
group
consist
patient
treat
antipseudomon
betalactam
plu
aminoglycosid
control
group
antipseudomon
betalactam
without
aminoglycosid
data
collect
length
stay
inpati
cost
readmiss
advers
event
attribut
therapi
clinic
outcom
result
two
hundr
twentyseven
patient
includ
analysi
patient
receiv
aminoglycosid
combin
therapi
patient
receiv
betalactam
therapi
without
aminoglycosid
mean
observ
lo
day
shorter
aminoglycosid
therapi
result
lower
overal
inpati
cost
signific
differ
identifi
comparison
readmiss
advers
event
attribut
therapi
conclus
short
cours
high
dose
aminoglycosid
combin
initi
antipseudomon
betalactam
therapi
hcap
may
pharmacoeconom
impact
shorten
lo
reduc
overal
cost
ft
mic
ceftazidim
predict
probabl
microbiolog
outcom
treatment
nosocomi
pneumonia
caus
gramneg
bacteria
ae
muller
n
punt
jw
mouton
rotterdam
maastricht
nijmegen
nl
object
ceftazidim
caz
broad
spectrum
cephalosporin
activ
gramneg
microorgan
gn
includ
p
aeruginosa
ft
mic
shown
correl
microbiolog
outcom
mo
anim
model
invitro
pharmacokinet
model
howev
clinic
data
still
lack
explor
relationship
caz
exposur
mo
gramneg
patient
nosocomi
pneumonia
np
treat
caz
g
tid
infus
hour
determin
pkpd
index
valu
correl
outcom
use
data
recent
random
doubleblind
phase
clinic
trial
compar
efficaci
ceftobiprol
combin
caz
linezolid
method
pharmacokinet
pk
demograph
data
patient
three
clinic
trial
includ
np
studi
extract
exist
databas
construct
popul
pk
model
caz
use
nonmem
individu
concentr
time
curv
ft
mic
determin
everi
individu
patient
use
covari
andor
data
spars
sampl
mic
use
analys
highest
mic
gn
microorgan
cultur
baselin
end
treatment
eot
conclus
asp
initi
assess
extend
infus
doripenem
demonstr
trend
toward
improv
outcom
lower
cost
era
escal
p
aeruginosa
resist
asp
must
implement
altern
dose
strategi
exist
antibiot
optim
patient
outcom
softwar
enabl
optim
precis
dosag
adjust
voriconazol
achiev
predefin
serum
concentr
target
critic
patient
program
lapk
abil
rightdos
provid
estim
voriconazol
regimen
enabl
predefin
serum
concentr
eg
trough
concentr
mgl
obtain
assess
silico
result
use
prior
inform
contain
densiti
file
popul
analysi
concentrationtim
profil
patient
could
predict
high
degre
accuraci
despit
patient
nonlinear
pharmacokinet
updat
multipl
model
file
obtain
patient
big
doser
program
provid
predict
dosag
requir
achiev
predefin
trough
concentr
mgl
individu
patient
process
dosag
optimis
begin
first
dose
interv
mean
therapeut
nontox
serum
concentr
potenti
achiev
first
hour
dose
conclus
softwar
potenti
enabl
achiev
desir
voriconazol
serum
concentr
optim
precis
manner
potenti
use
tool
clinician
prospect
clinic
studi
requir
assess
perform
softwar
critic
ill
patient
antimicrobi
resist
environ
method
number
environment
site
newli
built
nurs
home
n
select
monitor
prior
n
post
habit
n
resid
select
site
includ
five
site
within
two
singl
room
sr
site
share
area
sa
seven
site
daycar
dc
area
copan
eswab
enrich
overnight
pepton
water
cultur
onto
seri
chromogen
agar
detect
extend
spectrum
betalactamas
esbl
produc
enterobacteriacea
meticillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
vre
suspect
isol
mrsa
confirm
use
pastorerxtm
staphplu
kit
antimicrobi
suscept
test
esbl
confirm
disk
synergi
test
pcr
sequenc
vre
confirm
growth
blood
bile
aesculin
agar
resist
vancomycin
clsi
disk
diffus
method
vitek
identif
result
environment
contamin
mrsa
detect
initi
round
test
detect
staff
exist
nh
begun
work
commiss
subsequ
habit
mrsa
detect
swab
collect
week
period
area
mrsa
commonli
found
floor
bed
frame
bed
side
locker
arm
chair
toilet
seat
tabl
door
handl
object
hospit
import
foci
intens
antimicrobi
use
select
dissemin
antimicrobi
resist
amr
within
hospit
set
well
recognis
potenti
hospit
effluent
carri
amr
bacteria
environ
well
studi
gener
hospit
effluent
enter
municip
stream
wastewat
treatment
plant
wwtp
discharg
environ
evalu
impact
hospit
effluent
amr
escherichia
coli
municip
effluent
abil
secondari
wastewat
treatment
remov
amr
e
coli
method
water
two
municip
effluent
system
evalu
one
system
receiv
effluent
major
teach
hospit
second
wwtp
influent
effluent
sampl
occas
total
e
coli
amr
e
coli
modifi
probabl
number
method
galvin
et
al
twosampl
ttest
use
evalu
differ
two
system
impact
wastewat
treatment
total
amr
e
coli
number
result
amr
e
coli
includ
resist
ampicillin
tetracyclin
ciprofloxacin
detect
influent
effluent
wwtp
plant
significantli
reduc
total
number
e
coli
p
p
gener
reduc
number
amr
e
coli
statist
signific
differ
two
system
respect
e
coli
ampicillin
sulphonamid
ciprofloxacin
wastewat
inflow
wwtp
howev
e
coli
resist
tetracyclin
streptomycin
significantli
numer
influent
includ
hospit
effluent
conclus
amr
e
coli
common
municip
wastewat
signific
variat
sampl
sampl
term
number
e
coli
number
amr
e
coli
present
secondari
wwtp
reduc
number
total
e
coli
amr
e
coli
discharg
gener
environ
result
show
evid
consist
impact
hospit
effluent
number
e
coli
resist
ampicillin
sulphonamid
ciprofloxacin
influent
wwtp
suggest
may
impact
number
e
coli
resist
tetracyclin
streptomycin
object
potenti
risk
aquacultur
public
health
includ
develop
antibiot
resist
abr
bacteriagen
reservoir
reach
human
food
chain
goal
assess
occurr
flux
abr
gene
among
enterococccu
two
ab
free
trout
aquacultur
receiv
water
secondari
river
method
two
portugues
trout
aquacultur
traa
trab
ab
use
feed
contain
copper
cu
given
fish
studi
winter
summer
sampl
collect
river
watersedi
locat
upstream
n
downstream
n
tra
watersedi
juvenileadult
fish
tank
feed
fish
enrich
pepton
water
plate
slanetzbartley
plain
supplement
ab
suscept
ab
studi
disc
diffus
clsi
aim
studi
investig
antibiot
resist
ar
profil
virul
hallmark
environment
bacteria
isol
wastewat
receiv
river
materi
method
sampl
analyz
classic
microbiolog
analysi
identif
faecal
coliform
e
coli
enterococci
pseudomona
aeruginosa
accord
sr
en
iso
document
antibiot
suscept
profil
assess
classic
disk
diffus
method
clsi
doubl
disk
diffus
test
dddt
chromogen
etest
adher
cellular
substrat
assess
hela
cell
solubl
virul
factor
quantifi
use
specif
media
differ
biochem
substrata
reveal
haemolysin
lecithinas
gelatinas
lipas
dnase
amylas
iron
chelat
agent
simpl
multiplex
pcr
assay
use
identifi
genet
support
resist
gene
betalactam
blatem
blashv
blactxm
blavim
blaimp
blaps
blacmi
aminoglycosid
aac
ib
aac
ieaph
tetracyclin
teta
tetb
result
isol
bacteri
strain
identifi
klebsiella
sp
citrobact
sp
enterobact
sp
aeromona
sp
burkholderia
sp
cryseomona
sp
pseudomona
sp
enterococcu
sp
escherichia
coli
enterobacteriacea
test
strain
exhibit
resist
tetracyclin
aztreonam
aminoglycosid
total
strain
exhibit
acquir
antibiot
resist
phenotyp
enterococcu
strain
isol
wastewat
show
high
level
erythromycin
tetracyclin
resist
differ
betalactam
resist
gene
identifi
among
differ
speci
ie
blavim
blatem
blactxm
blacmi
major
aquat
strain
exhibit
high
abil
adher
cellular
substrat
produc
lipas
lecithinas
could
act
poreform
toxin
case
tissu
colon
result
present
studi
shown
wastewat
provid
favor
condit
growth
divers
bacteri
commun
constitut
basi
select
spread
antibiot
resist
virul
determin
high
risk
human
host
colon
dissemin
particular
mechan
resist
commun
object
era
increas
emerg
azoleresist
aspergillu
fumigatu
combin
antifung
agent
may
altern
approach
improv
therapeut
outcom
azoleresist
invas
aspergillosi
ia
efficaci
antifung
agent
describ
pharmacodynam
indic
pdi
area
concentrationtim
curv
mic
auc
mic
explor
whether
pdi
explain
efficaci
monotherapi
would
explain
efficaci
combin
therapi
anim
model
ia
method
femal
mice
infect
intraven
hour
prior
start
therapi
vczsuscept
vczresist
aspergillu
fumigatu
fourteen
day
efficaci
data
surviv
determin
variou
combin
regimen
mg
kg
voriconazol
vcz
plu
anidulafungin
afg
agent
singli
group
mice
treat
intraperiton
daili
seven
consecut
day
paramet
dose
determin
pharmacokinet
experi
use
calcul
pdi
strain
multipl
regress
analysi
use
determin
import
variou
pdi
monotherapi
efficaci
combin
regimen
predict
basi
linear
regress
analysi
singl
agent
highest
valu
predict
compar
observ
outcom
combin
therapi
determin
presenc
synerg
object
voriconazol
vcz
becom
drug
choic
treatment
invas
aspergillosi
although
strain
reduc
vitro
suscept
vcz
describ
clinic
breakpoint
yet
defin
pharmacokineticpharmacodynam
analysi
help
identifi
vcz
resist
isol
aim
studi
investig
efficaci
vcz
aspergillu
fumigatu
afm
use
novel
vitro
pharmacokineticpharmacodynam
pkpd
model
identifi
drugresist
isol
method
two
clinic
isol
afm
vcz
clsi
mic
mgl
wild
type
strain
mgl
mutat
tr
includ
standard
vcz
dosag
mgkg
simul
new
vitro
pk
simul
system
halflif
c
max
mgl
observ
patient
purkin
et
al
aac
new
system
consist
intern
compart
ic
ml
dialysi
tube
made
semiperm
cellulos
membran
allow
free
diffus
molecul
mw
kda
place
insid
extern
compart
ec
ml
glass
beaker
whose
content
dilut
peristalt
pump
rate
clearanc
vcz
human
plasma
aspergillu
conidia
inocul
insid
ic
vcz
ad
ic
ec
drug
level
determin
microbiolog
method
fungal
growth
measur
galactomannan
concentr
ic
sandwichelisa
biorad
area
drug
concentrationtim
curv
pk
paramet
area
galactomannan
concentrationtim
curv
aucgi
pd
paramet
determin
dose
isol
hour
percent
growth
inhibit
dose
calcul
voraucgi
gc
aucgi
vor
aucgi
certain
vcz
dose
wherea
aucgi
gc
aucgi
drug
free
control
result
simul
dose
mgkg
vcz
result
mghourl
correspond
lower
protein
bind
observ
patient
receiv
standard
dose
mgkg
mghourl
purkin
et
al
aac
take
account
popul
variabl
second
patient
growth
inhibit
observ
isol
mic
mgl
isol
mic
mgl
conclus
pkpd
analysi
vcz
vitro
activ
strongli
indic
afm
isol
vcz
clsi
mic
mgl
classifi
resist
object
vivoin
vitro
correl
antifung
combin
test
necessari
order
reliabl
assess
efficaci
combin
regimen
therefor
attempt
correl
vitro
checkerboard
test
posaconazol
po
amphotericin
b
object
select
digest
tract
decontamin
sdd
select
oropharyng
decontamin
sod
associ
improv
patient
outcom
lower
carriag
rate
antibioticresist
bacteria
arb
icupati
netherland
regimen
patient
receiv
oropharyng
decontamin
colistin
tobramycin
sdd
sod
patient
receiv
intestin
decolon
colistin
tobramycin
cours
cefotaxim
determin
unitwid
effect
sdd
sod
intestin
carriag
arb
clusterrandom
crossov
crco
studi
netherland
compar
month
sdd
sod
gonorrhoea
second
common
bacteri
sexual
transmit
infect
countri
across
europ
public
health
control
depend
prevent
measur
effect
antimicrobi
therapi
threaten
emerg
resist
therapeut
failur
current
therapi
surveil
gonococc
infect
paramount
import
monitor
preval
antimicrobi
resist
detect
drift
suscept
order
inform
nation
intern
guidelin
mani
countri
europ
maintain
nation
programm
mobil
popul
essenti
european
wide
approach
provid
time
coordin
inform
prevent
spread
antimicrobi
resist
gonorrhoea
across
europ
surveil
gonococc
antimicrobi
resist
across
europ
initi
sinc
compon
european
network
surveil
sexual
transmit
infect
coordin
european
centr
diseas
prevent
control
ecdc
aim
microbiolog
compon
improv
qualiti
laboratori
surveil
gonorrhea
chlamydia
includ
lgv
syphili
strengthen
surveil
neisseria
gonorrhoea
suscept
eueea
member
state
candid
countri
network
refer
expert
laboratori
particip
european
gonococc
antimicrobi
suscept
programm
eurogasp
programm
consist
number
compon
includ
sentinel
surveil
gonococc
resist
therapeut
antimicrobi
agent
extern
qualiti
assur
assess
laboratori
capac
train
cours
use
molecular
type
public
health
purpos
decreas
suscept
therapeut
failur
emerg
current
agent
choic
countri
extend
spectrum
cephalosporin
paramount
data
obtain
dissemin
time
manner
achiev
object
sentinel
surveil
antimicrobi
resist
establish
countri
initi
test
centralis
provid
annual
data
recent
extend
includ
decentralis
test
provid
data
twice
yearli
key
compon
eurogasp
provid
train
increas
capac
nonparticip
countri
improv
coverag
repres
neisseria
gonorrhoea
respons
caus
gonorrhoea
one
common
sexual
transmit
diseas
although
remark
progress
made
lower
incid
diseas
worri
gonorrhoea
becom
much
difficult
infect
treat
increas
morbid
cost
recent
scientif
commun
discuss
emerg
n
gonorrhoea
strain
resist
antimicrobi
drug
avail
new
strain
call
isol
japan
contain
genet
mutat
make
resist
penicillin
ciprofloxacin
tetracyclin
also
thirdgener
cephalosporin
includ
ceftriaxon
wide
recommend
first
line
treatment
gonorrhoea
around
world
multidrug
resist
gonococcu
may
consid
superbug
initi
futur
era
untreat
gonorrhoea
resist
esc
extendedspectrum
cephalosporin
cefixim
ceftriaxon
document
due
presenc
multipl
chromosom
chang
pena
gene
form
basi
reduc
susceptibilityresist
antimicrobi
resist
amrng
multidrug
resist
mdrng
recent
extens
drug
resist
n
gonorrhoea
xdrng
differ
class
antibiot
import
public
health
concern
gonorrhoea
data
european
surveil
antimicrobi
resist
gonorrhoea
cole
et
al
show
isol
decreas
suscept
cefixim
upward
trend
minimum
inhibitori
concentr
ceftriaxon
high
preval
resist
ciprofloxacin
azithromycin
itali
around
isol
test
antimicrobi
suscept
particular
among
gonococci
isol
seven
show
mdr
phenotyp
due
resist
four
differ
antibiot
includ
cefixim
mic
mgl
enhanc
systemat
sentinel
surveil
amr
mdr
gonorrhoea
promot
suscept
test
studi
genet
mechan
resist
prioriti
key
point
control
strategi
combat
spread
mdr
gonococci
sustain
integr
intern
effort
reduc
rate
gonorrhoea
misus
antibiot
requir
stem
emerg
spread
multidrugresist
strain
nonmammalian
model
infect
dictyostelium
model
studi
pathogenesi
mycobacteri
infect
soldati
geneva
ch
pathogen
mycobacteria
mycobacetrium
tuberculosi
marinum
utilis
common
strategi
invad
phagocyt
innat
immun
system
manipul
otherwis
bactericid
phagocyt
apparatu
increas
success
celltocel
transmiss
marinum
closest
rel
mycobacteria
tuberculosi
complex
provid
power
model
studi
pathogenesi
tuberculosi
genet
tractabl
model
organ
drosophila
zebrafish
soil
amoeba
dictyostelium
discoideum
becom
popular
experiment
model
studi
cellautonom
innat
immun
respons
discoideum
human
phagocyt
share
sever
conserv
function
engulf
kill
digest
microorgan
phagocytosi
use
discoideum
host
identifi
character
mycobacteri
host
factor
modul
resist
infect
celltocel
spread
studi
bacteria
sens
kill
role
nadphoxidas
ro
product
studi
specif
role
three
nox
isoform
ro
product
suscept
mycobacteria
infect
also
studi
role
three
paralog
famili
scaveng
receptor
type
b
one
present
surfac
act
receptor
two
lysosom
implic
traffick
hydrolas
like
tuberculosi
macrophag
marinum
interfer
phagosom
matur
modul
membran
traffick
event
compart
develop
quantitativecompar
proteom
techniqu
live
cell
imag
variou
probe
phagolysosom
pathway
studi
mechan
matur
arrest
final
stage
infect
marinum
tuberculosi
escap
vacuol
cytosol
studi
complex
import
put
mycobacteri
poreform
toxin
autophagi
pathway
genesi
mainten
breakag
compart
overal
studi
demonstr
conserv
pathogen
virul
strategi
host
defenc
mechan
ensur
success
discoideum
power
simpl
hostpathogen
model
system
studi
mechan
mycobacteri
infect
context
recent
effort
direct
use
altern
system
screen
small
chemic
interfer
infect
either
antimycobacteria
virul
host
immunityboost
compound
result
ratio
two
strain
skew
toward
one
predomin
effect
lost
phagocyt
deplet
mathemat
model
pathogen
dynam
consist
small
number
bacteria
surviv
within
phagocyt
lead
dissemin
infect
confirm
mous
septic
arthriti
model
inject
bacteria
form
abscess
kidney
use
two
mark
strain
abscess
aros
commonli
expect
predominantli
one
bacteri
popul
suggest
nich
exist
bacteria
evad
host
defenc
ultim
reestablish
foci
infect
test
whether
nich
within
subpopul
phagocyt
individu
popul
neutrophil
macrophag
deplet
zebrafish
neutrophildeplet
larva
show
better
surviv
compar
macrophag
deplet
lower
varianc
ratio
two
sa
strain
suggest
neutrophil
might
provid
nich
sa
avoid
host
kill
conclus
predict
understand
natur
phagocyt
nich
enabl
manipul
provid
novel
therapeut
strategi
treatment
sa
diseas
find
evolutionari
conserv
innat
immun
signal
pathway
govern
antimicrobi
respons
drosophila
highli
stimul
understand
metazoan
immun
mechan
two
major
pathway
toll
imd
activ
drosophila
fat
bodi
cell
follow
bacteri
infect
lead
synthesi
larg
quantiti
antimicrobi
peptid
secret
hemolymph
pathway
also
differenti
activ
expos
epitheli
tissu
trachea
gut
genitalia
follow
bacteri
recognit
immun
receptor
signal
ensur
conserv
molecul
proteas
adapt
kinas
nfkb
transcript
factor
ubiquitin
also
signal
mechan
conserv
fli
human
notabl
demonstr
imd
ubiquitin
lysin
ub
chain
requir
signal
transduct
control
deubiquitinas
besid
humor
respons
drosophila
differenti
phagocyt
cell
deriv
hemocyt
blood
cell
lineag
ensur
bacteri
phagocytosi
well
cytokin
antimicrobi
peptid
secret
express
pseudomona
aeroginusa
exo
toxin
target
rhogtpas
specif
disrupt
hemocyt
phagocyt
function
vivo
demonstr
essenti
contribut
phagocytosi
drosophila
immun
togeth
feasibl
use
transgenesi
investig
vivo
mechan
action
bacteri
toxin
fact
find
sever
laboratori
human
pathogen
use
similar
virul
factor
infect
insect
mammal
open
avenu
use
drosophila
nonmammalian
host
monitor
bacteri
virul
exampl
role
type
iii
secret
system
quorum
sens
pseudomona
aeruginosainduc
fli
kill
demonstr
date
origin
field
research
consist
explor
hostpathogen
interact
use
oral
rout
infect
either
natur
drosophila
pathogen
human
pathogen
evalu
local
immun
respons
includ
tissu
damag
repair
line
other
observ
pseudomona
strain
establish
biofilm
drosophila
crop
anterior
midgut
display
reduc
virul
toward
host
undoubtedli
fli
still
high
amount
inform
deliv
molecular
mechan
physiolog
antibacteri
defens
bacteri
virul
live
organ
c
elegan
widelyus
model
biolog
adopt
grow
commun
research
investig
pathogen
virul
host
defenc
use
c
elegan
dissect
molecular
cellular
basi
innat
immun
fungal
infect
c
elegan
respond
specif
differ
type
infect
activ
distinct
signal
pathway
fungal
infect
epidermi
result
product
multipl
effector
protein
includ
antimicrobi
peptid
candid
approach
smallscal
em
screen
use
fluoresc
report
identifi
mani
compon
innat
immun
cascad
involv
regul
gene
show
conserv
pathway
involv
protein
kinas
c
act
upstream
mapk
cascad
ziegler
et
al
noncanon
tgfbeta
pathway
zugasti
ewbank
regul
respect
two
pathway
link
stat
factor
requir
express
gene
dierk
et
al
current
focus
mainli
regul
conduct
parallel
highthroughput
approach
order
get
complet
understand
network
regul
gene
conduct
largescal
em
screen
isol
independ
allel
block
induct
report
infect
clone
direct
wholegenom
resequenc
also
conduct
complementari
rnai
screen
use
librari
cover
whole
genom
autom
analysi
platform
togeth
result
give
global
view
gene
pathway
regul
antifung
peptid
gene
express
relev
find
mammalian
innat
immun
discuss
dierk
k
polanowska
j
omi
engelmann
gut
lembo
f
ewbank
jj
pujol
n
unusu
regul
stat
protein
famili
transport
c
elegan
epiderm
innat
immun
cell
host
microb
ziegler
k
kurz
cl
cypowyj
couillault
c
pophillat
pujol
n
ewbank
jj
figur
par
plana
vitrectomi
perform
approxim
round
worm
remov
immatur
adult
angiostrongylu
cantonensi
identifi
parasitologist
bursa
indic
male
worm
figur
absenc
headach
eosinophilia
lumbar
punctur
perform
anthelminth
drug
prescrib
still
cn
symptom
eyesight
improv
due
retin
detach
conculs
preval
angiostrogylu
rare
compar
ocular
parasit
toxocara
gnathostoma
cysticercosi
howev
parasit
caus
sever
disabl
patient
histori
take
patient
eat
habit
care
fundoscop
examin
lead
proper
diagnosi
better
treatment
outcom
moreov
prevent
diseas
encourag
thorough
cook
mollusk
paraten
host
import
result
studi
includ
men
women
averag
age
year
mean
time
perman
spain
day
frequent
countri
origin
equatori
guinea
ecuador
seneg
nigeria
ethiopia
eighteen
percent
patient
immigr
rest
travel
frequent
symptom
abdomin
pain
eosinophilia
rest
asymptomat
patient
show
posit
serolog
test
one
patient
microscop
visual
posit
thirteen
patient
eosinophilia
blood
mean
limit
hiv
coinfect
present
eight
patient
median
cell
count
cellsmm
one
patient
htlvi
coinfect
underli
diseas
hepat
c
chronic
hepat
b
patient
treat
ivermectin
none
patient
develop
hyperinfect
syndrom
patient
serolog
becam
neg
six
month
treatment
two
patient
leav
followup
rest
yet
follow
patient
surviv
conclus
presenc
infect
stercolari
frequent
highrisk
patient
although
without
symptom
prevent
potenti
fatal
hyperinfect
syndrom
necessari
realiz
screen
sever
stool
examin
serolog
test
risk
group
infect
institut
treatment
object
dientamoeba
fragili
origin
describ
apathogen
protozoan
organ
year
mani
report
provid
evid
pathogen
potenti
protozoa
patient
fragili
infect
suffer
chronic
gastrointestin
complaint
remain
unexplain
thorough
investig
therefor
often
treat
intent
erad
fragili
infect
gut
sinc
consensu
exist
treatment
dientamoebiasi
perform
retrospect
followup
studi
compar
efficaci
paromomycin
clioquinol
metronidazol
method
patient
includ
januari
januari
fragili
demonstr
stool
sampl
result
followup
stool
sampl
avail
paromomycin
three
daili
dose
mg
day
clioquinol
three
daili
dose
mg
day
metronidazol
three
daili
dose
mg
day
prescrib
offlabel
inform
consent
patient
patient
receiv
treatment
wait
see
polici
fragili
demonstr
stool
patient
case
could
includ
studi
patient
follow
tft
result
avail
result
treatment
paromomycin
n
result
parasitolog
cure
fragili
case
one
patient
parasit
load
reduc
treatment
clioquinol
n
erad
fragili
case
two
patient
parasit
load
reduc
treatment
treatment
metronidazol
n
result
parasitolog
cure
fragili
case
three
patient
parasit
load
reduc
even
increas
two
patient
receiv
treatment
wait
see
polici
n
fragili
spontan
clear
case
parasit
load
untreat
patient
clear
fragili
rather
variabl
patient
decreas
parasit
load
note
substanti
increas
also
observ
conclus
result
show
fragili
infect
spontan
clear
increas
untreat
case
although
metronidazol
often
list
drug
choic
paromomycin
shown
effect
drug
erad
fragili
adult
parasitolog
cure
rate
almost
aim
present
studi
analyz
blastocysti
subtyp
among
isol
pediatr
patient
saintpetersburg
identifi
correl
subtyp
gastrointestin
symptom
method
one
thousand
seventythre
stool
sampl
collect
healthi
children
children
gastrointestin
disord
seventi
eight
isol
posit
blastocysti
isol
analyz
specif
primer
type
employ
pcr
result
analysi
level
blastocysti
colon
show
subtyp
common
symptomat
asymptomat
group
subtyp
detect
isol
subtyp
subtyp
subtyp
subtyp
found
isol
asymptomat
group
without
gastrointestin
symptom
symptomat
group
mainli
detect
subtyp
separ
togeth
subtyp
subtyp
isol
interestingli
patient
group
subtyp
sensit
metronidazol
treatment
conclus
present
studi
suggest
subtyp
common
genotyp
pediatr
patient
saintpetersburg
quit
possibl
subtyp
nonpathogen
genotyp
blastocysti
time
subtyp
might
associ
metronidazol
resist
blastocysti
fact
clearli
demonstr
need
preliminari
identif
parasit
treatment
human
giardiasi
consid
zoonot
infect
although
role
anim
transmiss
human
still
unclear
consid
zoonot
potenti
genotyp
assemblag
b
believ
repres
major
risk
human
health
sinc
appear
infect
wide
rang
wild
domest
host
speci
studi
analys
dna
sampl
isol
human
anim
stool
specimen
get
insight
differ
g
lamblia
assemblagesgenotyp
present
portug
potenti
involv
anim
domest
sylvat
transmiss
g
lamblia
infect
human
faecal
sampl
collect
clinic
laboratori
school
dog
sampl
obtain
kennel
situat
wolv
dna
faecal
sampl
obtain
field
studi
wolv
taxonomi
protect
natur
park
mont
north
portug
parasitolog
studi
perform
microscopi
observ
direct
examin
concentr
copropack
saf
biomed
sl
g
lamblia
coproantigen
detect
perform
immunochromatographi
kit
tpi
betagiardin
gene
locu
amplifi
nestedpcr
pcr
product
submit
pcrrflp
analysi
sequenc
drodamina
termin
cycl
sequenc
kit
read
perform
use
abi
prism
automat
dna
sequenc
obtain
sequenc
individu
analyz
comput
platform
chroma
lite
technelysium
pti
ltd
blast
clustalw
mega
result
show
giardia
human
isol
n
divid
two
main
assemblag
b
canin
isol
n
belong
assemblag
assemblag
c
assemblag
also
identifi
coinfect
includ
assemblag
c
coinfect
includ
assemblag
dog
interest
find
identif
genotyp
tradit
link
human
g
lamblia
infect
dog
sampl
wolv
isol
n
includ
genotyp
phylogenet
analysi
reveal
close
relationship
human
anim
assemblag
isol
find
suggest
domest
sylvat
anim
may
play
import
role
zoonot
transmiss
cycl
parasit
work
support
fct
pocti
feder
long
realli
take
antitoxoplasma
igg
antibodi
avid
reach
full
matur
object
previou
cochran
review
show
oral
iron
supplement
malaria
endem
area
associ
increas
mortal
clinic
malaria
preform
broader
metaanalysi
systemat
review
order
assess
effect
type
iron
supplement
children
malaria
endem
area
malariarel
outcom
overal
mortal
method
systemat
review
metaanalysi
random
control
trial
compar
iron
supplement
oral
parenter
fooddrink
fortif
vs
placebo
treatment
control
intervent
includ
iron
children
live
malaria
endem
area
trial
report
malariarel
outcom
exclud
primari
outcom
includ
clinic
malaria
overal
mortal
risk
bia
assess
use
domainbas
evalu
data
extract
independ
two
review
rel
risk
rr
confid
interv
ci
pool
use
fix
effect
metaanalysi
heterogen
signific
inconsist
measur
background
malaria
morbid
mortal
uganda
continu
escal
despit
standard
prevent
control
measur
current
inplac
wherea
prompt
accur
laboratori
diagnosi
malaria
key
effect
manag
malaria
clinic
syndrom
diagnosi
wide
use
uganda
resourc
poor
countri
object
determin
incid
antimalari
drug
abus
among
patient
clinic
diagnos
malaria
bushenyi
uganda
methodolog
crosssect
studi
undertaken
outpati
depart
ten
health
center
ii
bushenyi
uganda
april
june
rapid
diagnost
test
malaria
parasit
perform
recruit
femal
patient
male
patient
clinic
diagnos
malaria
fifteen
health
worker
ten
particip
health
centr
ii
interview
criteria
use
prescrib
antimalari
drug
ten
key
inform
interview
perceiv
treat
without
laboratori
result
rapid
diagnost
test
use
malaria
test
result
health
worker
found
particip
health
centr
ii
bushenyi
district
awar
new
polici
routin
malaria
laboratori
diagnosi
malaria
case
suspect
still
use
presumpt
treatment
malaria
base
clinic
sign
symptom
access
laboratori
servic
antimalari
drug
wrongli
prescrib
febril
patient
total
time
malaria
diagnos
health
center
thu
studi
show
antimalari
drug
correctli
administ
febril
patient
total
time
malaria
fever
suspect
confirm
fact
febril
patient
receiv
malaria
drug
simpli
abus
malaria
diseas
conclus
studi
find
signific
differ
mortal
patient
bsi
due
esbl
posit
e
coli
bsi
nonesbl
produc
e
coli
howev
patient
suffer
bsi
esbl
produc
e
coli
stay
significantli
longer
hospit
patient
bsi
due
nonesbl
produc
e
coli
strain
furthermor
determin
mani
patient
sepsi
due
esbl
posit
ecoli
strain
directli
receiv
adequ
antimicrobi
therapi
microbiolog
report
probabilist
link
england
hospit
episod
statist
he
data
captur
data
admiss
discharg
date
report
children
posit
blood
cultur
taken
two
day
admiss
defin
ha
bsi
analys
term
pathogen
amr
result
total
episod
paediatr
bsi
report
labbas
studi
period
success
link
he
inpati
record
episod
bsi
fulfil
criteria
ha
bsi
median
age
time
bsi
two
year
commonli
report
organ
coagulaseneg
staphylococci
enterococcu
spp
staphylococcu
aureu
escherichia
coli
klebsiella
spp
overal
resist
nation
recommend
empir
therapi
sepsi
broadspectrum
antipseudomon
betalactam
antibacteri
conclus
studi
link
high
proport
nation
microbiolog
data
clinic
data
proport
ha
bsi
quit
low
reflect
high
number
case
present
commun
posit
blood
cultur
within
two
day
admiss
although
proport
case
may
recent
healthcar
contact
amr
recommend
nation
empir
therapi
ha
bsi
low
studi
demonstr
data
linkag
use
tool
expand
epidemiolog
investig
determin
proport
ha
bsi
children
treat
case
enterococc
endocard
ampicillin
plu
gentamicin
associ
case
daptomycin
alon
associ
ampicillin
two
case
therapi
surgeri
necessari
case
enterococc
endocard
specif
hlar
enterococc
endocard
treat
ampicillin
plu
daptomycin
associ
three
case
one
three
due
e
faecium
daptomycin
alon
two
case
ampicillin
alon
one
case
ampicillin
plu
levofloxacin
one
case
associ
daptomycin
plu
ampicillin
success
use
two
case
enterococc
endocard
report
overal
mortal
rate
among
enterococc
endocard
patient
treat
daptomycin
alon
associ
ampicillin
favour
outcom
conclus
report
main
case
seri
enterococci
result
third
caus
infecti
endocard
studi
enterococcu
faecali
repres
main
enterococc
isol
strain
hlar
increasingli
common
resist
mechan
account
enterococc
endocard
case
although
limit
number
report
show
good
result
daptomycin
use
either
alon
associ
ampicillin
treatment
infect
tigecyclin
tetracyclin
chloramphenicol
rifampicin
ciprofloxacin
determin
broth
microdilut
method
daptomycin
etest
method
use
result
interpret
eucast
clsi
breakpoint
patient
clinic
epidemiolog
data
provid
questionnair
also
analyz
result
among
patient
men
women
gender
report
age
distribut
follow
newborn
age
age
age
year
old
data
mortal
rate
frequent
caus
hospit
bloodstream
infect
bacteraemia
septicaemia
diseas
includ
abdomin
infect
chest
infect
endocard
pelvic
infect
mening
risk
factor
involv
hospit
last
month
icu
stay
surgeri
among
isol
classifi
enterococcu
faecali
enterococcu
faecium
enterococcu
spp
ratio
nonsuscept
among
e
faecali
e
faecium
follow
penicillin
ampicillin
vancomycin
teicoplanin
gentamicin
streptomycin
linezolid
tigecyclin
tetracyclin
chloramphenicol
rifampicin
ciprofloxacin
daptomycin
respect
conclus
nearli
number
e
faecali
efaecium
observ
invas
infect
may
till
june
poland
infect
affect
mainli
patient
older
year
mortal
rate
high
ratio
nonsuscept
older
antibiot
observ
except
glycopeptid
good
suscept
new
antibiot
tigecyclin
linezolid
daptomycin
detect
special
mdr
preval
isol
blood
patient
age
year
year
individu
agent
show
downward
trend
ns
increas
age
isol
children
one
less
commonli
mdr
agent
especi
ciprofloxacin
show
less
ns
older
patient
rti
p
aeruginosa
show
similar
pattern
ns
age
blood
isol
origin
genitourinari
tract
less
often
mdr
compar
known
sourc
conclus
main
factor
predict
increas
mdr
p
aeruginosa
icu
locat
younger
age
except
infant
genitourinari
focu
infect
associ
reduc
mdr
multipl
ns
blood
respiratori
infect
unduli
preval
recent
year
isol
ns
agent
ns
ns
occasion
isol
ns
five
test
agent
overal
enterobacteriacea
resist
third
gener
cephalosporin
aminosid
fluoroquinolon
resist
rate
abaumannii
ceftazidim
imipenem
resist
rate
p
aeruginosa
ceftazidim
imipenem
respect
conclus
trend
resist
like
increas
resist
invas
e
coli
high
preval
resist
thirdgener
cephalosporin
fluoroquinolon
aminosid
k
pneumonia
isol
increas
preval
resist
carbapenem
baumannii
decreas
resist
methicillin
aureu
howev
compar
earsnet
surveil
report
north
south
gradient
data
like
suggest
infect
control
measur
hospit
marseil
lead
lower
preval
resist
bacteria
bloodstream
infect
compar
nation
data
west
nile
viru
wnv
mosquitoborn
flaviviru
belong
japanes
enceph
antigen
complex
famili
flavivirida
wnv
maintain
enzoot
cycl
bird
ornithophil
mosquito
mainli
culex
speci
human
hors
mammal
consid
incident
deadend
host
infect
human
mainli
occur
asymptomat
approxim
case
febril
ill
infect
occur
neuroinvas
diseas
often
sever
even
lethal
elderli
immunocompromis
individu
first
isol
district
west
nile
uganda
last
year
viru
respons
sever
human
equin
outbreak
europ
mediterranean
basin
recent
year
epidem
caus
wnv
human
hors
becom
frequent
southern
european
countri
itali
greec
increas
number
wnv
outbreak
associ
emerg
novel
viral
strain
display
higher
virul
greater
epidem
potenti
human
addit
wnv
lineag
lineag
isol
recent
year
european
countri
recent
research
find
wnv
epidemiolog
biolog
vaccin
drug
develop
present
avsiczupanc
ljubljana
si
hantavirus
host
small
mammal
emerg
pathogen
gain
attent
last
decad
hantavirus
rodentborn
although
sever
novel
hantavirus
unknown
pathogen
potenti
identifi
varieti
insectivor
shrew
mole
hantaviru
primarili
carri
distinct
rodentinsectivor
speci
maintain
cyclic
transmiss
persist
infect
rodent
incident
infect
human
hantavirus
found
worldwid
known
caus
two
seriou
often
fatal
human
diseas
hemorrhag
fever
renal
syndrom
hfr
asia
europ
hantaviru
cardiopulmonari
syndrom
hcp
america
mortal
rate
vari
hfr
hcp
diseas
acut
febril
infect
usual
acquir
inhal
aerosol
dust
particl
contamin
viru
contain
rodent
excreta
hfr
character
renal
failur
hemorrhag
manifest
vari
petechia
sever
intern
bleed
pneumonia
cardiovascular
dysfunct
characterist
hcp
increas
permeabl
micro
vascular
endothelium
seem
common
effect
hantaviru
infect
although
pathogenesi
hantaviru
infect
poorli
understood
suggest
direct
viral
cytopatholog
immun
mechan
may
play
import
role
complex
pathogenesi
diagnosi
acut
hantaviru
infect
primarili
base
serolog
sinc
viral
rna
regularli
detect
blood
urin
patient
immun
inactiv
viru
vaccin
licens
certain
asian
countri
moreov
sever
classic
molecular
vaccin
approach
preclin
stage
develop
specif
therapi
use
europ
although
ribavirin
interferona
success
use
trial
china
amplitud
magnitud
hantaviru
outbreak
increas
environment
chang
may
affect
geograph
distribut
abund
dynam
carrier
rodent
speci
thu
epidemiolog
hantaviru
diseas
hantavirus
diseas
caus
deserv
attent
research
public
health
offici
increas
clinician
awar
regard
impact
public
health
autom
bacteriolog
lab
choos
optim
autom
lab
inocul
sampl
agar
media
broth
repetit
fastidi
work
amen
autom
sever
autom
inocul
system
avail
differ
procedur
characterist
wasp
copan
innova
bectondickinson
mainli
repres
mechan
human
task
use
steril
calibr
loop
wherea
other
previisola
biomerieux
inoqula
kiestra
repres
true
innov
autom
use
steril
comb
steril
bead
respect
system
advantag
disadvantag
clue
summar
recent
review
articl
greub
prodhom
clin
microbiol
infect
provid
tempt
help
clinic
microbiologist
make
decis
inde
choic
one
system
take
account
characterist
instrument
well
characterist
laboratori
type
sampl
process
import
aspect
import
guid
choic
includ
compat
li
system
ii
compat
downstream
autom
procedur
autom
coloni
pick
system
andor
autom
agar
plate
read
take
plasmid
go
global
gene
global
antibiot
resist
issu
reflect
complex
global
problem
antibiot
use
select
resist
bacteria
use
antibiot
extens
treat
prevent
infect
human
anim
sequela
impact
also
environ
resist
old
antibiot
product
mani
resist
gene
recogn
today
evolv
millennia
ago
gene
move
bacteri
ecosystem
genera
environ
anim
includ
human
host
eventu
reach
speci
caus
infect
subject
suscept
test
multiresist
enterobacteriacea
one
greatest
challeng
encount
clinic
microbiologist
wit
two
wave
sinc
broad
usag
oxyiminocephalosporin
select
first
esbl
produc
particularli
ctxm
enzym
lesser
extent
bacteria
acquir
ampc
counter
increas
use
carbapenem
seriou
infect
consequ
face
intern
onslaught
enterobacteriacea
acquir
divers
array
carbapenemas
acquir
betalactamas
usual
encod
plasmid
encod
resist
multipl
antibiot
class
genom
sequenc
reveal
plasmid
built
modular
fashion
fundament
selfrepl
backbon
essenti
gene
accumul
resist
gene
success
round
transposit
recombin
event
plasmid
consid
success
readili
transmiss
bacteri
strain
speci
genera
andor
host
success
bacteri
strain
clone
scenario
contribut
global
dissemin
esbl
carbapenemas
exposur
antibiot
obviou
direct
select
pressur
new
antibiot
develop
preserv
efficaci
must
prioriti
prescrib
time
place
public
health
system
breakdown
geographycatastroph
tsunamiearthquak
antibiot
resist
definit
rise
trend
worldwid
nosocomi
also
communityacquir
multidrug
resist
bacteria
report
quit
often
lead
complic
therapeut
strategi
ultim
therapeut
failur
poor
outcom
mean
even
good
sanitari
condit
highli
advanc
healthcar
set
manag
infect
relat
multidrug
resist
bug
quit
difficult
obvious
public
health
system
breakdown
induc
catastrophewar
lead
poor
sanit
emerg
practic
poor
access
medic
sever
patholog
trauma
limit
healthcar
worker
rise
risk
occurr
spread
epidem
resist
bacteria
unfortun
frequent
current
experi
situat
consid
improv
futur
manag
also
opportun
analys
epidemiolog
resist
event
happen
geograph
area
limit
data
avail
order
prevent
dissemin
bug
area
clinic
experiment
immunolog
object
staphylococci
aureu
coagulaseneg
staphylococci
cn
may
infect
bone
fibroblast
cell
order
persist
intracellularli
small
coloni
variant
scv
bacteriainfect
cell
may
target
natur
killer
nk
cell
innat
lymphocyt
special
recognit
kill
intracellular
pathogen
hypothes
low
peripher
natur
killer
cell
activ
may
risk
factor
bone
joint
infect
bji
scv
staphylococci
method
crosssect
studi
includ
immunocompet
patient
follow
institut
past
current
treat
chronic
bji
due
staphylococci
scv
phenotyp
scv
bji
group
eight
orthopaed
implant
seven
due
aureu
three
cn
defin
typic
phenotyp
aspect
coloni
preoper
specimen
cultur
control
group
includ
nine
patient
chronic
staphylococci
bji
without
scv
phenotyp
scvbji
group
implant
five
due
aureu
four
cn
ii
six
patient
chronic
bji
due
pathogen
bji
group
three
implant
iii
healthi
volunt
hv
pbmc
isol
patient
analyz
surfac
intracellular
perforin
express
use
multiparamet
flow
cytometri
separ
set
experi
pbmc
stimul
hour
without
cell
classic
nk
cell
target
degranul
exposur
intracellular
ifng
express
gate
nk
cell
measur
flow
cytometri
object
human
leishmaniasi
dichotomi
role
cell
protect
clearli
defin
studi
base
express
total
memori
vs
cell
popul
isol
volunt
selfheal
cutan
leishmaniasi
cl
cytokin
product
analys
method
leishmanin
skin
test
lst
perform
volunt
blood
sampl
collect
volunt
histori
cl
caus
either
l
major
l
tropica
healthi
volunt
nonendem
area
use
enrich
cocktail
mab
magnet
nanoparticl
total
memori
cell
isol
autolog
peripher
blood
mononuclear
cell
pbmc
cell
nonnaiv
cell
deplet
cell
posit
select
use
microbead
monocyt
deriv
macrophag
mdm
produc
incub
adher
monocyt
crpmi
day
isol
lymphocyt
popul
cocultur
autolog
mdm
presenc
pha
solubl
leishmania
antigen
sla
cytokin
product
titrat
cultur
supernat
hour
incub
part
sla
cultur
cell
harvest
stimul
pmaionomycin
calcium
permeabil
stain
intracellular
ifng
analyz
use
flow
cytomet
result
mean
diamet
skin
indur
significantli
higher
cl
volunt
mm
compar
healthi
control
mm
p
mean
sd
percentag
memori
cell
cell
retriev
pbmc
stimul
isol
memori
cell
cl
volunt
induc
significantli
higher
ifng
product
compar
control
p
signific
differ
seen
product
ifng
naiv
cell
product
memori
cell
cl
control
significantli
higher
number
memori
cell
cl
volunt
posit
intracellular
ifng
cell
control
p
signific
differ
found
frequenc
ifng
posit
cell
cl
control
conclus
role
cell
sourc
ifng
product
suggest
studi
memori
popul
shown
respons
ifng
product
volunt
histori
cl
purif
differ
memori
subset
need
studi
cytomegaloviru
protein
highli
conserv
among
clinic
strain
although
major
target
humor
cellular
immun
respons
object
cytomegaloviru
cmv
larg
tegument
protein
gener
strong
humor
cellular
immun
respons
multipl
epitop
dispers
kda
protein
analog
cmv
antigen
host
immun
pressur
may
expect
gener
genet
divers
particularli
cmv
strain
patient
chronic
lymphocyt
leukaemia
cll
may
strong
evolutionari
forc
immunoglobulin
ig
express
select
leukem
cell
interact
cell
constitut
leukocyt
fraction
cll
patient
nevertheless
knowledg
genom
divers
gene
code
among
clinic
strain
limit
far
method
screen
consecut
cll
patient
presenc
cmvdna
sequenc
gene
determin
genom
divers
among
clinic
cmv
strain
result
analyz
respect
cmvseroposit
sequenc
ig
express
leukem
cell
refer
sequenc
cmv
strain
use
detect
patient
primari
cmv
infect
n
addit
cll
patient
treat
antibodi
n
previous
studi
avail
via
pubm
n
result
cmvdna
detect
cmvspecif
igg
antibodi
cll
patient
interestingli
cmvdna
detect
cmvseroneg
patient
igvh
gene
usag
associ
neither
detect
cmvdna
cmvseroposit
phylogenet
analysi
differ
sequenc
n
includ
five
sequenc
cll
patient
reveal
low
sequenc
variabl
moreov
variabl
observ
clinic
strain
restrict
specif
stretch
gene
uniformli
distribut
entir
analyz
sequenc
conclus
contrast
cmv
antigen
glycoprotein
b
found
highli
conserv
among
clinic
cmv
strain
function
appear
essenti
cmv
consid
low
evolutionari
rate
despit
presum
strong
host
immun
pressur
incorpor
novel
vaccin
strategi
potenti
gener
strong
immun
respons
vaccin
individu
introduct
immun
senesc
may
defin
age
depend
dysregul
dysfunction
immun
system
associ
increas
suscept
infecti
diseas
poor
protect
immun
vaccin
recent
evid
observ
studi
suggest
persist
infect
human
cytomegaloviru
hcmv
might
propag
immun
senesc
potenti
hcmvinduc
loss
cell
cytokin
dysregul
object
directli
investig
whether
persist
hcmv
infect
influenc
vaccin
induc
primari
immun
respons
healthi
elderli
individu
method
perform
prospect
control
vaccin
trial
healthi
elderli
volunt
subdivid
two
group
hcmvposit
n
hcmvneg
n
individu
use
licens
vaccin
tick
born
enceph
viru
tbev
fsmeimmun
cc
vaccin
induc
tbevspecif
antibodi
cell
respons
analys
longitudin
elisa
neutralis
test
nt
ifngelispot
hcmvspecif
cell
respons
quantifi
ifngelispot
intracellular
cytokin
stain
polychromat
flow
cytometri
cba
flex
appli
detail
analys
pbmc
popul
circul
cytokin
respect
immunogen
tbevvaccin
use
marker
immunocompet
neg
correl
immun
senesc
predictor
vaccin
immunogen
analys
multivari
logist
regress
result
geometr
mean
titer
gmt
tbevspecif
elisa
neutral
antibodi
cell
frequenc
significantli
lower
hcmvposit
compar
hcmvneg
elderli
particularli
earli
primari
immun
nt
week
vs
p
hcmvinfect
associ
profound
alter
lymphocyt
subset
distribut
cell
activ
differenti
regul
blood
dendrit
cell
signific
chang
cytokin
level
multivari
model
poor
immunogen
tbevvaccin
associ
hcmvinfect
number
hcmvspecif
cell
smoke
low
level
daili
physic
activ
cytokin
level
cell
number
conclus
data
demonstr
hcmvinfect
impair
protect
immun
tbev
vaccin
healthi
elderli
individu
probabl
cell
base
mechan
propag
immun
senesc
sever
studi
role
hemozoin
hz
releas
plasmodium
blood
stage
show
immunosuppress
effect
disrupt
macrophagedendrit
cell
function
although
find
still
controversi
project
aim
studi
possibl
effect
hz
infect
immun
object
first
studi
kinet
hz
rodent
model
effect
hz
immun
respons
vaccin
irradi
malaria
sporozoit
investig
method
mice
infect
plasmodium
berghei
treat
chloroquin
cq
mice
sacrif
organ
liver
spleen
bone
marrow
blood
investig
presenc
hz
look
interfer
hz
vaccin
mice
infect
p
berghei
follow
treatment
cq
mice
clear
parasit
hz
still
remain
organ
mice
immun
whole
irradi
sporozoit
day
challeng
live
sporozoit
liver
infect
load
determin
hour
challeng
realtim
pcr
parallel
mice
inject
hz
immun
follow
challeng
nativ
synthet
hz
produc
character
sever
method
result
result
show
hz
detect
host
day
spleen
major
organ
hz
deposit
immun
mice
previou
malaria
infect
seem
reduc
protect
rel
immun
mice
also
mice
inject
hz
time
vaccin
undetect
level
antibodi
sporozoit
hz
character
sem
show
hz
produc
us
structur
equival
other
crystal
size
rang
um
conclus
highli
endem
area
continu
infect
malaria
potenti
lead
certain
level
hz
accumul
host
organ
thu
hz
role
immunesuppress
potenti
interfer
respons
infect
vaccin
result
seem
indic
mayb
case
hz
appear
caus
degre
immunesuppress
capabl
reduc
protect
efficaci
malaria
vaccin
use
whole
irradi
parasit
shown
higher
liver
infect
mice
previou
blood
stage
undetect
antibodi
product
sporozoit
immun
given
togeth
hemozoin
object
staphylococcu
aureu
pantonvalentin
leukocidin
pvl
poreform
toxin
associ
skin
soft
tissu
infect
ssti
sever
osteomyel
necrotis
pneumonia
pvl
preval
aureu
strain
highli
variabl
worldwid
recent
epidemiolog
data
indic
preval
rate
pvlposit
isol
highest
africa
declin
west
central
africa
north
africa
whether
variat
pvl
preval
influenc
immun
pvl
gener
popul
unknown
address
question
compar
level
pvl
antibodi
gener
popul
franc
europ
algeria
north
africa
seneg
west
africa
method
blood
sampl
drawn
adult
popul
evid
infect
lyon
franc
n
alger
algeria
n
dakar
seneg
n
pvl
alphatoxin
antibodi
level
determin
elisa
alphatoxin
present
aureu
strain
antibodi
level
consid
reflect
level
popul
exposur
aureu
result
compar
franc
median
pvl
antibodi
level
higher
algerian
popul
higher
senegales
popul
p
differ
mannwhitney
utest
pvl
seroposit
rate
franc
algeria
seneg
respect
p
differ
chisquar
test
hand
signific
differ
alphatoxin
antibodi
level
among
patient
three
countri
show
observ
differ
pvl
antibodi
level
bias
variat
popul
exposur
aureu
conclus
pvl
antibodi
level
gener
popul
franc
algeria
seneg
vari
wide
match
variat
pvlposit
aureu
strain
preval
increas
northsouth
gradient
conclud
immun
pvl
given
popul
relat
local
pvl
preval
light
recent
report
suggest
pvldirect
immun
protect
sever
deepseat
infect
might
enhanc
suscept
ssti
find
import
implic
understand
vari
clinic
pattern
pvlassoci
infect
low
high
pvl
preval
area
effect
immunotherapi
use
aureu
autovaccin
chronic
staphylococc
diseas
object
increas
antibiot
resist
aureu
strain
continu
restrict
therapeut
potenti
diseas
caus
pathogen
therefor
treatment
chronic
staphylococc
infect
continu
employ
autovaccin
prepar
kill
aureu
strain
isol
patient
studi
aim
evalu
aureu
autovaccin
efficaci
context
develop
cytokin
respons
materi
method
treatment
aureu
autovaccin
appli
group
adult
patient
includ
patient
chronic
suppur
cutan
aureu
infect
patient
chronic
aureu
infect
upper
respiratori
tract
strain
aureu
isol
dermal
lesion
throat
smear
identifi
use
id
staph
test
biomerieux
level
human
cytokin
estim
use
high
sensit
elisa
test
r
ebiosci
determin
serum
cytokin
level
perform
autovaccin
use
ii
middl
therapi
use
aureu
autovaccin
iii
hour
follow
termin
therapi
use
aureu
autovaccin
seri
subcutan
inject
hand
bacteriolog
examin
target
aureu
conduct
twice
first
term
third
term
smear
dermal
lesion
present
throat
smear
result
first
term
mean
level
studi
cytokin
follow
tnfa
pgml
pgml
ifng
pgml
pgml
pg
ml
pgml
second
term
significantli
elev
level
studi
cytokin
disclos
patient
mean
level
follow
tnfa
pg
ml
pgml
ifng
pgml
pgml
iiird
term
significantli
elev
level
studi
disclos
patient
mean
amount
tnfa
pgml
pgml
ifng
pgml
pgml
level
differ
significantli
term
parallel
iind
stage
patient
manifest
presenc
aureu
conclus
patient
chronic
symptomat
aureu
infect
treatment
aureu
autovaccin
induc
increas
cytokin
respons
monocytesmacrophag
lymphocyt
seem
determin
clinic
efficaci
accompani
elimin
pathogen
object
evalu
effect
levamisol
combin
standard
treatment
vs
standard
treatment
phagocyt
function
polymorphonuclear
leucocyt
pmn
monocyt
determin
also
antibodi
depend
cytotox
isol
monocyt
patient
activ
brucellosi
method
patient
randomli
divid
two
group
groupi
receiv
standard
treatment
doxycyclin
mg
twice
daili
streptomycin
g
daili
week
group
ii
receiv
standard
treatment
groupi
plu
levamisol
mg
daili
week
demograph
data
clinic
featur
patient
document
design
form
chemiluminenesc
cl
oxid
burst
use
determin
pmn
monocyt
phagocyt
activ
blood
sampl
collect
isol
monocyt
adcc
detect
use
nucleat
target
cell
suspens
nm
object
outcom
aureu
bloodstream
infect
bsi
depend
varieti
factor
host
mediat
organ
mediat
cation
polypeptid
found
human
key
compon
innat
immun
system
respons
kill
phagocytos
bacteria
immunoregul
assess
suscept
aureu
isol
caus
bsi
kill
method
ten
aureu
isol
caus
complic
ten
caus
uncompl
bsi
randomli
select
assess
suscept
methicillinsuscept
aureu
mssa
methicillinresist
aureu
mrsa
isol
includ
n
n
isol
posit
multipl
peptid
resist
factor
mprf
gene
code
lysylphosphatidylglycerol
lpg
synthas
except
one
caus
complic
infect
one
caus
uncompl
infect
bactericid
activ
determin
viabl
cell
count
follow
incub
cfuml
aureu
lgml
hour
compar
assay
contain
object
recent
work
lab
demonstr
polyclon
bcell
activ
tiii
antigen
mimic
eg
addextran
abl
inhibit
tcrinduc
prolifer
activ
tcell
base
fact
tiii
antigen
present
bacteria
investig
whether
n
meningitidi
abl
induc
bcell
activ
suppress
tcell
prolifer
activ
method
primari
human
pbmc
expos
fix
n
meningitidi
whole
bacteria
purifi
neisseria
outer
membran
vesicl
flow
cytometri
assay
design
measur
stimulatori
interact
b
tcell
prolifer
measur
use
cfse
dilut
assay
cellular
activ
assess
express
activ
marker
enrich
experi
neg
select
provid
pure
primari
b
popul
cellcontact
experi
result
interestingli
smallest
ratio
bacteria
per
cell
fix
wild
type
meningococcu
result
profound
inhibit
tcell
prolifer
activ
higher
bacteri
count
fail
inhibit
tcell
activ
inhibit
tcell
prolifer
mild
experi
perform
lipooligosaccharid
lo
defici
mutant
show
similar
suppress
pattern
smallest
inocula
effect
dose
suggest
lo
mechan
inhibit
purifi
fresh
heat
outer
membran
vesicl
n
meningitidi
n
lactamica
demonstr
contain
suppress
factor
effect
even
small
concentr
impli
capsul
key
factor
either
purif
experi
suggest
bcell
might
cell
type
respons
phenomenon
howev
seem
requir
accessori
cell
pbmc
achiev
regulatori
phenotyp
latest
experi
e
coli
pneumonia
clarifi
suppress
effect
may
exhibit
bacteria
n
meningitidi
result
inhibit
dose
sensit
vari
among
organ
conclus
small
bacteri
inocula
n
meningitidi
outer
membran
vesicl
abl
inhibit
tcell
prolifer
activ
still
unclear
whether
b
tcell
contact
requir
solubl
factor
within
pbmc
key
factor
microorgan
seem
exhibit
phenomenon
work
examin
specif
bacteri
compon
scaveng
receptor
necessari
delay
convers
oral
therapi
communityacquir
pneumonia
mainli
caus
physician
misconcept
lack
guidelin
knowledg
organis
factor
result
prospect
cohort
studi
background
hospitalis
patient
communityacquir
pneumonia
cap
earli
switch
intraven
iv
oral
antibiot
clinic
stabl
patient
safe
result
shorter
length
hospit
stay
lo
howev
implement
rate
earli
switch
strategi
clinic
practic
evalu
identif
barrier
earli
switch
strategi
may
form
basi
target
intervent
improv
implement
object
evalu
whether
physician
base
switch
oral
treatment
guidelin
advic
patient
physician
factor
influenc
switch
oral
treatment
whether
physician
perceiv
barrier
earli
switch
method
prospect
cohort
studi
dutch
teach
hospit
octob
april
consecut
adult
patient
admit
iv
treatment
cap
identifi
screen
admiss
list
day
three
antibiot
treatment
clinic
respons
score
object
paramet
clinic
stabil
treat
resid
interview
switch
strategi
potenti
barrier
individu
case
addit
resid
specialist
respons
treatment
choic
interview
evalu
knowledg
adher
guidelin
advic
result
enrol
patient
exclud
leav
patient
analysi
treat
physician
interview
base
clinic
paramet
switch
oral
antibiot
possibl
patient
day
treatment
perform
patient
factor
delay
switch
high
curbscor
admiss
p
oxygen
treatment
p
high
temperatur
p
high
respir
rate
p
day
clinic
experi
physician
relat
durat
iv
therapi
physician
barrier
n
earli
switch
clinic
stabl
patient
mainli
practic
consider
n
organis
factor
n
misconcept
n
strikingli
physician
awar
guidelin
advic
patient
mark
clinic
stabl
resid
meet
object
paramet
clinic
stabil
conclus
switch
iv
oral
antibiot
often
unnecessari
delay
patient
hospitalis
cap
tailor
intervent
aim
identifi
barrier
like
reduc
durat
iv
treatment
consequ
lo
delay
patient
hospitalis
cap
tailor
intervent
aim
identifi
barrier
like
reduc
durat
iv
treatment
consequ
lo
antibiot
treatment
communityacquir
pneumonia
rational
clusterrandomis
crossov
studi
design
accord
dutch
guidelin
empir
treatment
patient
communityacquir
pneumonia
cap
requir
hospitalis
icu
admiss
consist
either
monotherapi
betalactam
betalactam
macrolid
combin
therapi
quinolon
monotherapi
howev
scientif
evid
strategi
conflict
well
design
prospect
studi
therefor
necessari
observ
studi
hamper
bia
indic
choic
therapi
may
influenc
differ
determin
sever
diseas
patient
overal
prognosi
result
younger
patient
frequent
treat
antibiot
atyp
coverag
compar
older
patient
although
theoreticallyposs
adjust
differ
multivari
analysi
mani
determin
may
hidden
result
residu
confound
random
control
trial
rct
avoid
bia
indic
may
suffer
inform
bia
individu
randomis
rct
requir
written
inform
consent
particip
patient
therefor
rct
patient
alreadi
start
antibiot
treatment
consent
obtain
initi
antibiot
may
differ
antibiot
random
sinc
initi
treatment
crucial
outcom
design
may
sever
compromis
accur
evalu
given
drawback
design
design
multi
centr
clusterrandom
crossov
studi
evalu
cost
effect
three
antibiot
treatment
strategi
betalactam
monotherapi
betalactam
macrolid
combin
therapi
fluorchinolon
monotherapi
patient
admit
suspicion
cap
gener
ward
dutch
hospit
elig
inclus
hospit
use
one
three
treatment
arm
standard
empir
therapi
period
four
consecut
month
prefer
treatment
rotat
one
two
regimen
order
chang
randomis
per
hospit
therebi
control
interhospit
variabl
minim
season
influenc
primari
endpoint
mortal
result
analys
perprotocol
stratif
base
cap
sever
well
intentiontotreat
analysi
conclus
studi
provid
innov
design
evalu
cost
effect
current
empir
treatment
cap
without
pitfal
rct
observ
studi
use
procalcitonin
guid
antibiot
therapi
patient
acut
exacerb
copd
resourcelimit
set
casecontrol
studi
v
nangia
k
gandhi
delhi
object
exacerb
chronic
obstruct
pulmonari
diseas
copd
trigger
bacteri
infect
henc
may
requir
antibiot
therapi
intervent
studi
assess
procalcitonin
guid
therapeut
strategi
reduc
antibiot
usag
acut
exacerb
copd
method
total
consecut
patient
hospit
acut
exacerb
copd
enrol
singl
center
prospect
comput
random
studi
case
procalcitonin
group
first
dose
antibiot
cours
carri
serum
procalcitonin
level
elev
patient
control
group
receiv
antibiot
per
accept
standard
decid
attend
physician
primari
end
point
total
antibiot
usag
hospitalis
upto
week
secondari
end
point
includ
measur
clinic
outcom
like
success
selfreport
function
statu
lung
function
steroid
dosag
length
inhospit
stay
death
result
mean
day
antibiot
receiv
hospit
significantli
lower
procalcitonin
group
mean
sd
vs
p
risk
reduct
antibiot
exposur
total
dosag
antibiot
receiv
also
significantli
lesser
procalcitonin
group
vs
p
even
week
mean
day
antibiot
exposur
significantli
lower
procalcitonin
group
vs
p
mean
total
dosag
antibiot
receiv
vs
p
also
signific
risk
reduct
antibiot
exposur
inter
group
statist
analysi
done
use
chisquar
anova
test
p
valu
consid
signific
group
well
match
demograph
clinic
profil
mean
length
hospit
stay
differ
vs
p
either
group
clinic
improv
lung
function
usag
steroid
non
invas
ventil
support
support
therapi
similar
group
conclus
serum
procalcitonin
serv
good
reliabl
biomark
differenti
bacteri
non
bacteri
exacerb
copd
thu
guid
usag
antibiot
like
tremend
impact
econom
burden
diseas
specif
resourc
limit
set
countri
like
india
object
find
previou
hospitalacquir
pneumonia
hap
studi
indic
efficaci
tigecyclin
tgc
mg
lower
imipenemcilastatin
imi
especi
subject
ventil
associ
pneumonia
vap
primari
object
studi
compar
efficaci
safeti
two
higher
tgc
dosag
regimen
imi
regimen
hap
subject
method
phase
multicentr
doubleblind
studi
subject
hap
stratifi
vap
nonvap
random
one
three
treatment
arm
tgc
mg
hour
tgc
mg
hour
imi
g
hour
receiv
treatment
day
primari
secondari
endpoint
clinic
respons
clinic
evalu
ce
clinic
modifi
intenttotreat
cmitt
popul
testofcur
toc
respect
result
subject
receiv
studi
drug
subject
clinic
evalu
median
age
subject
year
male
vap
apach
ii
score
prior
antibiot
failur
median
therapi
durat
day
clinic
respons
shown
tabl
eightysix
subject
report
treatment
emerg
advers
event
teae
frequent
report
teae
gastrointestin
disord
incid
numer
higher
incid
tgc
mg
group
seriou
ae
sepsissept
shock
numer
higher
tgc
mg
n
tgc
mg
n
imi
n
group
seventeen
death
occur
subject
receiv
tgc
mg
tgc
mg
imi
respect
signal
improv
efficaci
tgc
mg
dose
level
observ
howev
conclus
specul
given
small
studi
size
background
novel
porphyrin
antibacteri
demonstr
bactericid
activ
vitro
staphylococcu
aureu
sa
low
potenti
induc
mutat
resist
two
phase
studi
conduct
two
studi
site
evalu
safeti
toler
pharmacokinet
pk
antistaphylococc
activ
intranas
gel
multipl
ascend
dose
method
subject
healthi
adult
confirm
nasal
carrier
sa
safeti
assess
includ
haematolog
biochemistri
urinalysi
ecg
vital
sign
nasal
examin
placebo
administ
anterior
nare
two
three
time
daili
day
antistaphylococc
activ
assess
throughout
treatment
nasal
swab
subsequ
cultur
result
sixti
eight
subject
receiv
femal
male
nine
subject
receiv
placebo
control
five
concentr
test
mgg
appli
day
two
three
time
day
treatment
well
toler
dose
mild
short
live
nasal
ae
report
subject
group
typic
mild
transient
chang
sensat
last
hour
day
none
ae
consequ
administr
assess
clinic
signific
nasal
examin
follow
dose
reveal
drug
relat
sign
increas
secret
erythema
signific
chang
laboratori
paramet
ecg
vital
sign
pk
assess
detect
limit
indic
detect
system
absorpt
meaning
reduct
sa
colonis
evid
concentr
mgg
subset
heavili
colon
individu
semiquantit
cultur
n
mgg
n
regist
reduct
sa
load
end
treatment
sa
carriag
absent
scant
reduc
moder
conclus
repeat
intranas
administr
day
well
toler
concentr
mgg
bd
good
preliminari
indic
antistaphylococc
activ
justifi
investig
propionibacterium
acn
gramposit
aerotoler
anaerob
found
predomin
skin
form
part
resid
microbiota
repres
major
opportunist
pathogen
within
cutan
group
propionibacteria
link
sometim
controversi
rang
infect
condit
histor
role
p
acn
certain
infect
almost
certainli
underestim
due
diagnost
protocol
poor
sensit
detect
bacterium
combin
dismiss
contamin
recov
today
data
emerg
p
acn
whole
genom
sequenc
project
phylogenet
genet
popul
analys
studi
transcriptom
proteom
level
challeng
understand
bacterium
capac
caus
diseas
particular
isol
four
genet
divis
ia
ib
ii
iii
p
acn
differ
regard
inflammatori
potenti
product
specif
virul
determin
includ
protein
phase
antigen
variat
signatur
camp
factor
homologu
haemolysin
lipas
recent
studi
found
clear
associ
isol
type
ia
divis
includ
global
dispers
clonal
lineag
acn
vulgari
contrast
isol
type
ib
ii
iii
divis
rare
associ
condit
although
appear
frequent
recov
soft
tissu
medic
implantrel
infect
addit
discuss
p
acn
epidemiolog
relat
acn
consid
recent
data
studi
investig
possibl
link
p
acn
infect
prostat
gland
prostat
cancer
develop
review
grow
bodi
evid
support
p
acn
import
pathogen
relat
biofilm
infect
prosthet
joint
new
aspect
pathogen
potenti
propionibacterium
acn
compar
genom
sequenc
analys
recent
descript
human
skin
microbiom
contribut
valuabl
new
inform
composit
distribut
microorgan
associ
skin
gramposit
bacterium
propionibacterium
acn
ubiquit
found
skin
resid
within
sebac
follicl
face
back
presenc
p
acn
thought
benefici
eg
protect
colon
harm
microorgan
howev
emerg
evid
suggest
p
acn
act
opportunist
pathogen
number
inflammatori
diseas
bacterium
well
known
associ
acn
vulgari
common
skin
diseas
affect
adolesc
howev
despit
decad
research
exact
role
bacterium
acn
remain
enigma
recent
research
highlight
potenti
import
p
acn
strain
ident
determin
diseas
outcom
colon
assumpt
base
fact
dispar
acn
isol
strain
isol
healthi
individu
moreov
strain
ident
seem
major
impact
host
tissu
adhes
inflammatori
potenti
p
acn
decid
appli
compar
genom
transcriptom
analysi
pinpoint
major
differ
commens
diseaseassoci
strain
p
acn
data
highlight
presenc
genom
region
island
possibl
contribut
pathogen
target
strainspecif
p
acn
factor
novel
therapeut
strategi
cure
acn
p
acn
associ
diseas
ad
advantag
minim
disturb
fragil
balanc
skin
microbiota
second
studi
appli
microarraybas
approach
compar
host
cell
respons
p
acn
therebi
use
differ
tissuederiv
cell
type
found
infect
scenario
differ
drastic
cell
type
term
trigger
cellular
signal
event
data
also
suggest
hosttissu
tropism
part
determin
p
acn
invas
inflammatori
capac
persist
infect
could
contribut
sever
p
acn
patholog
nonskin
infect
site
year
clinic
microbiolog
year
clearli
show
major
evolut
clinic
microbiolog
avail
novel
diagnost
tool
base
highlevel
technolog
howev
mani
question
often
ask
laboratori
use
system
clinic
relev
result
obtain
new
technolog
face
time
unravel
role
unsuspect
microorgan
even
question
impact
microbi
flora
also
quickli
obtain
correct
identif
addit
resist
mechan
therebi
enabl
improv
infect
control
bacteri
viral
agent
mass
spectrometri
malditof
esitof
even
lcmsm
parallel
integr
nuclear
amplif
system
allow
characteris
pathogen
reagent
short
turnaround
time
potenti
impact
patient
care
eg
tuberculosi
surveil
microbi
resist
characteris
microbi
flora
metagenom
approach
presenc
absenc
activ
infectionmight
allow
definit
specif
microbi
pattern
defin
patholog
condit
final
obtain
nearli
correct
identif
rapidli
bacteria
yeast
outmost
import
epidemiolog
surveil
infect
cystic
fibrosi
immunosuppress
patient
exampl
altogeth
microbiolog
enter
era
new
technolog
tri
review
list
devic
use
clinic
relev
solut
best
manag
infecti
diseas
year
clearli
show
major
evolut
clinic
microbiolog
avail
novel
diagnost
tool
base
highlevel
technolog
howev
mani
question
often
ask
laboratori
use
system
clinic
relev
result
obtain
new
technolog
face
time
unravel
role
unsuspect
microorgan
even
question
impact
microbi
flora
also
quickli
obtain
correct
identif
addit
resist
mechan
therebi
enabl
improv
infect
control
bacteri
viral
agent
mass
spectrometri
malditof
esitof
even
lcmsm
parallel
integr
nuclear
amplif
system
allow
characteris
pathogen
reagent
short
turnaround
time
potenti
impact
patient
care
eg
tuberculosi
surveil
microbi
resist
characteris
microbi
flora
metagenom
approach
presenc
absenc
activ
infectionmight
allow
definit
specif
microbi
pattern
defin
patholog
condit
final
obtain
nearli
correct
identif
rapidli
bacteria
yeast
outmost
import
epidemiolog
surveil
infect
cystic
fibrosi
immunosuppress
patient
exampl
altogeth
microbiolog
enter
era
new
technolog
tri
review
list
devic
use
clinic
relev
solut
best
manag
infecti
diseas
object
object
understand
origin
success
metallobetalactamas
gene
method
multipl
align
perform
kb
dna
found
upstream
downstream
avail
gene
follow
align
sequenc
found
upstream
resist
gene
use
geneiou
pro
softwar
biomatt
ltd
nz
gc
calcul
use
slide
window
total
gc
content
gene
calcul
use
dnastar
softwar
result
gc
graph
gene
upstream
sequenc
indic
larg
chang
gc
upstream
within
gene
interestingli
gc
chang
dramat
within
gene
share
first
amino
acid
observ
unlik
happen
chanc
align
sequenc
upstream
found
acinetobact
baumanii
gene
indic
gene
ident
sequenc
includ
element
insert
upstream
start
codon
furthermor
ident
continu
gene
precis
point
gc
dramat
chang
conclus
unequivoc
evid
form
frame
fusion
event
gene
previou
metallobetalactamas
gene
fusion
caus
addit
six
amino
acid
ad
nterminu
preprotein
explain
recent
describ
rag
nterminu
chang
cleavag
site
also
membran
target
fusion
may
happen
two
rout
firstli
delet
event
upstream
composit
transposon
could
occur
remov
sequenc
upstream
start
codon
major
gene
secondli
structur
could
construct
element
initi
captur
move
grow
problem
gene
analysi
sequenc
adjac
orii
structur
acinetobact
speci
indic
insert
region
similar
gc
baumanii
ad
evid
hypothesi
construct
fusion
event
also
given
new
promot
sequenc
natur
genet
engin
event
may
link
recent
success
ident
sequenc
upstream
gene
indic
fusion
recent
line
current
knowledg
emerg
wailan
dl
paterson
silvey
sidjabat
brisban
au
object
recent
emerg
new
carbapenem
resist
mechan
new
delhi
repres
signific
threat
class
b
carbapenemas
found
numer
speci
enterobacteriacea
nosocomi
pathogen
also
human
intestin
flora
e
coli
gene
abl
spread
rapidli
resid
plasmid
capabl
type
horizont
gene
transfer
process
call
conjug
studi
investig
rate
conjug
plasmid
transfer
frequenc
ndm
carri
plasmid
e
coli
resembl
acquisit
ndm
gene
normal
human
flora
gastrointestin
tract
method
total
five
ndm
produc
enterobacteriacea
k
pneumonia
e
coli
e
cloaca
use
donor
strain
recipi
strain
sodium
azid
resist
e
coli
conjug
perform
overnight
donor
recipi
ratio
macconkey
agar
transconjug
analys
acquir
plasmid
phenotyp
genotyp
test
includ
nucleas
digest
conjug
machineri
incac
plasmid
tra
gene
determin
prior
conjug
process
result
replicon
type
ndm
plasmid
k
pneumonia
e
coli
incac
type
e
cloaca
incfii
one
ndm
plasmid
five
donor
strain
could
transfer
conjug
conjug
rate
inac
ndm
plasmid
k
pneumonia
e
coli
transconjug
per
recipi
respect
also
observ
synergist
effect
meropenem
ceftazidim
combin
sodium
azid
mitig
ndm
produc
transconjug
growth
inclus
submic
ciprofloxacin
environ
vitro
enhanc
conjug
rate
time
ndm
plasmid
conjug
alter
tra
operon
may
lead
defect
conjug
machineri
within
transconjug
conclus
spread
ndm
plasmid
occur
astound
rate
process
conjug
process
enhanc
introduct
ciprofloxacin
environ
conjug
either
stimul
plasmid
transfer
increas
frequenc
furthermor
plasmid
becom
modifi
conjug
process
gener
altern
size
plasmid
multipl
plasmid
potenti
enhanc
spread
ndm
gene
characteris
incfiityp
encod
plasmid
escherichia
coli
r
bonnin
p
nordmann
carattoli
l
poirel
le
fr
rome
object
resist
carbapenem
enterobacteriacea
report
worldwid
studi
initi
isol
multidrugresist
e
coli
strain
gue
communityacquir
india
aim
work
character
featur
incfiityp
plasmid
special
focu
associ
genet
structur
method
complet
sequenc
work
flow
perform
use
illumina
genom
analyz
iix
system
illumina
inc
san
diego
ca
assembl
carri
use
assembl
order
produc
contig
illumina
gaiix
read
pcrgap
closur
perform
final
assembl
plasmid
result
blast
analysi
complet
nucleotid
sequenc
perform
comparison
refer
incfii
plasmid
bear
extendedspectrum
betalactamas
gene
confirm
pguendm
belong
incfiityp
plasmid
show
signific
synteni
two
scaffold
except
region
contain
accessori
gene
gene
local
multidrug
resist
mdr
region
bp
region
bracket
two
copi
insert
seqeunc
opposit
orient
creat
composit
transposon
order
get
insight
gene
success
dissemin
comparison
genet
structur
previous
identifi
identifi
plasmid
pgue
perform
appear
common
modul
alway
identifi
modul
compos
fragment
contain
promot
region
gene
bleomycin
resist
gene
truncat
phosphoribosylanthranil
isomeras
conclus
studi
character
incfii
plasmid
backbon
known
success
consid
current
repres
major
vehicl
dissemin
gene
function
part
scaffold
correspond
identifi
incf
plasmid
origin
link
way
contain
modul
acquir
result
seri
recombin
event
involv
insert
sequenc
acinetobact
johnsonii
emerg
hospit
sewag
object
investig
presenc
hospit
sewag
could
accumul
high
densiti
antimicrobialresist
organ
serv
hot
spot
transfer
resist
gene
method
hospit
sewag
obtain
influx
wastewat
treatment
plant
hospit
dilut
aliquot
streak
onto
plate
contain
mgl
meropenem
incub
overnight
coloni
grown
plate
screen
blandm
pcr
speci
identif
establish
partial
sequenc
rrna
gene
clonal
related
isol
carri
blandm
determin
ericpcr
mate
attempt
obtain
conjug
plasmid
carri
blandm
use
escherichia
coli
recipi
genet
context
blandm
investig
pcr
map
invers
pcr
use
selflig
hinciior
hindiiirestrict
genom
dna
templat
result
seventi
coloni
grew
plate
contain
meropenem
two
carri
blandm
confirm
sequenc
whole
code
sequenc
two
isol
identifi
acinetobact
johnsonii
speci
usual
found
aquat
environ
rare
caus
clinic
infect
two
isol
differ
ericpcr
pattern
suggest
differ
clonal
origin
despit
repeat
attempt
transconjug
obtain
two
isol
case
adjac
complet
version
upstream
ble
mediat
bleomycin
resist
trpf
encod
phosphoribosylanthranil
isomeras
downstream
figur
side
locat
specifi
aminoglycosid
cinh
encod
recombinas
conclus
sewag
hospit
western
china
found
contain
might
clinic
origin
could
threat
public
health
hospit
sewag
import
often
overlook
reservoir
antimicrobi
resist
determin
warrant
attent
structur
like
due
recombin
two
copi
suggest
could
serv
hot
spot
homolog
recombin
gener
variat
genet
context
background
cmvrecipi
receiv
graft
cytomegaloviru
cmv
donor
rd
high
risk
develop
cmv
infect
diseas
univers
prophylaxi
least
month
prefer
option
still
doubt
best
strategi
use
patient
pt
method
kidney
liver
rd
pt
resitra
cohort
transplant
infect
spanish
network
studi
analys
develop
cmv
infect
diseas
accord
prophylaxi
receiv
studi
result
one
hundr
ninti
five
kidney
liver
transplant
pt
rd
cmv
rd
pt
develop
cmv
diseas
lateonset
diseas
univers
prophylaxi
month
administ
pt
eighteen
pt
develop
cmv
infect
also
develop
cmv
diseas
among
pt
receiv
univers
prophylaxi
develop
cmv
infect
also
develop
cmv
diseas
focu
pt
receiv
univers
prophylaxi
develop
cmv
diseas
pt
develop
cmv
diseas
directli
without
observ
cmv
replic
previou
cmv
diseas
develop
therefor
without
possibl
earli
preemptiv
therapi
among
pt
develop
cmv
infect
without
cmv
diseas
receiv
preemptiv
therapi
mean
time
cmv
infect
pt
receiv
receiv
univers
prophylaxi
day
respect
trend
toward
develop
late
cmv
diseas
univers
prophylaxi
group
p
multivari
analysi
receiv
univers
prophylaxi
ci
presenc
reject
requir
steroid
ci
receiv
kidney
transplant
compar
liver
transplant
ci
independ
factor
associ
increas
risk
cmv
infect
hand
receiv
univers
prophylaxi
ci
receiv
kidney
transplant
compar
liver
transplant
ci
independ
factor
associ
increas
risk
cmv
diseas
result
support
benefit
univers
prophylaxi
least
month
rd
patient
risk
associ
strategi
base
preemptiv
therapi
pt
addit
factor
use
steroid
treat
reject
type
transplant
may
alter
natur
histori
cmv
infect
pt
background
although
gener
consid
cytomegaloviru
cmv
infect
import
role
longterm
evolut
solid
organ
transplant
sot
recipi
realli
littl
consist
inform
prove
correl
method
analyz
cohort
sot
recipi
institut
surviv
day
transplant
tx
patient
follow
least
year
episod
cmv
infect
detect
antigenemia
andor
realtim
pcr
diseas
prospect
follow
death
graft
loss
hospit
patient
receiv
antivir
prophylaxi
evid
cmv
infect
defer
therapi
dt
group
use
propens
score
data
two
group
match
comparison
dt
done
result
total
patient
underw
kidney
transplant
among
group
dt
group
match
enrol
patient
cmv
immunoglobulin
g
posit
baselin
characterist
durat
dialysi
well
match
group
cmv
viremia
requir
antivir
treatment
occur
patient
group
dt
group
p
graft
loss
also
similar
group
vs
p
howev
seven
patient
dt
group
experienc
organ
involv
cmv
diseas
wherea
group
patient
die
due
cmv
relat
event
conclus
show
advantag
dt
prevent
cmv
episod
requir
antivir
treatment
mortal
kidney
transplant
recipi
intermedi
risk
cmv
diseas
cmv
antigenemia
test
posit
six
patient
antivir
treatment
use
patient
time
hospit
significantli
greater
cmv
group
p
howev
differ
surgeri
need
within
month
ibd
flare
multivari
analysi
independ
risk
factor
associ
develop
cmv
diseas
patient
ibd
flare
age
ci
ulcer
coliti
ic
corticosteroid
resist
ic
howev
risk
factor
associ
develop
cmv
diseas
patient
ibd
diagnosi
done
cmv
diseas
also
immunosuppress
treatment
cyclosporin
infliximab
ci
low
level
albumin
conclus
cmv
diseas
signific
increas
infecti
complic
patient
ibd
significantli
increas
hospit
time
need
addit
surgeri
ulcer
coliti
older
age
corticosteroid
resist
risk
marker
develop
complic
ibd
patient
flare
immunosuppress
therapi
cyclosporin
infliximab
also
risk
factor
patient
previouslydiagnos
ibd
phage
therapi
propos
therapeut
treatment
bacteri
infect
almost
centuri
ago
felix
dherel
year
discoveri
penicillin
despit
rapid
world
diffus
therapi
lack
scientif
knowledg
bacteriophagesbacteria
relationship
discoveri
antibiot
precipit
abandon
except
mainli
east
european
countri
antibiot
becam
routin
therapi
second
half
last
centuri
scientif
knowledg
bacteriophag
led
birth
molecular
biolog
today
increasingli
public
health
problem
caus
antibioticresist
bacteria
major
drive
forc
renew
interest
phage
therapi
togeth
rediscoveri
bacteriophag
use
treat
bacteri
infect
human
year
east
european
countri
recent
work
perform
anim
model
highlight
potenti
use
bacteriophag
medicin
past
year
shown
use
mice
bacteriophag
use
treat
acut
lung
infect
caus
pseudomona
aeruginosa
work
perform
two
differ
p
aeruginosa
strain
two
differ
bacteriophag
later
extend
demonstr
bacteriophag
could
also
use
prevent
protect
mice
lethal
lung
infect
day
investig
led
us
identif
two
new
group
bacteriophag
recent
investig
relationship
bacteriophag
intestin
flora
first
show
bacteriophag
abl
infect
bacteria
grow
biofilm
form
vitro
ex
vivo
second
use
mous
model
colon
enteroaggreg
escherichia
coli
strain
demonstr
bacteriophag
replic
continu
sever
week
upon
addit
initi
high
dose
bacteriophag
could
show
ileal
concentr
e
coli
strain
strongli
reduc
howev
strain
could
total
clear
gut
light
two
exampl
phage
therapi
get
closer
realiti
anymor
resembl
myth
even
numer
question
still
yet
found
answer
despit
reduct
diseas
attribut
widespread
use
proteinconjug
polysaccharid
vaccin
pcv
pneumococcu
retain
role
princip
pathogen
respiratori
tract
caus
mani
case
otiti
media
acut
sinus
pneumonia
occasion
exacerb
chronic
lung
diseas
diseas
outsid
respiratori
tract
includ
bacteremia
recogn
focu
mening
septic
arthriti
endocard
periton
osteomyel
complex
polysaccharid
capsul
repel
ingest
kill
innat
immun
mechan
polymorphonuclear
leukocyt
peptidoglycan
princip
constitu
cell
wall
pneumolysin
stimul
intens
inflammatori
respons
diseas
respiratori
tract
result
host
fail
clear
organ
inflammatori
product
accumul
treatment
extracn
infect
remain
straightforward
pneumococci
remain
suscept
betalactam
antibiot
commonli
use
dose
fluoroquinolon
even
mening
case
respond
commonli
recommend
high
dose
thirdgener
cephalosporin
newer
antibiot
ceftarolin
appear
effect
penicillinresist
organ
widespread
use
pcv
led
emerg
replac
strain
use
pcv
almost
certain
effect
limit
use
polysaccharidebas
vaccin
futur
pneumolysin
major
virul
factor
pneumococci
protein
express
surfac
current
investig
potenti
vaccin
compon
last
two
decad
first
six
communitybas
studi
gyneacolog
schistosoma
haematobium
recommend
diseas
refer
urogenit
schistosomiasi
term
current
use
francophon
scientif
literatur
studi
shown
women
may
genit
lesion
even
without
urinari
ova
symptom
furthermor
lesion
present
adult
age
group
independ
adult
risk
water
contact
refractori
treatment
least
month
cervix
fallopian
tube
vagina
common
gynaecolog
site
present
ova
lesion
caus
host
respons
dead
viabl
schistosomiasi
egg
may
render
women
genit
schistosomiasi
suscept
hiv
typic
genit
chang
sandi
patch
patholog
blood
vessel
may
make
women
suscept
superinfect
caus
contact
bleed
decreas
fertil
abort
discharg
bleed
research
need
find
simpl
lowtech
diagnosi
treatment
chronic
lesion
explor
prevent
effect
mass
drug
administr
symptom
sandi
patch
hpv
hiv
epidem
toy
gadget
esourc
id
cm
specialist
digit
toy
make
life
easi
hospit
one
would
chanc
look
back
far
futur
surpris
see
would
label
time
live
second
renaiss
mind
thrill
progress
internet
main
catalyz
period
internet
process
continu
produc
new
remark
chang
late
two
articl
pinpoint
two
major
chang
first
one
www
dead
state
routin
webpag
popular
anymor
social
media
replac
look
progress
facebook
best
exampl
second
articl
head
end
laptop
cours
wide
usag
laptop
condol
mr
steve
job
appl
chang
everyth
although
armageddon
ship
develop
smartphon
mainli
iphon
medic
practic
tablet
pc
main
tool
sever
advantag
tool
small
mobil
high
capac
afford
store
everyth
multitask
open
develop
easili
broadcast
data
share
easi
two
main
oper
system
io
android
introduct
icloud
onlin
data
storag
opportun
enabl
access
share
data
comput
devic
mainli
mobil
advantag
internet
access
high
capac
devic
begin
find
import
place
medic
practic
use
variou
medic
paramed
small
softwar
enabl
us
use
devic
like
well
develop
comput
perform
task
gadget
exampl
view
radiolog
imag
use
hospit
inform
system
bedsid
give
medic
pharmaceut
order
search
medic
databas
possibl
nowaday
lot
applic
find
way
use
daili
medic
practic
medic
institut
daili
medic
practic
exampl
given
revolut
end
yet
futur
internet
wide
open
develop
develop
may
lead
us
new
horizon
predict
time
exampl
given
sinc
trend
involv
northern
area
veneto
region
observ
case
identifi
area
affect
previou
year
wnv
nat
screen
blood
tissu
organ
donat
identifi
four
wnv
rnaposit
blood
donor
one
wnv
rnaposit
organ
donor
resid
area
symptomat
human
case
identifi
wnvposit
organ
donor
miss
nat
test
transmit
infect
three
five
recipi
two
kidney
recipi
develop
wnnd
excret
wnv
rna
urin
rapid
detect
case
allow
prevent
transmiss
tissu
recipi
follow
experi
monitor
wnv
rna
urin
wnv
natposit
blood
donor
subject
wnv
rna
remain
posit
urin
long
becom
undetect
peripher
blood
whole
genom
sequenc
two
human
wnv
strain
isol
veneto
region
demonstr
wnv
lineag
clade
phylogenet
relat
wnv
strain
circul
itali
western
mediterranean
basin
previou
year
diverg
observ
genom
wnv
strain
isol
strain
isol
veneto
region
conclus
forth
consecut
year
human
case
wnv
diseas
occur
veneto
region
affect
region
wnv
nat
screen
blood
organ
donat
detect
rel
high
rate
posit
case
wnv
rna
detect
urin
repres
sensit
test
genet
comparison
wnv
strain
isol
itali
recent
year
indic
viru
might
reintroduc
migratori
bird
sever
time
might
circul
evolv
conclus
comparison
data
outbreak
indic
shift
mild
ill
toward
larger
sever
manifest
diseas
could
interpret
epidemiolog
transit
pattern
lahor
region
countryserolog
virolog
condit
highli
indic
local
acquir
outbreak
dhf
larger
magnitud
futur
highlight
need
rigor
vector
control
measur
vaccin
develop
continu
educ
clinician
primari
care
physician
crucial
earli
recognit
dhf
especi
patient
prior
histori
df
sever
studi
demonstr
toscana
viru
tosv
promin
caus
cn
infect
febril
ill
mediterranean
countri
specif
southern
franc
howev
still
littl
data
reflect
circul
tosv
gener
popul
previou
studi
conduct
sera
blood
donor
report
approxim
possess
igg
specif
toscana
viru
suggest
previou
infect
de
lamballeri
et
al
recent
studi
conduct
blood
donor
found
preval
order
magnitud
brisbarr
et
al
howev
small
number
sampl
preclud
investig
distribut
accord
age
total
sera
collect
patient
admit
andor
hospit
public
hospit
marseil
toscana
viru
serolog
prescrib
includ
studi
sera
collect
approxim
gener
popul
contact
tosv
demonstr
activ
circul
detail
analysi
suspect
case
period
clinic
data
sequenti
serum
specimen
csf
sampl
use
laboratori
techniqu
viru
isol
vero
cell
line
realtim
rtpcr
sequencebas
confirm
well
seroconvers
assess
use
indirect
immunofluoresc
viru
neutral
test
plaquereduct
neutral
assay
use
allow
document
unambigu
total
case
acut
infect
tosv
geograph
demograph
clinic
virolog
characterist
case
investig
compar
data
literatur
better
understand
clinic
epidemiolog
pictur
tosv
remain
neglect
pathogen
import
larg
underestim
conclus
seropreval
data
record
clinic
case
togeth
indic
tosv
preval
autochthon
arboviru
southeastern
franc
far
ahead
west
nile
viru
dengu
viru
chikungunya
viru
background
respiratori
infect
remain
major
caus
morbid
mortal
worldwid
novel
respiratori
virus
human
coronavirus
hcov
bocavirus
human
metapneumoviru
recogn
common
caus
respiratori
diseas
hcov
drew
attent
scientif
commun
identif
sarscoronaviru
sinc
least
two
addit
coronavirus
associ
human
ill
discov
report
exist
literatur
describ
exist
virus
peru
method
respiratori
sampl
collect
influenza
like
ill
ili
case
particip
populationbas
respiratori
surveil
studi
peru
studi
initi
june
follow
approxim
particip
household
live
four
geograph
distinct
locat
across
peru
lima
central
coast
urban
tumb
tropic
coastrur
cusco
highlandssemirur
puerto
maldonado
amazon
rainforesturban
sampl
test
realtim
rtpcr
influenza
b
subgroup
sampl
neg
influenza
select
perform
addit
test
addit
respiratori
virus
use
multiplex
luminex
rvp
assay
result
sampl
posit
hcov
none
posit
major
case
male
age
one
particip
month
old
three
adult
year
old
particip
hcov
infect
start
ili
diseas
episod
mid
april
mid
decemb
howev
particip
start
diseas
mid
may
juli
winter
season
peru
hcov
case
observ
four
site
three
lima
four
cusco
two
puerto
maldonado
tumb
discuss
knowledg
first
report
hcov
infect
human
peru
preval
studi
similar
previou
report
clear
season
hcov
also
found
hcov
infect
four
site
peru
suggest
hcov
circul
urban
rural
area
peru
infect
common
popul
contrast
studi
virus
preval
found
posit
sampl
could
explain
biennial
behavior
previous
report
object
alert
surveil
major
issu
field
infecti
diseas
id
sever
exampl
past
decad
highlight
warn
system
reveal
major
pathogen
outbreak
weekli
monitor
microbiolog
data
involv
syndrom
target
surveil
implement
sinc
marseil
univers
hospit
uh
use
epim
hous
comput
program
method
epim
use
microsoft
excel
softwar
analys
weekli
number
clinic
sampl
send
microbiolog
diagnosi
core
pointofcar
laboratori
marseil
uh
weekli
number
posit
test
surveil
primarili
syndromebas
use
natur
sampl
regardless
pathogen
sought
ii
secondarili
focus
pathogen
includ
critic
term
mortal
implic
nosocomi
infect
antimicrobi
resist
epim
calcul
set
data
mean
valu
standard
deviat
sd
new
data
compar
instantli
histor
one
signific
increas
beyond
mean
valu
sd
gener
red
color
signal
data
plot
graphic
result
year
event
enter
epim
correspond
paramet
includ
categori
sampl
pathogen
diagnost
test
antibacteri
resist
pattern
new
paramet
gradual
ad
mean
durat
surveil
year
rang
year
besid
monitor
infectionspathogen
known
season
epim
prove
effici
detect
sever
abnormalprevi
unknown
event
includ
notabl
increas
incid
klebsiella
pneumonia
bloodstream
infect
summer
ii
low
incid
influenza
infect
iii
increas
pharyng
group
streptococcu
ga
associ
ga
invas
infect
influenza
iv
increas
imipenemresist
acinetobact
baumannii
v
increas
hepat
e
case
first
trimest
conclus
epim
homemad
simpl
versatil
program
proven
effici
detect
abnorm
event
relat
id
well
suit
unpredict
futur
improv
may
includ
optim
critic
threshold
alert
specif
monitor
clinic
unit
autom
data
transfer
lab
comput
system
neutrophil
increas
tuberculosi
evid
vitro
studi
patient
pulmonari
diseas
c
ong
p
elkington
c
ugartegil
f
roncaroli
j
friedland
london
uk
object
neutrophil
major
phagocyt
cell
lung
patient
activ
pulmonari
tuberculosi
tb
matrix
degrad
phenotyp
tb
result
tissu
damag
activ
matrix
metalloproteinas
mmp
unoppos
tissu
inhibitor
timp
investig
factor
regul
neutrophil
mmp
secret
tb
vitro
patient
method
neutrophil
healthi
volunt
infect
mycobacterium
tuberculosi
mtb
stimul
condit
media
mtbinfect
monocyt
comtb
analysi
secret
elisa
luminex
array
zymographi
gene
express
investig
use
realtim
pcr
neutrophil
granul
format
assess
confoc
microscopi
induc
sputum
sampl
healthi
control
tb
patient
analys
brain
biopsi
patient
central
nervou
systemtb
studi
immunohistochemistri
result
neutrophil
secret
upregul
mtb
time
depend
tb
multipl
infect
comtb
stimul
neutrophil
result
fold
upregul
secret
respect
p
increas
p
increas
fold
respect
compar
gene
express
increas
fold
fold
respect
comtb
stimul
hour
p
confoc
microscopi
demonstr
colocalis
earli
endosom
marker
indic
newli
synthesis
significantli
elev
induc
sputum
sampl
tb
patient
compar
healthi
control
correl
neutrophil
marker
neutrophil
gelatinas
associ
lipocalin
myeloperoxidas
brain
biopsi
specimen
patient
cnstb
demonstr
neutrophil
surround
tb
granuloma
present
conclus
neutrophil
gene
express
secret
upregul
follow
direct
infect
tb
stimul
monocytedepend
tb
network
increas
mmptimp
ratio
result
proteolyt
environ
may
lead
patient
morbid
associ
tissu
destruct
introduct
tuberculosi
tb
characteris
extens
tissu
destruct
caus
mortal
morbid
mycobacteri
spread
greatest
burden
diseas
lie
southern
africa
fuell
hiv
epidem
hiv
coinfect
tb
caus
diverg
patholog
markedli
reduc
inflammatori
host
damag
evid
advanc
immunocompromis
matrix
metalloproteinas
mmp
key
proteas
extracellular
matrix
remodel
implic
tb
tissu
destruct
littl
known
role
tbhiv
coinfect
object
investig
hypothesi
differenti
mmp
activ
tbhiv
underli
greater
patholog
spectrum
tbhiv
coinfect
quantifi
mmp
cytokin
induc
sputum
patient
newli
diagnos
pulmonari
tb
without
hiv
coinfect
comparison
control
patient
correl
mmp
cytokin
induc
sputum
clinic
measur
immunopatholog
pulmonari
cavit
chest
xray
infiltr
score
sputum
smear
statu
also
count
result
fourtyfour
induc
sputum
sampl
patient
cape
town
south
africa
analys
mmp
cytokin
multiplex
array
tb
patient
significantli
increas
compar
control
hivinfect
tb
patient
advanc
hiv
count
significantli
reduc
p
respect
correl
clinic
paramet
tissu
destruct
includ
chest
xray
infiltr
score
p
r
sputum
afb
score
r
significantli
increas
cavitatori
vs
noncavitatori
tb
p
see
figur
contrast
differ
cytokin
tb
patient
without
hiv
infect
detect
tnfalpha
concentr
correl
chest
xray
infiltr
score
paramet
immunopatholog
conclus
advanc
hiv
infect
associ
reduc
mmp
concentr
potenti
explain
reduc
inflammatori
immunopatholog
associ
close
clinic
paramet
tissu
destruct
patholog
provid
evid
caus
role
defin
role
mmp
immunopatholog
tbhiv
coinfect
may
enabl
develop
immunomodulatori
therapi
reduc
tbrelat
morbid
object
examin
respiratori
burst
monocyt
polymorphonuclear
leucocyt
pmn
determin
monocyt
antibodi
depend
cellular
cytotox
adcc
method
patient
present
compat
symptom
relev
imag
posit
tubercul
cultur
suggest
histolog
tissu
diagnosi
tuberculosi
consecut
enrol
studi
patient
compar
age
sex
match
healthi
volunt
demograph
data
clinic
featur
patient
document
design
form
isol
pmn
isol
monocyt
respiratori
burst
studi
stimul
phorbol
myrist
pma
measur
chemiluminesc
cl
respons
adcc
isol
monocyt
determin
util
turbidimetr
measur
nucleat
target
cell
suspens
result
thirteen
patient
cultur
posit
pulmonari
tuberculosi
six
patient
extrapulmonari
consecut
enrol
studi
made
male
six
femal
mean
age
year
patient
compar
age
sex
match
nineteen
healthi
volunt
main
symptom
patient
decreas
order
fever
cough
weight
loss
respiratori
burst
whole
blood
patient
significantli
differ
compar
control
mean
cl
respons
vs
respect
p
likewis
mean
cl
respons
respiratori
burst
pmn
also
significantli
differ
patient
control
mean
respons
vs
p
howev
mean
cl
respons
monocyt
show
differ
patient
control
vs
mycobacterium
avium
subsp
paratuberculosi
map
etiolog
agent
john
diseas
chronic
granulomat
enter
cattl
domest
wild
rumin
speci
symptom
includ
intestin
inflamm
poor
nutrient
uptak
sever
diarrhoea
emaci
untreat
ultim
death
infect
host
pathogen
also
strongli
implic
caus
agent
crohn
diseas
human
yet
evid
support
remain
inconclus
nevertheless
john
diseas
preval
worldwid
signific
impact
global
agricultur
economi
novel
prophylact
therapeut
strategi
requir
control
spread
present
studi
efficaci
express
recombin
map
protein
probiot
lactobacillu
strain
therapeut
applic
investig
bioinformat
screen
complet
map
genom
set
map
gene
encod
put
antigen
secret
cytosol
surfac
express
protein
identifi
five
select
map
gene
fuse
express
vector
creat
transcript
fusion
control
express
util
nisin
induc
control
express
nice
system
subsequ
fusion
vector
map
transform
lb
salivariu
induc
midlog
phase
vv
nisin
h
static
mrna
isol
rtpcr
analysi
roch
use
confirm
express
map
gene
within
host
strain
level
nisin
dosedepend
control
express
also
examin
protein
analysi
carri
use
sd
page
agil
bioanalyz
control
overexpress
map
proteinsantigen
gra
gener
regard
safe
host
numer
therapeut
applic
addit
control
subunit
vaccin
overexpress
modul
host
immun
respons
via
direct
oral
administr
antigen
express
lb
salivariu
strain
may
form
basi
prophylact
vaccin
anim
perhap
even
human
seen
parasitolog
clinic
trichinosi
trichinellosi
produc
larval
stage
nematoda
parasit
belong
trichinella
spp
widespread
human
anim
domest
pig
far
import
sourc
infect
parasit
present
contin
except
antarctica
area
raw
pork
hors
game
anim
meat
consum
much
involv
geograph
distribut
document
countri
relat
cultur
religi
food
habit
common
area
raw
pork
meat
wide
consum
advanc
stage
diseas
trichinella
larva
becom
encapsul
remain
nonencapsul
clinic
cours
diseas
relat
trichinella
speci
infect
dose
number
trichinella
larvaegram
immunolog
background
host
previou
trichinella
infect
acut
trichinellosi
easier
detect
popul
diagnosi
consequ
appropri
treatment
often
time
evolut
good
prognosi
common
howev
complic
cardiovascular
neurolog
ocular
respiratori
digest
associ
mortal
rate
estim
chronic
trichinellosi
determin
long
cours
diseas
hazard
discov
sequel
often
associ
diagnosi
base
morpholog
identif
parasit
serolog
screen
confirmatori
molecular
diagnosi
eosinophilia
increas
muscl
enzym
relev
appropri
treatment
initi
soon
possibl
mani
state
includ
eu
member
state
notif
diseas
compulsori
spite
control
measur
appli
mani
countri
europ
still
endem
foci
gramneg
bacilli
current
epidemiolog
oxacarbapenemas
klebsiella
n
woodford
london
uk
carbapenemas
belong
subgroup
escap
environment
bacteria
genu
shewenella
increasingli
detect
clinic
isol
enterobacteriacea
betalactamas
initi
identifi
turkey
scatter
report
mainli
klebsiella
pneumonia
isol
sever
countri
middleeast
mediterranean
region
especi
north
africa
hospit
outbreak
caus
produc
carbapenemas
describ
turkey
recent
sever
european
countri
k
pneumonia
strain
sequenc
type
implic
european
spread
carbapenemas
although
resist
gene
detect
mani
clone
inde
genera
gene
usual
locat
transposon
found
enterobacteriacea
divers
geograph
origin
highlyrel
conjug
plasmid
c
recent
describ
variant
carbapenemas
differ
four
amino
acid
gene
associ
element
distinct
transposon
much
smaller
plasmid
c
accur
detect
enzym
enterobacteriacea
may
pose
problem
diagnost
refer
laboratori
unless
confirmatori
molecular
test
use
mani
produc
remain
suscept
vitro
imipenem
andor
meropenem
absenc
resist
mechan
esbl
also
oxyiminocephalosporin
highlevel
resist
piperacillintazobactam
temocillin
may
use
marker
enzym
strain
show
reduc
carbapenem
suscept
intern
studi
need
monitor
spread
carbapenemas
result
mandatori
mrsa
bacteraemia
surveil
record
mrsa
bacteraemia
case
england
give
rate
case
per
popul
mrsa
account
aureu
bacteraemia
contrast
situat
mere
year
previous
surveil
programm
report
mrsa
case
give
rate
four
fold
higher
case
per
popul
aureu
bacteraemia
mrsa
repres
c
reduct
mrsa
year
low
mrsa
rate
coincid
nh
trust
record
trust
apport
mrsa
bacteraemia
case
ie
case
discov
third
day
post
hospit
admiss
mandatori
surveil
launch
latter
part
mrsa
bacteraemia
england
reach
peak
c
case
c
aureu
bacteraemia
thu
use
dataset
alon
estim
mrsa
rate
last
low
current
voluntari
surveil
provid
data
pre
howev
voluntari
scheme
risk
underascertain
thu
mrsa
rate
calcul
former
lower
latter
figur
exampl
surveil
captur
mrsa
case
compar
mandatori
give
mrsa
rate
respect
consid
data
mrsa
rate
lowest
rate
sinc
mrsa
rate
aureu
bacteraemia
due
mrsa
mandatori
rate
compar
lowest
rate
sinc
rate
calcul
howev
underestim
conclus
rate
bacteraemia
due
mrsa
england
drop
unpreced
degre
recent
year
rate
per
popul
lowest
rate
almost
certainli
sinc
computerassist
surveil
nosocomi
bloodstream
infect
compil
data
electron
hospit
registri
object
report
implement
result
computerassist
monitor
nosocomi
bloodstream
infect
bsi
furthermor
calcul
speci
specif
rate
nosocomi
bsi
compar
drug
resist
pattern
select
hospit
commun
acquir
infect
method
patient
posit
blood
cultur
lillebaelt
hospit
includ
studi
episod
bsi
defin
posit
blood
cultur
signific
pathogen
concomitantli
treatment
patient
antibiot
new
episod
bsi
defin
new
cultur
microorgan
week
later
growth
anoth
pathogen
two
day
previou
posit
blood
cultur
nosocomi
infect
hai
defin
posit
blood
cultur
obtain
two
day
hospit
admiss
inform
microbiolog
find
admiss
data
compil
electron
registri
hospit
result
total
episod
bsi
detect
distribut
gramposit
neg
strain
yeast
anaerob
bacteria
respect
nosocomi
infect
compris
bsi
detect
studi
howev
proport
hai
streptococcu
pneumonia
haemophilu
influenza
group
b
betahemolyt
streptococci
wherea
episod
candida
speci
enterococcu
faecium
serratia
marcescen
nosocomi
origin
escherichia
coli
staphylococcu
aureu
commonli
isol
hai
respect
mrsa
caus
hai
aureu
none
commun
acquir
bsi
cai
percentag
penicillinresist
respect
e
coli
esbl
seen
hai
cai
surprisingli
resist
ampicillin
cefuroxim
ciprofloxacin
gentamicin
highest
e
coli
bsi
episod
cai
origin
rate
bsi
select
speci
present
eg
e
coli
nosocomi
bsi
rate
depart
oncolog
per
bed
day
conclus
computerassist
surveil
hospit
commun
acquir
blood
stream
infect
correspond
drug
resist
pattern
relev
empir
treatment
patient
implement
hospit
incid
rate
select
nosocomi
bsi
may
assist
evalu
infect
control
measur
background
infect
caus
carbapenemaseproduc
enterobacteriacea
major
concern
public
health
emerg
carbapenemas
especi
mediterranean
basin
patient
method
observ
prospect
studi
conduct
set
outbreak
univers
hospit
madrid
spain
adult
patient
posit
blood
cultur
juli
novemb
includ
gene
search
pcr
result
twenti
six
patient
men
bacteremia
caus
produc
bacteria
includ
k
pneumonia
e
coli
k
oxytoca
ertapenem
mcgml
imipenem
mcgml
meropenem
mcgml
median
age
median
charlson
index
nosocomi
except
three
healthcar
relat
communityacquir
episod
observ
median
time
hospit
admiss
posit
blood
cultur
day
patient
surgeri
admiss
patient
urinari
cateth
two
central
venou
cathet
five
time
bacteremia
median
antibiot
ddd
receiv
bacteremia
carbapenem
ddd
sourc
infect
intrabdomin
patient
urinari
catheterrel
primari
bacteremia
other
regard
sever
present
median
pitt
score
eighteen
patient
receiv
activ
antimicrobi
therapi
isol
use
antibiot
tigecyclin
amikacin
fosfomycin
colistin
combin
median
delay
date
isol
start
appropri
antimicrobi
therapi
mic
sensit
day
adequ
treatment
right
dose
rout
administr
day
patient
die
admiss
treat
seven
nontreat
relationship
bacteremia
death
direct
case
relat
seven
unknown
time
blood
cultur
death
day
among
surviv
median
time
blood
cultur
discharg
day
conclus
bsi
caus
produc
enterobacteria
associ
omin
prognosi
could
relat
dificulti
identif
limit
therapeut
option
toxic
avail
treatment
effort
made
identifi
outbreak
adopt
appropri
measur
control
nosocomi
spread
figur
time
male
excess
remain
fairli
constant
variat
age
group
report
main
sourc
mrsa
mssa
bacteraemia
line
respect
skin
soft
tissu
infect
respect
much
variat
meticillinresist
gender
age
group
amongst
age
line
predomin
gender
urinari
tract
infect
uti
common
amongst
male
compar
femal
mrsa
vs
p
mssa
vs
p
howev
variat
minim
year
group
appar
group
conclus
aureu
report
amongst
men
howev
analysi
organ
age
group
show
variat
sourc
bacteraemia
may
drive
gender
age
specif
trend
observ
analysi
requir
object
obtain
data
trend
incid
central
lineassoci
bloodstream
infect
clabsi
popul
larg
teach
institut
difficult
day
cathet
exposur
patient
usual
measur
intens
care
unit
icu
altern
could
monitor
catheterrel
bloodstream
infect
crbsi
confirm
microbiolog
depart
evalu
recent
trend
incid
aetiolog
crbsi
larg
teach
institut
correspond
clabsi
method
assess
incid
aetiolog
crbsi
synchron
presenc
microorgan
blood
cultur
signific
semiquantit
count
cathet
tip
period
compar
adult
icu
implement
care
bundl
hospit
depart
result
record
admiss
episod
bsi
admiss
episod
crbsi
incid
crbsi
rang
admiss
mean
admiss
signific
overal
reduct
incid
crbsi
detect
p
howev
adjust
number
blood
cultur
drawn
observ
signific
reduct
ci
p
incid
rate
adult
icu
care
bundl
appli
trend
similar
clabsi
crbsi
document
import
shift
aetiolog
signific
reduct
per
year
ci
p
staphylococcu
aureu
infect
conclus
show
microbiolog
depart
could
excel
watchtow
monitor
incid
aetiolog
crbsi
institut
observ
signific
reduct
incid
crbsi
adult
icu
remain
hospit
depart
shift
aetiolog
spectrum
crbsi
may
progress
gradual
decreas
gramposit
crbsi
signific
increas
gramneg
candida
infect
object
increas
use
perman
pacemak
pm
implant
cardiovert
defibril
icd
follow
sharp
increas
cardiac
devicerel
infect
endocard
cdie
aim
character
cdie
profil
tempor
trend
prognosi
method
cdie
diagnos
renn
univers
hospit
bed
tertiari
care
center
year
identifi
computer
databas
system
valid
two
expert
patient
includ
present
follow
clinic
sign
infect
local
sepsi
ii
microbiolog
document
blood
andor
lead
cultur
iii
lead
valvular
veget
detect
echocardiographi
data
retrospect
extract
medic
chart
prognost
factor
search
use
multivari
cox
proport
hazard
model
analys
tempor
trend
data
compar
data
previou
studi
perform
institut
use
similar
inclus
criteria
method
result
sixtysix
men
women
includ
median
age
year
iqr
cardiac
devic
implant
atrioventricular
block
n
nodal
diseas
n
includ
pm
icd
median
delay
last
intervent
cardiac
devic
cdie
diagnosi
day
iqr
patient
present
fever
n
posit
blood
cultur
n
fulfil
duke
criteria
definit
ie
n
frequent
pathogen
coagulaseneg
staphylococci
cn
n
staphylococcu
aureu
n
gramposit
cocci
n
gramneg
rod
n
percutan
extract
devic
attempt
case
success
total
extract
case
fifteen
death
attribut
cdie
factor
independ
associ
yearmort
chronic
obstruct
pulmonari
diseas
aor
rep
medic
record
linkag
system
index
medic
record
individu
seen
healthcar
provid
resid
oc
use
criteria
establish
center
control
prevent
ascertain
diagnosi
dswi
time
period
specif
incid
rate
inhospit
within
day
hospit
calcul
scorebas
predict
model
dswi
develop
logist
regress
model
use
regress
coefficientbas
score
method
gener
simpl
integerbas
point
score
predictor
variabl
score
assign
divid
beta
coeffici
absolut
valu
smallest
coeffici
model
round
nearest
integ
overal
risk
score
calcul
ad
compon
togeth
discrimin
model
assess
use
area
receiv
oper
curv
auc
valid
predict
rule
intern
use
bootstrap
method
result
thousand
four
hundr
twentyfour
resid
oc
underw
cabg
surgeri
isol
cabg
combin
cabg
valv
surgeri
incid
rate
dswi
ci
deriv
model
includ
auc
indic
strong
discrimin
abil
model
predict
probabl
dswi
possibl
score
shown
tabl
figur
first
us
populationbas
surveil
studi
cabg
patient
deriv
simpl
model
predict
risk
dswi
patient
educ
risk
potenti
intervent
incorpor
treatment
diminish
procliv
infect
highrisk
patient
object
adher
current
recommend
cr
manag
prosthet
joint
infect
pji
associ
better
outcom
aim
valid
recommend
multicentr
cohort
pji
analys
risk
factor
treatment
failur
method
prospect
cohort
analysi
patient
pji
follow
hospit
andalusia
spain
octob
octob
pji
defin
use
standard
criteria
modifi
tsukayama
classif
use
manag
compar
cr
zimmerli
n
engl
j
med
surgic
manag
categor
accord
cr
aggress
less
aggress
antimicrobi
therapi
classifi
adequ
follow
total
durat
week
prosthesi
remov
retent
earli
use
antibiot
accord
suscept
test
surgeri
use
antimicrobi
biofilm
activ
andor
good
oral
bioavail
partial
adequ
two
three
previou
criteria
inadequ
otherwis
cure
defin
lack
clinic
sign
symptom
infect
creactiv
protein
crp
mgl
absenc
prosthesi
loosen
logist
regress
analysi
perform
studi
risk
factor
treatment
failur
result
type
infect
acut
postsurg
chronic
acut
haematogen
surgic
cr
scr
follow
patient
antibiot
cr
adher
scr
associ
kneehip
pji
vs
shoulderankl
p
acut
pji
vs
chronic
pji
p
non
methicillinresist
aureu
infect
vs
p
crp
mgl
vs
p
adher
scr
higher
cure
rate
vs
p
adher
antimicrobi
cr
adequ
partial
adequ
inadequ
p
independ
factor
associ
failur
first
surgic
procedur
perform
treat
pji
hemiarthroplasti
ci
p
aureu
infect
ci
p
surgic
treatment
accord
cr
ci
p
inadequ
antimicrobi
treatment
ci
p
conclus
first
multicentr
studi
confirm
valid
cr
pji
adher
scr
need
improv
chronic
pji
shoulderankl
pji
object
object
studi
review
epidemiolog
microbiolog
arthroplasti
infect
particular
refer
surgic
antibiot
prophylaxi
method
retrospect
cohort
studi
conduct
across
hospit
year
period
januari
case
prosthet
joint
infect
involv
hip
knee
identifi
use
databas
victorian
healthcar
associ
infect
surveil
system
vicniss
definit
prosthet
joint
infect
base
cdcnhsn
definit
organspac
surgic
site
infect
inform
pertain
antibiot
prophylaxi
collect
appropri
agent
compar
antimicrobi
suscept
subsequ
isol
pathogen
descript
statist
use
summaris
report
data
analys
perform
use
stata
statacorp
colleg
station
tx
result
case
prosthet
joint
infect
identifi
review
microbiolog
cultur
result
methicillin
resist
staphylococc
speci
isol
infect
methicillin
resist
staphylococcu
aureu
methicillin
resist
coagulas
neg
staphylococc
speci
addit
gram
neg
bacilli
enterococc
speci
frequent
seen
polymicrobi
infect
major
patient
receiv
cefazolin
antibiot
prophylaxi
time
arthroplasti
basi
microbiolog
result
surgic
antibiot
prophylaxi
inadequ
patient
conclus
studi
highlight
need
continu
assess
adapt
local
guidelin
reflect
local
ecolog
higher
rate
methicillin
resist
staphylococc
speci
encount
cohort
argu
combin
glycopeptid
cefazolin
surgic
antibiot
prophylaxi
guidelin
object
obes
increas
england
increas
bmi
associ
increas
risk
number
diseas
includ
surgic
site
infect
ssi
assess
impact
increas
bmi
risk
ssi
england
data
submit
hpa
surgic
site
infect
surveil
servic
analys
method
surveil
data
oper
five
surgic
categori
abdomin
hysterectomi
coronari
arteri
bypass
graft
hip
replac
knee
replac
larg
bowel
surgeri
undertaken
particip
nh
hospit
england
extract
analysi
bodi
mass
index
classifi
underweight
kgm
normal
overweight
obes
obes
ii
obes
iii
patient
preoper
physic
health
measur
use
asa
score
infect
meet
standard
clinic
criteria
detect
initi
inpati
stay
readmiss
hospit
multivari
logist
regress
undertaken
examin
independ
bmi
risk
factor
risk
ssi
analys
perform
stata
result
data
submit
hospit
cumul
total
oper
undertaken
bmi
data
avail
patient
overweight
obes
risk
ssi
significantli
increas
overweight
rr
p
obes
patient
rr
p
compar
patient
normal
weight
adjust
surgic
categori
asa
score
oper
durat
wound
class
risk
ssi
increas
increas
bmi
overweight
vs
normal
p
obes
iii
vs
normal
p
effect
obes
vari
accord
surgic
categori
larg
bowel
surgeri
affect
patient
bmi
obes
vs
obes
p
abdomin
hysterectomi
least
affect
obes
vs
obes
p
conclus
overweight
obes
substanti
increas
risk
ssi
given
increas
preval
obes
england
like
bmi
increasingli
contribut
overal
risk
patient
develop
ssi
implic
manag
obes
surgic
patient
effect
increas
bmi
implic
antimicrobi
prophylaxi
patient
glycaem
control
suggest
area
clinic
research
interest
solut
improv
patient
manag
clinician
perspect
last
decad
relentless
effort
made
microbiologist
develop
rapid
costeffect
reliabl
method
diagnosi
autom
cultur
system
mass
spectrometri
dna
base
diagnosi
drastic
reduc
time
need
pathogen
identif
clinic
specimen
howev
recent
studi
rapid
bacteri
identif
msra
blood
cultur
fail
show
clinic
impact
coupl
immedi
commun
result
onward
clinician
either
infecti
diseas
specialist
pharmacist
clearli
rapid
microbi
identif
use
reach
clinician
charg
immedi
interpret
correctli
ideal
id
specialist
could
use
make
link
lab
clinician
charg
relev
specimen
howev
possibl
within
fund
clinic
studi
may
real
life
solut
could
provid
altern
approach
nowaday
physician
familiar
handheld
devic
use
bedsid
check
creatinin
clearanc
drug
interact
onward
physician
could
expect
near
futur
receiv
messag
ward
cell
phone
mister
x
posit
blood
cultur
four
vial
gram
neg
rod
stenotrophomona
maltophilia
bacterium
natur
resist
carbapenem
aminoglycosid
hospit
alreadi
use
electron
antimicrobi
stewardship
am
program
latter
could
even
add
patient
actual
treat
imipenem
consid
empir
use
cotrimoxazol
plu
ceftazidim
institut
use
antibiot
guid
latter
could
electron
link
microbiolog
result
hyperlink
rapid
microbiolog
diagnosi
link
advanc
solut
potenti
posit
improv
time
adequ
treatment
patient
well
infect
control
howev
still
mani
question
resolv
identifi
physician
actual
bedsid
ensur
live
inform
strictli
limit
critic
clinician
avoid
inappropri
interpret
lab
result
lie
talon
dachil
advanc
solut
electron
am
program
link
microbiolog
result
improv
commun
bench
bedsid
current
labor
berlin
serv
hospit
berlin
compris
three
campus
univers
medicin
berlin
nine
commun
hospit
vivant
group
berlin
increas
number
hospit
insid
outsid
berlin
major
repres
tertiari
specialti
care
hospit
process
implement
full
microbiolog
laboratori
autom
provid
time
inform
relev
patient
care
far
major
process
control
laboratori
inform
system
li
also
transmit
result
hospit
inform
system
present
urgent
result
identif
bacteria
caus
bloodstream
infect
antimicrobi
suscept
data
multiresist
pathogen
commun
via
phone
clinic
microbiologist
also
regularli
particip
clinic
round
discuss
critic
patient
howev
mere
number
hospit
geograph
distribut
make
direct
commun
ever
difficult
henc
forc
appli
new
inform
technolog
collect
clinic
data
requir
priorit
test
interpret
test
result
requir
intellig
versatil
open
middl
ware
control
lab
organ
also
commun
exist
laboratori
clinic
inform
system
without
compromis
data
safeti
secur
strangl
capac
exit
divis
use
smartphon
person
digit
assist
wireless
broadband
network
repres
promis
way
realtim
clinic
alert
without
decis
support
antimicrobi
therapi
hospit
hygien
implement
mobil
commun
platform
may
significantli
improv
manag
infecti
diseas
thu
prevent
develop
spread
antimicrobi
resist
system
interoper
improv
treatment
surveil
infect
today
laboratori
vitro
diagnost
devic
connect
inform
manag
system
either
directli
via
intermedi
system
steer
work
set
devic
exchang
work
order
correspond
result
stream
connect
ivd
devic
laboratori
inform
system
achiev
specialti
microbiolog
includ
enabl
clinic
laboratori
streamlin
intern
process
improv
level
qualiti
process
thu
contribut
meet
requir
overal
qualiti
manag
standard
iso
howev
connect
often
still
reli
nonstandard
commun
protocol
well
local
agre
code
vocabulari
identifi
object
type
specimen
analyt
microorgan
antibiot
result
high
cost
deploy
mainten
interfac
vendor
user
moreov
lack
standard
protocol
code
vocabulari
weigh
laboratori
capabl
commun
result
stakehold
surround
inform
system
clinician
wait
laboratori
report
share
electron
health
record
oper
region
countri
improv
continu
coordin
care
public
health
repositori
need
track
consolid
knowledg
ongo
statu
infect
broader
territori
europ
escmid
exampl
better
handl
laboratori
result
especi
microbiolog
result
occur
endtoend
connect
reli
stabl
standard
consist
vocabulari
use
way
system
potenti
deal
laboratori
result
intern
organ
integr
healthcar
enterpris
ihe
contribut
goal
endtoend
connect
provid
consist
set
profil
standard
ihe
laboratori
domain
cover
variou
use
case
laboratori
inform
exchang
recent
set
profil
complement
help
anoth
intern
organ
ivd
industri
connect
consortium
iicc
year
join
effort
ihe
iicc
produc
new
profil
call
laboratori
analyt
workflow
complet
set
ihe
profil
provid
laboratori
domain
clinic
inform
system
also
public
health
system
clinic
research
system
consolid
compar
result
come
differ
laboratori
appli
safe
reason
rule
result
thu
improv
treatment
surveil
infect
describ
result
patient
harbour
esblproduc
organ
isol
isol
mean
control
spread
multidrugresist
mdr
organ
subject
controversi
isol
make
sens
bacteria
efficaci
transmit
direct
contact
patient
surround
surfac
harbour
import
reservoir
recent
systemat
review
publish
articl
multifacet
strategi
includ
contact
precaut
isol
shown
associ
increas
probabl
control
spread
mdr
gram
neg
howev
isol
may
associ
advers
effect
pro
con
care
consid
mani
clonal
outbreak
esblproduc
klebsiella
pneumonia
colonis
patient
key
reservoir
describ
moreov
clone
k
pneumonia
well
known
great
abil
spread
crosstransmiss
within
healthcar
centr
usual
epidemiolog
behaviour
make
prudent
recommend
isol
patient
colonis
infect
esblproduc
k
pneumonia
recommend
may
appli
speci
klebsiella
enterobact
decis
difficult
case
esblproduc
escherichia
coli
two
argument
use
recommend
isol
case
fact
esblproduc
e
coli
shown
spread
clonal
fact
mobil
genet
element
associ
esbl
may
crosstransmit
use
e
coli
enterobacteria
vehicl
howev
clonal
spread
e
coli
actual
occur
commun
whether
acut
care
center
play
relev
role
amplifi
spread
far
clear
well
proven
nosocomi
outbreak
caus
esblproduc
e
coli
crosstransmiss
import
scarc
usual
affect
small
number
patient
final
preval
colonis
esblproduc
e
coli
commun
mani
area
may
high
feasibl
detect
isol
thu
combin
activ
aim
improv
hand
hygien
prudent
use
antibiot
select
organ
mainli
cephalosporin
fluoroquinolon
care
track
nosocomi
case
outbreak
readili
detect
reason
altern
isol
pateint
harbour
esblproduc
e
coli
except
might
patient
admit
icu
isol
may
prudent
clostridium
difficil
infect
cdi
commonest
caus
hospit
acquir
diarrhoea
adult
clinic
signific
cdi
children
less
certain
talk
describ
colonis
infect
cdi
childhood
term
risk
factor
epidemiolog
manag
propos
score
system
assess
sever
cdi
specif
criteria
children
discuss
proteom
particularli
suitabl
character
human
pathogen
high
life
cycl
complex
fungi
protein
content
express
level
may
affect
growth
state
life
cycl
morph
identif
type
fungi
convent
method
often
difficult
timeconsum
frequent
unusu
speci
inconclus
moreov
substanti
chang
medic
intens
care
organ
transplant
practic
drastic
increas
emerg
therapyrefractoryuncommon
fungi
herein
report
proteom
phenotyp
malditof
ms
employ
analyt
type
express
profil
yeast
yeastlik
speci
strain
variant
order
achiev
fungal
proteom
popul
studi
msbase
dentif
id
success
compar
refer
biochemicalbas
system
eg
corrobor
genotyp
id
target
rrna
hypervari
region
ms
id
show
high
analyt
perform
profil
heterogen
complement
even
outclass
exist
yeast
type
tool
variabl
reflect
high
biolog
complex
yeast
may
properli
exploit
provid
epidemiolog
trace
infect
dispers
pattern
furthermor
filament
fungi
eg
aspergillu
emericella
fusarium
geosmithia
neosartorya
penicillium
pseudallescheria
scedosporium
talaromyc
fomitopsi
may
correl
laboratoryadapt
refer
proteom
phenotyp
extend
diagnost
power
basic
databas
growth
timecours
sabouraud
agar
medium
defin
hour
point
best
peptid
extract
condit
full
recoveri
conidiaor
asciproduc
multihyph
morph
structur
highest
intraand
interclass
profil
correl
allow
engin
deriv
librari
ms
mould
id
may
refer
genotyp
routin
morphotyp
id
fingerprint
classifi
select
wilcoxonkruskalw
algorithm
comput
differ
algorithm
allow
model
construct
proteom
phenotyp
revolution
diagnost
mycolog
fulli
reflect
speciesmorph
varieti
often
overcom
taxonom
hindranc
gain
insight
descript
fungi
relev
medic
interest
need
implement
custom
fingerprint
databas
adhoc
gener
malditof
ms
proteom
phenotyp
boost
patienttailor
identif
protocol
diagnost
mycolog
sever
studi
perform
malditof
ms
use
identif
anaerob
bacteria
eg
prevotella
sp
fusobacterium
sp
clostridium
sp
bacteroid
sp
gramposit
anaerob
cocci
gpac
studi
malditof
ms
shown
superior
convent
identif
method
import
extens
databas
contain
refer
spectra
also
shown
studi
sever
studi
first
compil
databas
subsequ
use
identifi
unknown
strain
strain
identifi
malditof
ms
mostli
speci
refer
spectra
present
databas
multicent
studi
two
commerci
avail
malditof
ms
system
bruker
ms
shimadzu
ms
compar
abil
identifi
anaerob
bacteria
shimadzu
ms
system
perform
better
bruker
ms
system
howev
updat
bruker
ms
databas
result
improv
perform
compar
shimadzu
ms
system
confirm
import
extens
databas
moment
correct
speci
identif
obtain
compar
rrna
gene
sequenc
roughli
anaerob
bacteria
encount
human
clinic
specimen
strain
identifi
avail
databas
optim
identif
anaerob
bacteria
malditof
mass
spectrometri
detect
antimicrobi
resist
mechan
j
hrabak
plzen
cz
matrixassist
laser
desorptionionis
timeofflight
mass
spectrometri
malditof
ms
routin
use
identif
bacteria
fungi
potenti
appli
complex
diagnost
process
malditof
ms
capabl
detect
broad
spectrum
molecul
includ
structur
modif
molecular
level
detect
differ
mechan
resist
antimicrobi
may
soon
becom
avail
two
main
approach
use
purpos
identif
molecular
epidemiolog
marker
specif
drugresist
cell
ii
detect
destruct
modif
antibiot
molecul
former
approach
use
detect
methicillinresist
strain
staphylococcu
aureu
elucid
polymyxin
resist
gramneg
bacteria
result
structur
chang
lipopolysaccharid
latter
approach
first
appli
detect
modif
betalactam
betalactamas
method
detect
carbapenemas
base
hydrolysi
meropenem
ertapenem
recent
valid
malditof
ms
abl
detect
small
chang
carbapenem
molecul
eg
sodium
salt
variant
antibiot
therefor
hypothesis
assay
detect
modif
antibiot
molecul
eg
aminoglycosid
rapidli
develop
greatest
challeng
determin
mechan
drug
resist
quantif
antibiot
concentr
gener
quantif
molecul
use
malditof
ms
may
difficult
possibl
method
could
help
studi
efflux
porin
believ
malditof
ms
provid
mani
new
applic
applic
research
drug
resist
mechan
also
develop
routin
microbiolog
diagnost
karger
l
geue
greifswald
wusterhausen
de
mass
spectrometr
analysi
bacteri
raw
extract
revolutionis
microbiolog
recent
year
analysi
matrixassist
laser
desorptionionis
timeofflight
mass
spectrometri
malditof
ms
purpos
rapid
econom
result
spectra
inform
extraordinari
featur
identif
bacteria
lead
extens
approach
characteris
microorgan
like
yeast
fungi
also
tissu
cultur
whole
anim
especi
arthropod
interest
mani
user
focus
question
detail
maldityp
best
concern
bacteria
greatest
interest
taxonom
level
sampl
classifi
number
case
biovar
serotyp
reliabl
distinguish
contrast
identif
protein
peptid
mass
spectrometri
identif
analyt
maldityp
base
comparison
experiment
spectrum
mass
calcul
sequenc
databas
rather
comparison
analyt
spectrum
librari
refer
spectra
authent
sampl
although
wide
appli
theoret
aspect
mass
spectrumbas
classif
fulli
address
yet
number
commerci
inhous
softwar
implement
differ
classif
algorithm
use
complic
crossplatform
comparison
type
result
one
step
algorithm
use
classif
data
reduct
ie
select
mass
refer
sampl
spectra
use
classif
especi
necessari
distinct
close
relat
organ
like
subspeci
serotyp
spectra
present
limit
number
differ
mass
effort
characteris
spatial
tempor
distribut
shiga
toxinproduc
escherichia
coli
stec
isol
repres
serotyp
analys
maldityp
spectra
systemat
variat
data
reduct
step
classif
algorithm
optimis
paramet
classif
three
oserotyp
possibl
fals
rate
combin
two
three
group
paramet
could
adjust
accur
distinguish
two
group
new
sepsi
isf
awarde
lectur
malaria
predispos
bacteri
sepsi
malaria
pigment
key
factor
boura
r
frita
lisbon
pt
introduct
plasmodium
falciparum
infect
refer
sever
studi
risk
factor
bacteri
sepsi
especi
nontyphi
salmonella
profession
phagocyt
monocyt
granulocyt
first
line
defens
extern
pathogen
mechan
impair
could
lead
dissemin
bacteri
infect
contribut
increas
morbid
mortal
malaria
pigment
haemozoin
subproduct
parasit
metabol
releas
blood
stream
erithrocyt
lysi
ingest
cell
may
persist
object
studi
malaria
pigment
ingest
monocyt
granulocyt
influenc
function
particular
subsequ
phagocytosi
kill
bacteria
salmonella
enterica
serovar
typhimurium
method
monocyt
granulocyt
preincub
differ
amount
malaria
pigment
preincub
phagocyt
capac
assess
incub
ph
depend
dye
conjug
escherichia
coli
particl
phrodo
tm
particl
fluoresc
acid
environ
found
phagossom
measur
flow
cytometri
gfp
transfect
salmonella
use
assess
phagocytosi
live
bacteria
kill
bacteria
pigment
contain
phagocyt
result
monocyt
preincub
hour
micromolar
malaria
pigment
phagocyt
abil
impair
rel
control
factor
effect
observ
granulocyt
incub
concentr
malaria
pigment
phagocyt
capac
decreas
rel
control
effect
dose
time
depend
phagocyt
assay
use
salmonella
also
reveal
differ
pigment
contain
noncontain
monocyt
salmonella
phagocytos
monocyt
previous
preincub
malaria
pigment
show
higher
viabil
comparison
control
conclus
malaria
pigment
seem
impair
pahogocyt
acidifi
capac
phagocyt
furthermor
phagocyt
abil
kill
bacteria
seem
decreas
malaria
pigment
may
explain
malaria
patient
acquir
dissemin
bacteri
infect
easili
understand
pathogenesi
epidemiolog
genom
proteom
highthroughput
mlst
bring
molecular
type
next
level
sa
boer
wa
van
der
reijden
r
jansen
haarlem
nl
introduct
multilocu
sequenc
type
mlst
wide
use
system
type
microorgan
sequenc
analysi
seven
housekeep
gene
mlst
protocol
publish
mani
speci
onlin
databas
proven
power
resourc
studi
global
epidemiolog
main
advantag
mlst
compar
type
techniqu
unambigu
transfer
sequenc
data
main
disadvantag
high
cost
gener
sequenc
data
object
introduc
high
throughput
mlst
himlst
method
employ
next
gener
sequenc
ng
deliv
larg
quantiti
high
qualiti
mlst
data
low
price
method
himlst
protocol
consist
two
step
first
step
seven
mlst
target
amplifi
pcr
multiwel
plate
pcr
amplicon
strain
provid
uniqu
dna
tag
multiplex
identifi
mid
second
step
amplicon
pool
sequenc
singl
ng
run
gs
junior
roch
sequenc
run
mlst
profil
individu
strain
easili
gener
use
uniqu
mid
result
himlst
gener
mlst
profil
singl
run
himlst
employ
legionella
pneumophila
staphylococcu
aureu
pseudomona
aeruginosa
streptococcu
pneumonia
applic
mani
speci
moreov
use
mid
allow
combin
sequenc
differ
speci
singl
ng
run
current
himlst
reduc
cost
mlst
factor
compar
tradit
method
expect
cost
reduc
introduc
low
volum
pcr
autom
process
reagent
sequenc
data
way
himlst
capac
doubl
retain
high
qualiti
sequenc
conclus
introduct
himlst
pave
way
broad
employ
mlst
high
qualiti
cost
effect
method
type
microbi
speci
good
perform
object
methicillinresist
staphylococcu
aureu
mrsa
repres
seriou
threat
public
health
worldwid
particular
concern
mrsa
clone
lineag
predomin
unit
state
dissemin
countri
recent
year
noteworthi
pulsedfield
gel
electrophoresi
pfge
gold
standard
type
aureu
use
distinguish
classic
communityacquir
clone
spatyp
pantonvalentin
leukocidin
posit
relat
nosocomi
clone
spatyp
pvl
neg
therefor
object
studi
determin
applic
multiplelocu
variabl
number
tandem
repeat
fingerprint
mlvf
discrimin
two
relat
clone
addit
compar
exoproteom
respect
strain
secret
protein
repres
major
reservoir
aureu
virul
factor
method
like
isol
collect
staten
serum
institut
denmark
multiplex
pcr
subsequ
electrophoret
separ
agil
bioanalyz
perform
describ
sabat
et
al
secret
protein
collect
analyz
sdspage
result
mlvf
group
isol
two
distinct
cluster
n
b
n
importantli
isol
cluster
spatyp
wherea
isol
cluster
b
spatyp
furthermor
cluster
compos
sever
pattern
within
cluster
strain
yield
pattern
thu
major
strain
within
cluster
genet
close
relat
exoproteom
analys
complement
mlvf
data
sinc
differ
secret
protein
aureu
isol
cluster
b
clearli
detect
conclus
mlvf
discriminatori
power
need
distinguish
communityacquir
clone
close
relat
lineag
pfge
profil
addit
mlvf
allow
differenti
isol
spatyp
subclust
relev
epidemiolog
studi
addit
exoproteom
analys
communityacquir
clone
relat
nosocomi
lineag
provid
better
insight
virul
potenti
ultim
lead
better
understand
critic
determin
staphylococc
fit
pathogenesi
object
determin
impact
rapid
epidemiolog
type
control
transmiss
c
difficil
method
prospect
studi
conduct
hospit
unit
kingdom
month
faec
sampl
confirm
toxin
posit
c
difficil
period
increas
incid
pii
defin
two
patient
develop
c
difficil
day
period
ward
submit
type
hospit
randomis
control
test
arm
isol
test
arm
type
use
modifi
mlva
type
isol
control
arm
type
use
pcr
ribotyp
result
fed
back
time
manner
follow
report
result
pii
questionnair
sent
trust
evalu
whether
consid
type
result
aid
manag
total
number
patient
posit
c
difficil
hour
admiss
collect
hospit
model
use
neg
binomi
regress
model
includ
logarithm
number
bed
trust
offset
term
compens
differ
trust
size
result
total
sampl
pii
rang
pii
report
hospit
number
case
involv
pii
rang
mean
durat
pii
day
mlva
arm
ribotyp
sampl
type
result
avail
ribotyp
arm
mlva
arm
sampl
could
type
due
enough
sampl
isol
could
cultur
mean
turnaround
time
mlva
day
oppos
day
ribotyp
case
investig
consid
part
outbreak
method
use
investig
number
patient
acquir
c
difficil
hour
hospit
admiss
studi
period
mlva
arm
ribotyp
arm
binomi
regress
model
confirm
differ
intervent
control
group
respons
questionnair
respond
mlva
arm
state
result
aid
manag
oppos
ribotyp
arm
conclus
mlva
type
provid
rapid
turnaround
provid
result
aid
manag
outbreak
howev
due
multifacet
natur
control
c
difficil
studi
demonstr
differ
two
group
sid
n
n
isol
preval
constitut
two
main
pfge
cluster
account
collect
frequent
sag
gene
smez
follow
speg
spec
spej
spea
ssa
speh
spek
spei
spem
final
spel
cluster
mainli
character
presenc
spec
speg
smez
spea
speg
spej
smez
respect
detect
one
isol
resist
chloramphenicol
two
nonsuscept
levofloxacin
macrolid
resist
detect
isol
mostli
cmlsb
phenotyp
tetracyclin
resist
detect
isol
also
resist
macrolid
conclus
preval
cluster
carri
suggest
import
role
emm
type
skin
soft
tissu
infect
portug
cluster
also
previous
identifi
domin
cluster
among
invas
isol
portug
expect
except
spej
sag
encod
chromosom
gene
smez
speg
present
great
major
isol
associ
prophag
variabl
object
recent
studi
demonstr
capsular
locu
pneumonia
serotyp
associ
high
degre
genet
heterogen
new
serotyp
name
discov
among
strain
previous
identifi
serotyp
carri
capsular
locu
mutat
disrupt
wcje
gene
addit
genom
analysi
three
serotyp
pneumococc
strain
reveal
discord
serotyp
capsular
locu
correspond
associ
serotyp
aim
studi
verifi
capsular
locu
present
serotyp
pneumococc
strain
circul
itali
method
thirtyon
pneumococc
strain
serotyp
accord
quellung
reaction
obtain
invas
diseas
itali
year
analys
sinc
nucleotid
divers
capsular
loci
resid
wcje
code
put
oacetyl
transferas
entir
gene
amplifi
sequenc
result
strain
two
carri
wcje
gene
ident
carri
wcje
gene
ident
among
latter
two
strain
carri
amino
acid
substitut
due
distinct
singl
nucleotid
polymorph
snp
remain
nine
strain
show
disrupt
wcje
gene
consist
serotyp
particular
five
strain
show
wcje
gene
disrupt
transpos
element
insert
four
strain
insert
one
strain
four
strain
show
uniqu
mutat
includ
duplic
insert
snp
result
either
late
start
codon
prematur
stop
codon
respect
wild
type
sequenc
mutat
previous
describ
conclus
studi
highlight
itali
preval
capsular
genotyp
associ
serotyp
correspond
addit
presenc
isol
genotyp
demonstr
suggest
convent
serotyp
could
mask
real
epidemiolog
serogroup
like
serogroup
type
scheme
would
reconsid
near
futur
object
impact
nadir
reflect
time
cart
initi
immun
function
recal
antigen
longterm
yet
well
understood
preserv
polyfunct
tcell
profil
characteris
doubl
tripl
cytokin
secret
cell
thought
advantag
method
proofofprincipl
pilot
studi
evalu
influenza
aspecif
polyfunct
tcell
profil
ifng
tnfa
three
hivposit
patient
haart
high
low
nadir
compar
three
healthi
hivneg
control
bl
week
fig
low
nadir
associ
function
impair
influenza
aspecif
tcell
respons
immunis
despit
absolut
tcell
recoveri
cart
compar
healthi
control
hivpo
patient
cart
nadir
preliminari
find
need
verifi
lager
cohort
argu
substanti
benefit
earli
cart
initi
overal
prolifer
capac
pbmc
equal
group
distribut
cell
subset
within
prolifer
cell
significantli
differ
lower
frequenc
temra
p
higher
frequenc
tem
p
high
tem
p
inr
inr
less
pbmc
secret
upon
seb
stimul
cr
p
p
p
also
exhibit
distinct
distribut
cell
subpopul
less
temra
p
tn
p
tcm
p
tem
p
p
cr
conclus
termin
differenti
accumul
within
popul
among
treg
inr
termin
differenti
associ
compromis
effector
function
impair
treg
might
contribut
persist
immun
activ
turn
lead
higher
frequenc
within
cell
lack
abil
adequ
prolifer
order
reconstitut
cell
loss
upon
stimul
cell
subset
accumul
show
compromis
secret
capac
well
unabl
home
secondari
lymphoid
organ
like
tem
cell
essenti
growth
factor
teff
treg
cell
low
level
might
explain
persist
cell
deplet
well
chronic
immun
stimul
inr
incid
characterist
tenofovir
resist
mutat
nonb
subtyp
patient
fail
nontenofovircontain
antiretrovir
therapi
putcharoen
sirivichayakul
mekprasan
k
ruxrungtham
bangkok
th
object
tenofovir
tdf
potent
nucleosid
revers
transcriptas
inhibitor
nrti
mutat
usual
select
patient
fail
tdf
howev
select
ddi
nonb
subtyp
potenti
limit
use
tdf
subsequ
antiretrovir
regimen
azt
exert
activ
develop
countri
wide
use
antiretrovir
therapi
art
nontdf
contain
regimen
ddi
azt
aim
determin
incid
characterist
mutat
patient
fail
nontdf
contain
art
object
twenti
multidrug
resist
mdr
patient
achiev
success
virolog
suppress
darunavirritonavir
drvr
contain
regimen
follow
week
examin
evolut
intracellular
drug
resist
associ
mutat
ram
pattern
main
aim
analysi
assess
abil
archiv
viral
variant
reemerg
art
establish
role
therapi
failur
method
patient
belong
larger
cohort
antiretrovir
multidrug
experienc
subject
enrol
sapienza
univers
hospit
includ
studi
subject
alreadi
fail
sever
therapeut
regimen
mean
treatment
time
year
time
inclus
studi
week
drvr
start
subject
reach
rna
level
limit
detect
copiesml
hivdna
extract
peripher
blood
mononuclear
cell
amplifi
sequenc
use
trugen
assay
intracellular
drug
resist
mutat
detect
baselin
patient
patient
week
start
studi
result
week
followup
patient
undetect
viremia
baselin
subject
ram
provir
dna
relat
previou
art
interestingli
patient
intracellular
mutat
associ
drv
resist
specif
use
rega
rule
six
subject
show
genotyp
resist
drv
score
eight
intermedi
suscept
score
four
fulli
suscept
drv
score
week
follow
patient
intracellular
drv
genotyp
score
unchang
whilst
four
patient
genotyp
score
chang
due
loss
andor
acquisit
drv
ram
consid
patient
togeth
number
ram
increas
patient
median
valu
four
mutat
rang
decreas
patient
median
valu
three
mutat
rang
remain
patient
number
mutat
detect
week
similar
observ
mutat
conclus
although
perform
small
group
patient
studi
suggest
patient
treat
salvag
therapi
presenc
mdr
viru
cellular
reservoir
may
chang
affect
virolog
respons
week
follow
object
data
exist
distribut
subtyp
gambia
guineabissau
aim
increas
current
databas
field
import
maintain
molecular
diagnost
choos
epitop
hiv
vaccin
explor
potenti
differ
clinic
outcom
respons
antiretrovir
therapi
art
subtyp
art
introduc
gambia
also
aim
survey
presenc
baselin
hiv
drug
resist
newli
diagnos
individu
sinc
result
mif
level
higher
hivinfect
patient
hivneg
control
vs
ngml
mean
sd
p
median
mif
level
ahi
ngml
significantli
higher
chronic
infect
art
ngl
chronic
infect
effect
art
ngml
chronic
infect
fail
art
ngml
mif
level
patient
effect
art
lower
patient
art
p
last
decad
landscap
medic
specialti
microbiolog
european
union
eu
chang
dramat
mani
new
countri
recognis
microbiolog
full
specialti
join
eu
deleg
reach
major
european
union
medic
specialist
union
de
uem
consequ
new
monospecialist
uem
section
medic
microbiolog
becam
realiti
brussel
one
aim
uem
harmonis
medic
specialti
specialist
train
base
call
eu
doctor
direct
recent
inquiri
reveal
differ
time
spent
focu
variou
field
clinic
scientif
interest
microbiolog
train
show
wide
varieti
eu
countri
therefor
consensu
need
minimum
requir
perform
specialti
optim
level
appropri
eu
standard
profil
specialti
term
train
defin
mani
year
ago
profil
still
basi
train
programm
detail
logbook
accord
uem
chapter
train
medic
specialist
european
commun
train
program
logbook
implement
standard
assess
qualiti
train
center
trainer
develop
uem
chapter
train
contain
requir
year
train
program
adopt
recent
council
meet
napl
diagnosi
chaga
diseas
cd
acut
phase
reli
direct
observ
parasit
blood
microhematocrit
strout
method
refer
techniqu
pcr
recommend
congenit
case
higher
sensit
immunocompromis
patient
reactiv
trypanosoma
cruzi
may
also
detect
bodi
fluid
tissu
parasitolog
method
low
sensit
chronic
cd
thu
diagnosi
base
serolog
test
usual
indirect
haemagglutin
indirect
immunofluoresc
elisa
necessari
least
two
techniqu
posit
result
establish
diagnosi
chronic
cd
set
pcr
techniqu
enough
sensit
diagnosi
may
role
discord
case
current
two
drug
proven
efficaci
cruzi
infect
market
use
benznidazol
gener
prefer
nifurtimox
better
safeti
profil
tissu
penetr
possibl
higher
efficaci
toler
drug
good
signific
number
patient
develop
advers
reaction
lead
treatment
interrupt
case
assess
treatment
efficaci
difficult
affect
phase
cd
dose
length
treatment
endpoint
evalu
clinic
studi
trypanocid
treatment
proven
efficaci
acut
congenit
earli
chronic
infect
children
reactiv
use
much
doubt
patient
late
chronic
diseas
probabl
role
advanc
organ
involv
treatment
monitor
serolog
reliabl
test
cure
howev
children
serolog
negativ
take
year
therapi
adult
chronic
cd
may
take
year
parasitolog
method
xenodiagnosi
blood
cultur
poorli
sensit
pcr
could
use
tool
still
await
standard
clinic
valid
mani
challeng
overcom
cd
need
sensit
standard
cruzi
detect
techniqu
identifi
marker
diseas
progress
valid
surrog
marker
respons
therapi
also
urgent
need
better
drug
improv
efficaci
toler
paediatr
formul
newer
treatment
strategi
focus
therapi
length
drug
combin
retreat
therapi
failur
manag
immunosupress
patient
isol
suscept
vancomycin
daptomycin
weak
correl
vmic
dmic
rs
p
factor
associ
vmic
increas
age
renal
failur
presenc
intravascular
cathet
healthcar
associ
acquisit
idu
wherea
mortal
day
associ
vmic
tabl
univari
analysi
age
copd
hous
statu
healthcar
associ
acquisit
associ
mortal
howev
statist
signific
multivari
analysi
conclus
suscept
test
reveal
blood
cultur
mrsa
isol
remain
suscept
vancomycin
daptomycin
advanc
age
renal
failur
presenc
intravascular
cathet
healthcar
associ
acquisit
associ
higher
vmic
associ
found
higher
vmic
mortal
invas
fungal
infect
ifi
import
caus
morbid
mortal
immunecompromis
patient
diagnosi
reli
culturebas
method
lack
sensit
delay
diagnosi
pcr
diagnosi
ifi
offer
attract
method
earli
diagnosi
howev
lack
standard
fungal
pcr
assay
limit
accept
diagnost
tool
current
consensu
optim
blood
fraction
isol
candida
dna
pcr
detect
limit
cfuml
whole
blood
wb
associ
improv
test
perform
candida
consensu
concern
type
specimen
volum
extract
method
target
pcr
format
platform
reach
european
aspergillu
pcr
initi
eapcri
form
aim
initi
provid
optim
standard
protocol
clinic
evalu
aspergillu
pcr
determin
diagnost
role
allow
inclus
diseas
diagnosi
criteria
standardis
aspergillu
pcr
assay
wb
serum
propos
eapcri
detect
aspergillu
wb
import
nucleic
acid
extract
protocol
achiev
satisfactori
analyt
sensit
highlight
pcr
test
wb
blood
volum
ml
effici
lyse
bead
beat
disrupt
fungal
cell
use
intern
control
pcr
exclud
fals
neg
dna
elut
volum
l
dection
aspergillu
serum
posit
associ
sensit
use
larger
sampl
volum
intern
control
pcr
pcr
target
region
shown
neg
associ
sensit
use
larger
elut
volum
ul
pcr
target
mitochondri
gene
demonstr
multicentr
clinic
trial
requir
determin
clinic
valid
util
candida
aspergillu
wb
serum
pcr
test
multicentr
comparison
wb
serum
pcr
requir
determin
optim
specimen
pcr
diagnosi
clinic
parasitolog
western
hospit
essenti
therapi
parasit
infect
larg
task
drug
e
caum
pari
fr
overal
mortal
rate
import
plasmodium
falciparum
malaria
europ
quinin
option
parenter
therapi
howev
intraven
artesun
becom
wide
avail
effect
quinin
sever
malaria
endem
countri
artesun
fastact
act
drug
efficici
sever
parasit
stage
includ
gametocyt
reduct
cytoadher
howev
data
toler
safeti
limit
continu
advanc
field
antiretrovir
therapi
dramat
improv
natur
histori
prognosi
hiv
infect
aid
due
high
efficaci
new
drug
drug
class
rate
virolog
suppress
patient
outpati
servic
current
around
nevertheless
sever
side
effect
describ
antiretrovir
antiretrovir
drug
class
addit
age
phenomenon
increas
risk
concomit
cardiovascular
renal
bone
diseas
patient
current
treatment
guidelin
recommend
first
line
antiretrovir
therapi
three
drug
regimen
backbon
two
nucleo
ide
revers
transcriptas
inhibitor
n
rti
third
drug
chosen
among
nonnucleosid
revers
transcriptas
inhibitor
nnrti
ritonavirboost
proteas
inhibitor
pir
regimen
contain
less
three
antiretrovir
drug
current
recommend
base
high
risk
virolog
failur
select
drug
resist
mutat
drm
previou
experi
nrtionli
base
approach
except
boost
pi
monotherapi
option
patient
intoler
nrti
requir
treatment
simplif
provid
never
experienc
virolog
failur
admit
except
circumst
nevertheless
investig
possibl
new
treatment
paradigm
remain
attract
due
high
potenc
low
risk
select
drug
resist
mutat
pir
base
therapi
establish
long
term
toxic
even
newer
current
prefer
n
rti
particular
renal
bone
toxic
tenofovir
debat
potenti
associ
increas
cardiovascular
risk
abacavir
describ
cohort
studi
new
treatment
strategi
thu
evalu
order
tri
respond
unmet
medic
need
hivinfect
patient
metabol
complic
increas
risk
concomit
cardiovascular
renal
diseas
talk
review
evid
regard
safeti
efficaci
altern
treatment
paradigm
base
older
newer
antiretrovir
drug
drug
class
also
tri
defin
optim
candid
regimen
observ
carriag
similar
kpcharbor
plasmid
within
genet
distinct
strain
interhospit
spread
two
major
clone
belong
also
identifi
clone
blavim
gene
identifi
clone
gene
locat
plasmid
similar
previous
describ
clone
israel
clone
identifi
two
hospit
harbor
addit
incac
plasmid
carri
ampc
betalactamas
one
patient
intraabdomin
infect
sustain
clone
treatment
colistin
carbapenem
suscept
isol
lack
plasmid
carri
isol
site
success
treat
carbapenem
anoth
patient
develop
sepsi
sustain
clone
day
strain
suscept
carbapenem
neg
isol
urin
strain
rearrang
occur
plasmid
caus
loss
gene
conclus
find
evidenc
unexpect
high
spread
carbapenemaseproduc
kp
urban
area
differ
strain
identifi
carri
gene
associ
common
plasmid
pkpqil
type
plasmid
repres
major
vehicl
diffus
among
differ
strain
circul
area
howev
two
major
clone
identifi
also
indic
suggest
inter
intrahospit
spread
conclus
conclus
report
clonal
outbreak
kpcproduc
k
oxytoca
austria
involv
five
patient
last
month
outbreak
kpcproduc
k
pneumonia
describ
frequent
outbreak
kpcproduc
k
oxytoca
yet
describ
best
knowledg
observ
provid
insight
epidemiolog
clinic
import
kpc
carbapenemas
pose
seriou
clinic
threat
also
produc
k
oxytoca
object
nosocomi
infect
sustain
carbapenemresist
klebsiella
pneumonia
kp
global
health
problem
activ
surveil
maintain
hospit
rome
demonstr
increas
carbapenem
resist
kp
associ
product
carbapenemas
two
major
clone
entir
plasmid
content
strain
investig
highthroughput
sequenc
ascertain
contribut
plasmid
success
clone
method
full
sequenc
plasmid
perform
appli
sequenc
flx
procedur
librari
obtain
total
plasmid
dna
purifi
two
archetyp
strain
contig
least
coverag
obtain
gsflx
gassembl
softwar
assembl
pcrbase
gap
closur
method
result
four
differ
plasmid
identifi
within
strain
incfiikfibk
plasmid
carri
identifi
strain
similar
plasmid
pkpqil
identifi
kp
strain
israel
respect
former
pkpqil
composit
transposon
confer
kanamycin
resist
acquir
pkpqil
strain
identifi
itali
strain
contain
anoth
incfiikfiblik
plasmid
name
pkpnit
highli
relat
plasmid
identifi
kp
usa
confer
resist
arsen
copper
silver
plasmid
pkpnit
show
feclik
iron
iii
dicitr
transport
system
glutat
abctransport
system
class
integron
carri
trimethoprim
streptomycin
resist
gene
orf
chloramphenicol
macrolid
resist
gene
mpha
one
strain
also
carri
incac
plasmid
carri
ampc
betalactamas
novel
plasmid
belong
untyp
group
also
identifi
within
strain
presenc
multipl
resist
put
virul
plasmid
within
clone
endow
strain
formid
set
resist
gene
toxic
compound
metal
antimicrobi
drug
presenc
iron
iii
uptak
system
like
involv
capac
bacterium
acquir
iron
human
host
studi
contribut
descript
characterist
kp
clone
current
repres
seriou
potenti
risk
nosocomi
set
background
complex
epidemiolog
kpcproduc
enterobacteriacea
kpce
k
pneumonia
kpn
clone
document
hospit
sinc
colon
patient
main
reservoir
multiresist
bacteria
determin
length
carriag
loc
kpce
patient
infect
andor
colon
isol
method
patient
nine
femal
median
age
year
rang
infect
andor
colon
kpce
routin
colon
screen
contact
precaut
swab
cultur
chromidesbl
medium
biomerieux
throat
rectum
taken
weekli
three
consecut
neg
cultur
discharg
identif
malditof
phenotypickpc
product
modifi
hodg
test
boron
acid
disc
method
confirm
kpc
identifi
pcr
sequenc
harbour
clone
character
pfge
mlst
loc
defin
time
elaps
first
last
document
posit
cultur
kpce
cp
clonal
persist
ratio
averag
day
colon
per
clone
averag
day
followup
per
patient
result
seventyf
throat
rectal
specimen
obtain
kpce
isol
recov
throat
rectal
swab
rectal
colon
demonstr
patient
half
concomitantli
posit
pharyng
cultur
none
patient
pharyng
colon
mean
durat
followup
first
posit
kpce
cultur
day
median
rang
loc
kpce
patient
posit
surveil
cultur
day
median
rang
kpce
clone
k
pneumonia
patient
two
e
coli
eco
two
patient
one
patient
cocolon
eco
clone
kpn
clone
show
differ
cp
valu
eco
clone
detect
followup
period
cp
conclus
rectum
sensit
sampl
site
detect
kpce
colon
pharyng
colon
present
absenc
rectal
carriag
k
pneumonia
clone
exhibit
differ
lengthsofcolon
loc
valu
variabl
encourag
need
identifi
clonal
factor
involv
long
persist
could
enhanc
clone
transmiss
clinic
strain
isol
differ
bodi
site
blood
urin
rectal
swab
sputum
patient
hospit
particular
antibiot
resist
profil
chang
speci
identif
antimicrobi
suscept
obtain
system
isol
suspect
kpc
product
base
synergist
activ
phenylboron
acid
imipenem
meropenem
ertapenem
colistin
tigecyclin
suscept
assess
also
e
test
total
isol
chosen
repres
investig
genotyp
pcr
blakpclik
gene
sequenc
perform
pfge
multilocu
sequenc
type
mlst
use
investig
clonal
related
result
isol
result
kpcposit
harbour
gene
carbapenem
mic
rang
mgl
mgl
isol
resist
colistin
rang
mgl
wherea
five
isol
still
sensit
tigecyclin
pfge
analysi
reveal
spread
one
preval
clone
belong
show
seven
pulsotyp
clonal
variant
pt
two
sporad
clone
belong
pt
pt
b
sever
isol
distinct
genotyp
patient
found
suggest
colon
strain
may
occasion
replac
phenotyp
molecular
heterogen
circul
hospit
support
hypothesi
k
pneumonia
infect
colon
dynam
process
clone
could
result
singl
locu
mutat
occur
high
risk
clone
worldwid
distribut
emerg
colistinresist
could
attribut
select
pressur
excess
inadequ
colistin
use
coproduct
geslik
aeromona
spp
isol
hospit
effluent
brazil
metallobetalactamaseencod
gene
identifi
among
produc
four
isol
also
carri
blageslik
gene
n
cavia
n
hydrophila
isol
speci
share
ericpcr
pattern
mic
mgl
rang
four
isol
follow
amoxacillin
clavulan
acid
cefotaxim
ceftriaxon
ceftazidim
cefepim
aztreonam
ertapenem
imipenem
meropenem
gentamicin
tetracyclin
ciprofloxacin
trimethoprimsulfametoxazol
chloramphenicol
conclus
high
carbapenemresist
rate
observ
aeromona
spp
hospit
effluent
brazil
presenc
blageslik
waterborn
pathogen
may
hamper
appropri
treatment
infect
addit
sinc
gene
often
locat
broadhost
rang
plasmid
notabl
potenti
spread
find
strengthen
role
asp
environment
reservoir
resist
gene
broadspectrum
antimicrobi
environ
bacteri
pathogenesi
new
virul
factor
biofilm
intestin
anaerob
bacteria
vitro
abil
adher
grow
monoor
dualspeci
biofilm
c
vuotto
g
donelli
r
cardin
p
mastrantonio
rome
object
basi
recent
data
close
associ
exist
clog
biliari
stent
develop
lumen
polymicrobi
biofilm
twelv
anaerob
strain
isol
explant
stent
belong
genera
bacteroid
clostridium
fusobacterium
finegoldia
prevotella
veillonella
investig
abil
adher
grow
sessil
mode
form
vitro
monoor
dualspeci
biofilm
method
abil
adher
form
biofilm
vitro
evalu
quantit
biofilm
product
assay
strain
investig
grow
monoand
dualspeci
biofilm
field
emiss
scan
electron
microscopi
fesem
confoc
laser
scan
microscopi
clsm
experi
dualbiofilm
format
plan
basi
anaerob
strain
isol
clog
biliari
stent
select
coupl
anaerob
strain
belong
differ
speci
contribut
polimicrobi
biofilm
develop
result
demonstr
abil
test
strain
adher
grow
sessil
mode
differ
extent
possibl
point
synergist
interact
involv
speci
form
dualspeci
biofilm
fesem
analysi
allow
us
distinguish
two
biofilmform
bacteri
speci
basi
differ
featur
rod
spearshap
bacilli
vs
cocci
morpholog
approach
offer
chanc
approxim
evalu
rel
contribut
two
interact
speci
form
mix
biofilm
conclus
far
know
first
report
abil
vitro
adher
form
singledualspeci
biofilm
exhibit
anaerob
strain
belong
speci
bacteroid
orali
clostridium
difficil
clostridium
baratii
clostridium
fallax
clostridium
bifermentan
finegoldia
magna
fusobacterium
necrophorum
vitro
develop
dualspeci
biofilm
coupl
fusobacterium
necrophorum
veillonella
spp
bacteroid
fragili
finegoldia
magna
finegoldia
magna
clostridium
difficil
particular
signific
mention
select
criteria
find
favour
possibl
coaggreg
speci
belong
intestin
microbiota
form
vivo
sessilegrow
polimicrobi
commun
multiresist
gramposit
bacteria
continu
rise
threat
hospit
worldwid
complex
mechan
enabl
pathogen
exchang
genet
inform
especi
distribut
resist
determin
lead
propens
caus
hospit
outbreak
well
endem
spread
report
one
factor
respons
genet
exchang
name
specif
protein
socal
type
four
secret
system
repres
achil
heel
har
fight
often
untreat
infect
prototyp
gramposit
type
four
secret
system
present
plasmid
sever
protein
transfer
region
express
e
coli
rabbit
sera
rais
two
protein
ie
code
atpas
put
channel
compon
rabbit
sera
use
opsonophagocyt
assay
sera
rais
show
kill
homolog
strain
dilut
use
absorpt
sera
increas
amount
purifi
protein
kill
could
inhibit
test
larger
collect
strain
differ
speci
reveal
e
faecali
e
faecium
aureu
effect
kill
dilut
includ
one
vancomycinresist
aureu
strain
sever
camrsa
western
blot
analysi
demonstr
crossreact
protein
band
two
three
test
e
faecali
three
four
e
faecium
total
five
aureu
strain
respect
homolog
strain
e
faecali
express
protein
show
band
kda
use
mous
bacteremia
model
signific
reduct
coloni
count
seen
anim
receiv
compar
anim
receiv
antisera
challeng
homolog
e
faecali
well
e
faecium
camrsa
strain
anim
infect
homolog
e
faecali
carri
plasmid
protect
data
demonstr
target
opson
protect
antibodi
may
therefor
promis
broadli
crossprotect
vaccin
candid
target
multiresist
gramposit
pathogen
rat
model
kingella
kinga
pathogenesi
n
balashova
newark
us
object
kingella
kinga
gram
neg
coccobacillu
neisseriacea
famili
normal
inhabit
human
oropharyng
flora
emerg
pathogen
develop
new
method
bacteria
isol
pcridentif
techniqu
led
recognit
k
kinga
lead
caus
septic
arthriti
osteomyel
children
younger
year
old
bacterium
also
cardiovascular
pathogen
caus
infect
endocard
k
kinga
produc
potent
protein
toxin
rtxgroup
rtxa
method
kingella
kinga
septic
arthriti
isol
grown
columbia
agar
contain
sheep
blood
lgml
vancomycin
hour
number
bacteria
identifi
coloni
form
unit
count
activ
rtxa
purif
cytosol
fraction
toxindefici
mutant
creat
use
marin
transposon
mutagenesi
threeweek
old
spraguedawley
rat
use
anim
model
mammalian
cell
line
obtain
atcc
result
kingella
kinga
toxic
cohort
rat
inject
intraperiton
differ
dose
cellsanim
lethal
dose
cellsanim
septic
arthriti
model
right
rat
knee
joint
inject
intraarticularli
differ
dose
cell
left
knee
joint
inject
salin
thirti
one
percent
anim
inject
bacteri
cell
demonstr
featur
acut
inflamm
infect
joint
first
hour
histopatholog
examin
joint
adjac
bone
day
infect
reveal
sign
chronic
inflamm
rtxa
secret
rtxa
lgml
toxic
effect
human
rat
rabbit
mous
white
blood
cell
test
high
concentr
lgml
toxic
rtxa
also
detect
cell
type
includ
human
synovi
cell
osteoblast
toxic
effect
isogen
rtxa
mutant
mammalian
cell
condit
detect
conclus
first
studi
toward
develop
vivo
model
k
kinga
pathogenesi
bacterium
shown
caus
infect
rat
offspr
rat
model
knee
septic
arthriti
due
k
kinga
propos
rtxa
primarili
affect
multipl
type
leukocyt
suggest
toxin
role
host
immun
respons
evas
rtxa
respons
major
cytotox
effect
k
kinga
mammalian
cell
legionella
longbeacha
respiratori
infect
neutrophildeplet
mice
p
pusic
f
wensveen
z
trobonjaca
doric
gobin
rijeka
hr
object
neutrophil
infiltr
known
play
crucial
role
protect
lung
respiratori
pathogen
includ
legionella
legionella
longbeacha
infect
human
primarili
preval
australia
global
increas
report
case
past
decad
comparison
legionella
l
longbeacha
unusu
high
lethal
mice
caus
focal
bronchopneumonia
massiv
recruit
inflammatori
cell
lung
goal
investig
role
neutrophil
respiratori
infect
l
longbeacha
extent
mice
treat
monoclon
antibodi
mab
infect
surviv
bacteri
load
patholog
leukocyt
content
lung
analyz
compar
untreat
anim
method
control
mice
week
old
inocul
intratrach
subleth
dose
l
longbeacha
variou
time
point
inocul
mice
sacrif
leukocyt
isol
lung
myeloid
cell
stain
fac
analysi
mice
inject
either
ugdos
hour
hour
infect
surviv
assay
mice
observ
day
postinfect
enumer
bacteri
load
differ
time
point
cfu
lung
liver
determin
histolog
section
lung
prepar
stain
hemotoxylin
eosin
statist
signific
assess
use
twoway
analysi
varianc
student
test
graphpad
prism
softwar
result
flow
cytometri
analysi
reveal
predomin
neutrophil
first
hour
postinfect
mab
treat
mice
show
increas
suscept
infect
well
higher
bacteri
burden
sever
histopatolog
chang
lung
compar
nontreat
infect
mice
observ
effect
less
sever
lowdos
ab
treat
mice
highdos
treat
mice
conclus
neutrophildeplet
mice
l
longbeacha
caus
sever
infect
neutrophil
play
import
role
host
resist
bacterium
introduct
mycobacterium
tuberculosi
mtb
caus
approxim
million
death
year
extens
lung
destruct
hallmark
pulmonari
tuberculosi
caus
breakdown
extracellular
matrix
host
matrix
metalloproteinas
mmp
hypoxia
upregul
gene
express
secret
mani
inflammatori
mediat
via
hypoxiainduc
factor
hif
master
regul
adapt
respons
hypoxia
tissu
hypoxia
demonstr
anim
model
tuberculosi
tb
investig
hypoxia
human
diseas
perform
object
investig
hypothesi
hypoxia
increas
mmp
activ
tb
infect
depend
manner
method
human
respiratori
epitheli
cell
primari
human
monocytederiv
macrophag
mdm
either
directli
infect
mtb
stimul
condit
media
tb
infect
monocyt
comtb
experi
conduct
real
hypoxia
chemic
hypoxia
use
dimethyloxalyl
glycin
dmog
mmp
timp
concentr
measur
elisa
luminex
array
gene
express
pcr
promot
activ
dual
luciferas
assay
total
protein
measur
western
blot
analysi
result
hypoxia
increas
mtbinduc
secret
fold
p
secret
fold
p
compar
mtb
infect
cell
normoxia
addit
hypoxia
decreas
secret
specif
tissu
inhibitor
metalloproteinas
inhibit
mmp
manner
respiratori
epitheli
cell
upregul
gene
express
fold
hour
markedli
increas
promot
activ
p
nfkb
blockad
helenalin
significantli
downregul
secret
hypoxia
mdm
contrast
decreas
secret
mdm
p
lung
epitheli
cell
p
compar
normoxia
western
blot
analysi
mdm
infect
mtb
normoxia
demonstr
accumul
maxim
hour
respiratori
epitheli
cell
stabilis
occur
hour
via
network
effect
rather
direct
infect
mtb
first
time
tbdriven
hif
accumul
describ
parent
strain
mutat
found
drastic
impair
biofilm
format
hour
incub
mutat
affect
bacteri
attach
hela
cell
viabl
count
obtain
eukaryot
cell
lysi
sem
show
almost
attach
mutant
eukaryot
cell
compar
parent
strain
see
figur
conclus
ld
glutam
interconvers
key
process
baumannii
form
abiot
biofilm
attach
hela
eukaryot
cell
thu
glutam
racemas
gene
could
ultim
provid
effect
target
control
biofilm
pathogen
object
mulitidrug
resist
efflux
pump
confer
low
level
resist
varieti
antibiot
deterg
dye
salmonella
known
nine
mdr
efflux
system
belong
four
famili
efflux
pump
resistancenodul
divis
rnd
famili
multidrug
toxic
compound
extrus
mate
famili
atp
bind
cassett
abc
famili
major
facilit
superfamili
mf
show
genet
inactiv
efflux
system
result
inabl
form
compet
biofilm
use
well
character
acrabtolc
system
model
investig
hypothesi
inactiv
efflux
system
chang
express
biofilm
relat
gene
method
panel
singl
doubl
mutant
lack
compon
major
mdr
efflux
system
salmonella
investig
biofilm
quantifi
use
variou
model
variou
condit
use
high
throughput
crystal
violet
biofilm
assay
variou
phenotyp
assay
use
visualis
curli
proteinac
filament
cellulos
polysaccharid
product
import
compon
salmonella
biofilm
extracellular
matrix
differ
express
biofilm
relat
gene
wildtyp
efflux
mutant
determin
use
qrtpcr
result
sixteen
efflux
mutant
form
significantli
less
biofilm
wildtyp
biofilm
assay
test
reason
biofilm
defect
lack
curli
express
cell
surfac
qrtpcr
show
defect
curli
express
result
repress
transcript
level
addit
genet
inactiv
multidrug
resist
efflux
pump
chemic
inactiv
efflux
pump
inhibitor
epi
pa
beta
n
cccp
chlorpromazin
also
inhibit
format
biofilm
wildtyp
strain
inactiv
inhibit
mdr
efflux
alter
global
regulatori
pathway
mediat
repress
curli
conclus
data
suggest
inactiv
acrb
tolc
trigger
regul
pathway
ultim
decreas
transcript
curli
operon
inhibit
format
matur
biofilm
also
show
phenomenon
specif
acrabtolc
even
rnd
efflux
pump
gener
effect
seen
four
differ
class
multidrug
resist
efflux
pump
object
staphylococcu
aureu
danger
bacteri
pathogen
whose
virul
express
variou
form
rang
pyogen
tissu
invas
system
toxic
shock
syndrom
latter
situat
prototyp
superantigen
toxic
shock
syndrom
toxin
encod
tst
carri
mobil
genet
element
present
aureu
strain
thu
transcript
regul
tst
partial
understood
evid
exist
regul
catabolit
regul
protein
ccpa
twocompon
srrab
sensor
quorum
sens
system
agr
global
accessori
regul
sara
studi
dissect
role
sara
sar
rnaiii
particular
emphasi
altern
stress
sigma
factor
sigmab
method
transcript
analysi
toxin
transcript
factor
express
level
perform
qrtpcr
express
analysi
western
blot
classic
bacteri
genet
procedur
direct
mutagenesi
phagemedi
transduct
use
obtain
mutant
aureu
strain
result
examin
tst
promot
regul
context
nativ
sequenc
context
within
pathogen
island
strain
strain
histor
use
discoveri
toxin
discov
sigmab
sara
emerg
particularli
import
modul
sigmab
strongli
repress
express
toxin
least
two
distinct
regul
pathway
furthermor
sar
anoth
member
sara
famili
shown
impart
addit
level
neg
regul
conclus
collect
result
extend
understand
complex
multifactori
regul
tst
sever
layer
neg
regul
new
find
suggest
sporad
mutat
key
neg
regul
profoundli
affect
enhanc
tst
express
old
new
strategi
target
healthcar
associ
infect
stand
object
assess
effect
hand
hygien
improv
program
hhip
european
intens
care
unit
icu
quantifi
effect
known
determin
method
conduct
intervent
studi
icu
unit
infer
month
baselin
period
phase
hhip
implement
month
intens
hhip
phase
use
moment
hand
hygien
concept
observ
perform
random
date
timeinterv
bed
space
last
month
studi
focu
shift
toward
anoth
nonrel
intervent
whilst
hhip
continu
continu
hhip
phase
mix
effect
logist
regress
model
perform
random
effect
phase
hospit
result
hand
hygien
opportun
observ
european
icu
hand
hygien
complianc
hhc
vari
wide
icu
baselin
rang
mean
ci
peer
high
complianc
abhr
cue
memori
hh
nurs
also
influenc
messag
peer
expect
compli
doctor
remind
abhr
alway
avail
risk
factor
new
ve
neg
checklist
posit
one
riskfactor
averag
trust
screen
checklist
patient
would
reduc
number
screen
week
identifi
posit
screen
high
risk
specialti
would
reduc
number
screen
week
identifi
ve
conclus
uptak
admiss
screen
low
especi
emerg
daycas
admiss
yield
mrsave
patient
use
checklist
activ
screen
would
reduc
number
mrsa
admiss
screen
identifi
ve
screen
high
risk
specialti
would
reduc
screen
identifi
ve
health
econom
model
use
data
determin
cost
effect
screen
polici
comparison
two
strategi
reduc
healthcar
associ
methicillinresist
staphylococcu
aureu
rate
surgic
patient
multicentr
intervent
studi
aim
compar
effect
two
strategi
healthcareassoci
mrsa
isol
rate
surgic
patient
method
prospect
intervent
studi
conduct
march
juli
surgic
ward
hospit
nine
countri
europ
israel
consist
month
minimum
baselin
month
intervent
month
washout
phase
two
intervent
enhanc
standard
control
ec
standard
precaut
intens
hand
hygien
hh
promot
ii
rapid
test
rt
admiss
mrsa
screen
topic
decolonis
therapi
contact
isol
patient
test
posit
mrsa
four
hospit
assign
strategi
two
hospit
use
combin
strategi
mix
multipl
segment
multilevel
poisson
regress
use
compar
monthli
rate
healthcareassoci
mrsa
isol
clinic
specimen
adjust
cluster
potenti
confound
result
admiss
surgic
ward
studi
period
ec
mix
arm
hh
complianc
increas
baselin
intervent
phase
p
rt
hospit
intervent
phase
patient
screen
mrsa
preval
admiss
addit
increas
rate
administr
topic
decolonis
therapi
p
adher
contact
precaut
conclus
compar
enhanc
standard
control
measur
hh
promot
mrsa
screen
effect
initi
reduc
rate
mrsa
isol
clinic
specimen
combin
two
strategi
result
mark
reduct
mrsa
rate
time
chang
polici
primarili
pcrbase
mrsa
screen
wider
use
culturescreen
halv
nosocomi
mrsa
acquisitioneven
disestablish
protect
isol
precaut
highpreval
region
germani
object
aim
studi
detect
preval
mrsa
admiss
number
nosocomi
mrsa
case
nc
tertiari
care
hospit
chang
alreadi
tradit
implement
screen
infect
control
polici
icp
method
studi
period
mrsa
screen
polici
accord
criteria
robert
koch
institut
rki
includ
addit
intens
care
unit
icu
patient
screen
perform
via
pcr
xpert
mrsa
cepheid
icu
preoper
cultur
ward
patient
unknown
mrsa
statu
isol
privat
room
screen
result
avail
case
surgic
intervent
mrsa
posit
patient
set
end
program
possibl
contact
surfac
protect
plastic
sheet
intensifi
educ
staff
concern
screen
indic
accord
rki
criteria
gener
screen
introduc
medic
ward
icu
patient
xpert
mrsa
pcr
replac
light
cycler
mrsa
advanc
test
roch
patient
screen
cultur
chromagar
mrsa
bd
icu
patient
unknown
mrsa
statu
treat
barrier
precaut
instead
protect
isol
protect
isol
done
ward
surgic
intervent
schedul
independ
mrsa
statu
without
addit
surfac
protect
measur
intervent
fulli
implement
defin
period
studi
period
first
quarter
changeov
period
nc
defin
mrsa
detect
day
admiss
result
mrsa
preval
incid
densiti
nc
studi
period
shown
figur
median
admiss
preval
chang
significantli
median
incid
densiti
nc
declin
patient
day
xpert
mrsa
pcr
show
fals
posit
result
yield
unnecessarili
isol
incid
densiti
patient
day
mean
number
patient
screen
increas
whilst
number
mrsa
pcr
declin
slightli
conclus
target
econom
attract
polici
compris
avoid
protect
singl
room
isol
surfac
coverag
chang
mrsa
screen
pcr
full
implement
screen
accord
rki
led
signific
decreas
nosocomi
mrsa
case
object
aim
evalu
costbenefit
infect
control
intervent
prevent
spread
methicillinresist
staphylococcu
aureu
mrsa
hospit
method
systemat
review
publish
clinic
studi
report
cost
save
infect
control
intervent
aim
prevent
spread
mrsa
hospit
studi
report
cost
save
associ
intervent
exclud
intervent
limit
oper
room
studi
cost
determin
laboratori
test
materi
search
pubm
nci
refer
use
term
relat
cost
econom
analys
mrsa
data
independ
extract
two
author
use
qualiti
health
econom
studi
qhe
tool
adapt
clinic
studi
maxim
score
qualiti
assess
report
save
cost
ratio
valu
indic
save
larger
cost
savecost
differ
discount
us
posit
valu
indic
net
save
result
eight
studi
publish
includ
current
analysi
perform
locat
differ
baselin
mrsa
preval
tabl
hospitalwid
search
destroy
polici
evalu
four
studi
includ
screen
admiss
patient
risk
isol
decolon
followup
screen
variabl
healthcar
worker
screen
suspens
work
visitor
environment
screen
anoth
two
studi
perform
less
comprehens
hospitalwid
intervent
two
studi
limit
special
set
orthoped
ward
intens
care
unit
qhe
score
rang
studi
report
perspect
cost
analysi
perform
sensit
analys
increment
analysi
discount
cost
compon
consid
includ
personnel
materi
medic
laboratori
save
result
avoid
bed
day
antibiot
prevent
infect
studi
report
infect
control
intervent
econom
justifi
sinc
savecost
ratio
median
ratio
rang
higher
ratio
associ
small
hospit
intervent
short
durat
net
global
save
discount
dollar
rang
conclus
publish
studi
report
posit
savecost
differ
intervent
control
intervent
aim
prevent
erad
mrsa
hospit
object
recent
data
show
burden
multidrugresist
microorgan
go
exponenti
increas
year
therefor
signific
implement
isol
procedur
gramneg
bacilli
gnb
strategi
improv
time
implement
appropri
antimicrobi
therapi
clinic
warrant
theradoc
electron
data
captur
system
abil
send
realtim
alert
clinician
via
email
electron
page
cultur
inform
updat
object
studi
assess
theradoc
could
util
decreas
ttat
improv
outcom
patient
gnb
method
retrospect
casecontrol
studi
perform
detroit
medic
center
dmc
control
group
consist
patient
gramneg
bacteremia
prior
implement
theradoc
case
group
consist
patient
gnb
decemb
august
theradoc
implement
case
group
period
time
blood
cultur
result
gnb
updat
microbiolog
laboratori
page
immedi
sent
antimicrobi
stewardship
pharmacist
updat
inform
pharmacist
made
antimicrobi
recommend
provid
base
cultur
result
institut
guidelin
clinic
data
result
thirti
eight
case
control
studi
group
well
match
baselin
characterist
except
patient
case
group
copd
vs
p
control
patient
higher
pitt
bacteremia
score
pb
iqr
vs
iqr
major
patient
group
urin
primari
sourc
infect
common
gnb
pathogen
eschericia
coli
compar
control
case
patient
experienc
significantli
shorter
delay
receipt
effect
therapi
measur
time
cultur
initi
posit
gnb
time
receipt
effect
therapi
p
tabl
case
significantli
decreas
durat
bacteremia
p
shorter
durat
hospit
bacteremia
p
conclus
autom
alert
use
significantli
decreas
time
receipt
effect
antimicrobi
therapi
mean
hour
improv
timeli
implement
effect
antimicrobi
therapi
associ
decreas
durat
hospit
day
intellig
electron
trigger
tool
optimis
intraven
oral
antibiot
switch
sprong
h
pot
dofferhoff
j
schouten
houterman
nabuursfranssen
k
kramer
voss
h
huntjensfleuren
nijmegen
nl
object
time
switch
intraven
antibiot
oral
import
improv
patient
safeti
reduc
cost
associ
intraven
therapi
reason
numer
intervent
devis
shown
improv
antibiot
switch
howev
intervent
usual
timeconsum
therefor
expens
difficult
implement
introduc
intervent
reli
computer
trigger
intellig
identifi
patient
candid
antibiot
switch
combin
weekli
discuss
switch
therapi
microbiologyinfecti
diseas
multidisciplinari
meet
intervent
aim
improv
rate
intraven
oral
antibiot
switch
method
intervent
perform
intern
medicin
ward
larg
teach
hospit
daili
autom
trigger
tool
select
patient
elig
switch
base
data
pharmaceut
patient
system
patient
identifi
elig
parenter
antibiot
use
hour
patient
inelig
switch
crp
rise
neutrophil
ml
leukocyt
inabl
receiv
oral
therapi
antibiot
prescrib
oral
option
avail
daili
round
per
candid
antibiot
switch
form
gener
given
resid
care
patient
inform
concern
abil
switch
reason
imped
switch
record
median
iv
day
per
iv
prescript
number
iv
prescript
hour
intervent
period
compar
similar
period
year
preced
intervent
result
form
gener
iv
antibiot
prescript
fill
return
case
form
led
ivor
switch
median
number
iv
day
reduc
vs
p
number
iv
prescript
longer
hour
reduc
vs
reason
switch
antibiot
therapi
inabl
receiv
oral
therapi
clinic
instabl
stop
antibiot
therapi
patient
conclus
design
intervent
use
computer
trigger
identifi
patient
candid
antibiot
switch
therapi
combin
frequent
short
term
educ
resid
effect
promot
antibiot
switch
therapi
reduc
number
iv
day
hour
object
outcom
patient
sepsi
better
initi
empir
antimicrobi
treatment
adequ
sever
studi
shown
adher
guidelin
antibiot
use
posit
influenc
clinic
outcom
howev
adequ
empir
therapi
relev
determin
outcom
qualiti
indic
qi
measur
element
use
assess
actual
qualiti
care
provid
systemat
deriv
guidelin
object
present
studi
develop
valid
set
qi
accur
measur
qualiti
antimicrobi
treatment
hospit
adult
sepsi
qi
sepsi
present
lack
deriv
qi
recent
publish
evidencebas
dutch
guidelin
antimicrobi
treatment
adult
patient
sepsi
wwwswabnlguidelin
method
randmodifi
five
step
delphi
procedur
use
multidisciplinari
panel
expert
apprais
priorit
grade
recommend
retriev
dutch
consensu
guidelin
antimicrobi
therapi
sepsi
select
qi
potenti
relev
clinic
outcom
antimicrobi
resist
cost
done
use
two
questionnair
mail
facetofac
consensu
meet
round
period
month
result
forti
recommend
initi
deriv
sepsi
guidelin
apprais
recommend
first
questionnair
potenti
qi
remain
consensu
meet
potenti
qi
merg
four
gener
qi
leav
potenti
qi
priorit
expert
result
final
set
five
potenti
qi
take
two
blood
cultur
togeth
cultur
suspect
site
infect
prescrib
empir
antibiot
therapi
accord
nation
guidelin
start
antibiot
intraven
start
antibiot
soon
possibl
prefer
within
hour
streamlin
antibiot
therapi
conclus
systemat
stepwis
method
combin
evid
expert
opinion
new
concis
therefor
measur
set
process
qi
antimicrobi
therapi
sepsi
obtain
qi
give
insight
actual
qualiti
given
care
could
use
determin
aspect
room
improv
test
feasibl
reliabl
casemix
sensit
indic
practic
next
step
use
qualiti
improv
project
improv
hospit
antimicrobi
prescrib
use
qualiti
indic
j
sneddon
patton
nathwani
e
watson
behalf
scottish
antimicrobi
prescrib
group
object
use
qualiti
indic
antimicrobi
prescrib
support
reduct
clostridium
difficil
infect
cdi
improv
prescrib
practic
method
scottish
antimicrobi
prescrib
group
sapg
issu
nation
guidanc
restrict
antibiot
associ
high
risk
cdi
within
antimicrobi
prescrib
polici
scottish
govern
introduc
target
reduct
cdi
sapg
develop
implement
follow
qualiti
indic
support
achiev
target
indic
record
empir
antibiot
choic
compliant
local
polici
target
complianc
b
durat
surgic
prophylaxi
hour
choic
compliant
local
polici
target
complianc
cdi
target
revis
use
best
class
approach
qualiti
indic
revis
focu
achiev
reliabl
sustain
improv
indic
requir
deviat
polici
document
indic
b
focus
use
singl
dose
elect
colorect
surgeri
result
march
cdi
rate
scotland
reduc
indic
acut
admiss
unit
median
complianc
indic
document
complianc
local
polici
indic
b
complianc
varieti
surgic
specialti
follow
revis
indic
septemb
indic
median
complianc
indic
document
complianc
local
polici
analysi
inform
deviat
polici
show
common
theme
breakthrough
collabor
clinic
team
compris
manag
medic
nurs
pharmaci
staff
set
map
process
prescrib
antibiot
design
test
chang
improv
clinic
practic
indic
b
septemb
median
complianc
antibiot
polici
median
complianc
singl
dose
measur
integr
within
surgic
checklist
achiev
sustain
conclus
prescrib
indic
effect
mean
improv
antimicrobi
prescrib
combin
measur
scrutini
improv
methodolog
lead
reliabl
sustain
improv
prescrib
practic
differ
stroke
corel
model
studi
common
commun
acut
hospit
hcai
reduct
target
variabl
dynam
antibiot
prescrib
method
multidisciplinari
team
compos
antimicrobi
pharmacist
consult
microbiologist
medic
team
review
iv
antimicrobi
prescript
schedul
weekli
round
medic
ward
rational
behind
choic
antimicrobi
agent
dose
durat
need
review
hour
iv
oral
switch
discuss
recommend
made
recommend
consist
eight
categori
stop
inappropri
choic
stop
iv
cours
document
stop
date
document
review
date
oral
switch
await
investig
continu
appropri
indic
long
durat
continu
oral
rout
compromis
result
month
period
june
octob
patient
iv
antimicrobi
cours
discuss
durat
iv
rang
day
review
antimicrobi
cours
stop
stop
date
recommend
antimicrobi
cours
switch
oral
antimicrobi
review
date
recommend
cours
investig
recommend
cours
deem
appropri
therefor
continu
graph
show
detail
result
period
studi
antimicrobi
expenditur
steadili
declin
demonstr
save
round
effect
initi
stop
antimicrobi
cours
well
instig
switch
oral
clinic
indic
round
also
effect
highlight
patient
requir
microbiolog
input
follow
appropri
investig
round
also
led
reduct
antimicrobi
expenditur
howev
confound
variabl
clinic
activ
season
variat
may
impact
explor
ongo
studi
feedback
clinic
team
shown
posit
educ
experi
improv
hospit
antibiot
use
success
french
experi
f
ollivi
j
caillon
n
foucher
thibaut
e
batard
f
ballereau
nant
fr
object
within
framework
nation
plan
preserv
effect
antibiot
region
health
author
commiss
medqual
network
conduct
project
improv
good
use
antibiot
ab
region
hospit
method
public
privat
hospit
practic
medicin
surgeri
obstetr
affect
region
program
sinc
within
region
antibiot
commiss
action
implement
valid
local
protocol
ab
treatment
surgic
prophylaxi
share
websit
broadcast
messag
appropri
use
ab
develop
work
group
organ
region
train
harmon
indic
monitor
ab
consumpt
bacteri
resist
propos
tool
decis
support
guid
improv
action
accord
monnet
perform
crosssect
studi
assess
evolut
implement
antibiot
stewardship
collect
annual
indic
antibiot
consumpt
bacteri
resist
result
region
hospit
particip
crosssect
survey
degre
implement
measur
manag
antibiot
increas
hospit
antibiot
advisor
vs
p
use
local
protocol
antibiot
therapi
prophylaxi
vs
p
antibiot
prescript
softwar
vs
p
hospit
pharmacist
dispens
antibiot
pharmaceut
analysi
vs
p
monitor
indic
ab
use
bacteri
resist
particip
hospit
increas
last
year
among
hospit
particip
annual
data
collect
ab
consumpt
decreas
year
signific
decreas
use
fluoroquinolon
pd
vs
pd
p
conclus
region
monitor
creat
profession
dynam
good
use
antibiot
everi
year
particip
region
hospit
project
increas
success
region
program
allow
extens
categori
hospit
rehabilit
center
nurs
home
requir
object
regular
feedback
antibiot
usag
data
help
promot
ration
prescrib
reduc
inappropri
use
potenti
slow
develop
spread
antimicrobi
stewardship
strategi
recommend
health
social
care
act
english
hospit
take
account
registr
care
qualiti
object
describ
frequenc
type
antibiot
usag
data
fed
back
clinician
english
hospit
method
electron
audit
email
antimicrobi
pharmacist
acut
hospit
nh
trust
england
n
survey
softwar
adob
acrobat
record
respons
analysi
excel
result
respons
rate
figur
show
report
antibiot
usag
provid
clinic
team
frequenc
inform
expenditur
commonli
provid
daili
defin
dose
ddd
packsprescript
ddd
report
split
parenter
oral
form
report
use
special
outpati
vs
inpati
use
antibiot
point
preval
studi
pp
conduct
trust
fed
back
less
frequent
clinician
expenditur
lumc
pcr
ribotyp
perform
webbas
questionnair
use
collect
clinic
epidemiolog
data
result
total
patient
includ
survey
isol
obtain
mean
incid
per
hospit
admiss
type
frequent
found
type
follow
type
type
found
twelv
outbreak
observ
mainli
associ
type
patient
clinic
inform
avail
half
femal
mean
age
year
patient
defin
communityonset
cdi
patient
use
antibiot
prior
start
diarrhoea
total
patient
sever
cdi
day
patient
cdi
die
two
death
attribut
cdi
death
contribut
cdi
half
patient
cdi
due
type
type
involv
attribut
contribut
death
type
conclus
conclud
incid
cdi
stabl
netherland
type
still
predomin
type
incid
rate
c
difficil
pcr
ribotyp
remain
low
previous
report
extrapol
data
sentinel
surveil
hospit
netherland
estim
hospit
patient
annual
develop
cdi
succumb
attribut
contribut
cdi
incid
per
bedday
exclud
repeat
posit
within
day
calcul
calendar
time
eiaposit
cultureposit
cdi
common
strain
compar
across
strain
use
stack
neg
binomi
regress
natur
cubic
spline
reflect
nonlinear
calendar
trend
result
studi
period
incid
eiaposit
cultureposit
cdi
declin
per
bedday
perannum
declin
incid
rate
ratio
ci
eiaposit
cultureposit
cdi
ouh
inpati
common
sequenc
type
st
pcrribotyp
ribotyp
ribotyp
ribotyp
ribotyp
ribotyp
ribotyp
ribotyp
also
ribotyp
ribotyp
less
common
st
account
cdi
neither
st
observ
cdi
account
cdi
perannum
declin
ci
ci
respect
studi
period
st
apart
also
declin
studi
period
significantli
slower
rate
pa
ci
p
vs
contrast
margin
evid
declin
way
common
st
instead
increas
estim
annual
increas
incid
ci
decreas
increas
p
vs
st
p
vs
although
absolut
level
still
remain
rel
low
conclus
declin
cdi
oxfordshir
inpati
driven
declin
suggest
may
particularli
suscept
hospitalbas
intervent
pcrribotyp
may
increas
oxfordshir
intervent
reduc
clostridium
difficil
infect
unintend
consequ
mortal
p
davey
patton
j
sneddon
nathwani
c
marwick
behalf
scottish
antimicrobi
prescrib
group
background
scottish
antimicrobi
prescrib
group
issu
nation
guidanc
restrict
antibiot
associ
higher
risk
clostridium
difficil
infect
studi
aim
determin
implement
guidanc
local
antibiot
prescrib
polici
unintend
consequ
mortal
admiss
one
nh
board
scotland
method
quasi
experiment
studi
design
interrupt
time
seri
analysi
use
segment
regress
use
data
obtain
octob
decemb
split
preintervent
postintervent
period
introduct
restrict
antibiot
polici
octob
monthli
data
antibiot
use
cdi
incid
mortal
use
adjust
clinic
activ
use
hospit
admiss
data
result
analysi
perform
patient
admit
acut
medic
admiss
unit
medicin
patient
admit
six
surgic
ward
surgic
chang
crude
caus
mortal
patient
medicin
surgeri
subgroup
analysi
age
charlson
comorbid
index
cci
score
reveal
chang
follow
intervent
separ
studi
hospit
show
patient
blood
cultur
taken
four
time
like
die
within
day
admiss
increas
risk
death
attribut
sepsi
ensur
increas
death
sepsi
mask
decreas
death
caus
mortal
analys
patient
blood
cultur
taken
statist
analysi
confirm
signific
abrupt
sustain
chang
intervent
medicin
surgeri
direct
chang
neg
demonstr
reduct
mortal
post
intervent
medicin
cohort
chang
slope
reduct
death
per
patient
per
month
p
ci
subgroup
analysi
age
cci
score
show
evid
increas
mortal
studi
provid
reassur
introduc
antibiot
polici
restrict
use
broadspectrum
antibiot
unintend
consequ
mortal
patient
sepsi
individu
ribotyp
admit
care
home
year
period
emerg
ribotyp
identifi
one
commun
one
acut
set
rate
cdi
among
inpati
age
year
decreas
significantli
sinc
p
figur
conclus
ni
uniqu
cdi
profil
ribotyp
domin
last
year
cdrn
ribotyp
servic
contribut
signific
reduct
cdi
primarili
earli
rapid
detect
possibl
outbreak
acut
commun
set
ribotyp
c
difficil
posit
isol
programm
avoid
select
bia
best
knowledg
extens
ribotyp
programm
exist
elsewher
studi
examin
morbid
mortal
associ
ribotyp
plan
emerg
outbreak
clostridium
difficil
region
longterm
care
facil
object
sinc
multipl
outbreak
clostridium
difficil
infect
cdi
report
netherland
outbreak
occur
mainli
hospit
caus
pcr
ribotyp
sinc
octob
increas
resid
long
term
care
facil
ltcf
diagnos
cdi
notic
retrospect
survey
perform
estim
incid
outcom
cdi
ltcf
method
region
laboratori
respons
diagnost
ltcf
one
gener
hospit
bed
particip
survey
june
april
request
clostridium
difficil
diagnost
ltcf
review
diagnost
includ
rapid
toxin
test
immunocard
toxin
b
meridian
select
cultur
c
difficil
case
cdi
defin
diarrhoeal
patient
posit
test
stool
sampl
either
posit
toxin
test
toxin
produc
c
difficil
detect
cultur
patient
record
use
determin
outcom
cdi
within
period
month
episod
isol
posit
stool
sampl
sent
refer
laboratori
leiden
univers
medic
centr
pcr
ribotyp
character
multiplelocu
variablenumb
tandemrepeat
analysi
mlva
appli
studi
genet
related
result
june
april
stool
sampl
ltcf
resid
test
cdi
sixtyon
resid
nine
ltcf
posit
cdi
overal
mortal
assess
resid
within
month
cdi
episod
avail
c
difficil
isol
differ
pcr
ribotyp
found
type
predomin
type
follow
type
type
type
mainli
found
ltcf
outbreak
adjac
hospit
mlva
appli
isol
ltcf
hospit
reveal
clonal
spread
one
specif
type
cdi
incid
hospit
studi
period
per
admiss
type
predomin
type
conclus
clonal
spread
c
difficil
pcr
ribotyp
found
three
region
ltcf
neighbour
hospit
prospect
surveil
initi
intervent
strategi
develop
impact
type
diagnost
method
clostridium
difficil
infect
rate
singl
institut
particip
mandatori
report
programm
background
mandatori
report
institut
clostridium
difficil
infect
cdi
incid
rate
becom
increasingli
common
numer
jurisdict
howev
type
laboratori
method
use
diagnos
cdi
stool
sampl
usual
left
discret
particip
institut
object
examin
prospect
differ
cdi
incid
rate
obtain
two
standard
laboratori
method
method
conduct
prospect
cohort
studi
patient
admit
iucpq
c
difficil
diagnost
assay
order
august
juli
submit
specimen
test
parallel
commerci
pcr
target
toxin
b
tcdb
gene
twotier
algorithm
base
eia
detect
glutam
deshydrogenas
gdh
toxin
b
toxab
follow
cell
cultur
cytotox
assay
ccna
case
posit
gdh
neg
toxab
eia
healthcareassoci
cdi
incid
rate
compar
incid
rate
ratio
calcul
use
univari
poisson
regress
result
overal
stool
sampl
patient
test
parallel
studi
period
repres
patientday
surveil
total
specimen
posit
pcr
posit
eiaccna
absolut
differ
case
p
chisquar
test
furthermor
case
posit
pcr
eiaccna
algorithm
case
posit
pcr
neg
eiaccna
four
case
neg
pcr
posit
eiaccna
overal
incid
rate
per
patientday
ci
pcr
per
patientday
ci
eiaccna
among
administr
period
studi
incid
rate
governmentimpos
target
case
per
patientday
period
use
pcr
period
use
eiaccna
incid
rate
ratio
compar
pcr
eiaccna
ci
p
wide
variat
magnitud
discord
two
diagnost
method
depend
administr
period
case
per
patientday
conclus
perform
pcr
instead
eiaccna
associ
increas
cdi
incid
densiti
context
mandatori
public
report
cdi
rate
rate
stratifi
accord
diagnost
method
improv
intraand
interhospit
comparison
investig
potenti
clostridium
difficil
outbreak
within
week
use
rapid
desktop
whole
genom
sequenc
object
demonstr
whether
newli
avail
rapid
desktop
whole
genom
sequenc
wg
investig
potenti
clostridium
difficil
infect
cdi
outbreak
within
clinic
relev
time
scale
method
sepoct
two
cluster
cdi
case
identifi
hospit
group
oxfordshir
three
cdi
case
occur
day
longstay
medic
ward
three
day
elect
surgeri
unit
dna
cultur
isol
last
preced
cdi
isol
locat
day
month
earlier
respect
sequenc
four
isol
time
use
illumina
miseq
platform
run
last
hour
pair
base
pair
read
map
refer
genom
stampi
variant
call
made
use
samtool
picard
python
script
velvet
de
novo
assembl
use
determin
insilico
multilocu
sequenc
type
mlst
provid
tradit
genotyp
comparison
wg
result
eight
isol
success
sequenc
mean
refer
genom
call
filter
total
sampl
prepar
sequenc
analysi
time
receipt
last
posit
cultur
week
four
medic
patient
share
time
space
ward
diagnosi
case
sequenc
data
reveal
singl
nucleotid
variant
snv
three
case
occur
within
day
exclud
possibl
transmiss
howev
one
isol
genet
ident
snv
case
day
highlight
like
import
case
transmiss
consid
initi
infect
control
investig
similar
conclus
would
drawn
use
mlst
exact
genet
match
two
relat
case
would
known
contrast
within
surgic
unit
three
cluster
case
spent
time
togeth
mlst
data
suggest
two
three
case
potenti
relat
howev
two
case
actual
snv
apart
refut
possibl
transmiss
intriguingli
one
surgic
case
differ
snv
medic
case
despit
neither
patient
hospit
last
year
case
live
mile
apart
conclus
compar
whole
genom
sequenc
distinguish
relat
unrel
isol
potenti
cdi
outbreak
set
rapid
turnaround
desktop
sequenc
demonstr
prospect
use
approach
focus
outbreak
investig
clostridium
difficil
whole
genom
sequenc
patient
leed
oxfordshir
demonstr
substanti
geograph
segreg
clinic
strain
